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3. ABBREVIATIONS AND DEFINITIONS 
 
ABBREVIATIONS 
• ADI-12 Anxiety-Depression Index-12 (continuous measure of mental distress) 
• AUC Area Under Curve 
• BMI Body Mass Index (kg/m2) 
• CI Confidence interval  
• CIDI Composite International Diagnostic Interview  
• DIS Diagnostic Interview Schedule 
• DSM-III Diagnostic and Statistical Manual of Mental Disorders, third edition 
• DSM-III-R Diagnostic and Statistical Manual of Mental Disorders, third revised edition 
• DSM-IV Diagnostic and Statistical Manual of Mental Disorders, fourth edition 
• ECA Epidemiologic Catchment Area 
• GAM Generalized Additive Model 
• HADS Hospital Anxiety and Depression Scale 
• HADS-A Anxiety subscale of HADS 
• HADS-D Depression subscale of HADS 
• HUNT 1 The Nord-Trøndelag Health Study 1984-86 
• HUNT 2 The Nord-Trøndelag Health Study 1995-97 
• HUSK The Hordaland Health Study 1997-99 
• ICD-10 International Classification of Diseases, tenth edition 
• MDD Major Depressive Disorder 
• MTHFR Methylenetetrahydrofolate reductase 
• NCS National Comorbidity Survey 
• OR Odds ratio 
• ROC Receiver Operating Characteristics 
• SES Socioeconomic status 
• tHcy Total homocysteine 
• PPV Positive Predictive Value: proportion of true cases among the test-positive 
subjects 
• NPV Negative Predictive Value: proportion of true non-cases among the test-
negative subjects 
 
 
 10 
DEFINITIONS 
• Anxiety disorder
(= ”pure anxiety 
disorder”) 
HADS-A > 8 and HADS-D < 8 
• Comorbid 
disorder 
Comorbid anxiety disorder and depression: HADS-A > 8 and HADS-D > 8. 
• Concurrent 
validity 
1) The correlation between two instruments that were meant to measure the 
same construct. 
2) A comparison of the case-finding properties of a test compared to another 
against a common external “gold standard” criterion. 
• Confounder A variable that is imbalanced between the exposure groups to be compared 
(i.e. associated with the exposure), and associated with the outcome, leading 
to a biased effect of the exposure. It should not be a cause of the exposure or 
the outcome. 
• Depression  
(= ”pure 
depression”) 
HADS-D > 8 and HADS-A < 8 
• Determinant A (risk) factor that brings about change in a health condition. 
• Discriminant 
validity 
The correlation between two measures that are assumed to assess different 
constructs. A low correlation indicates good discriminate validity. 
• Endophenotype Neurophysiological, biochemical, endocrinological, neuroanatomical, 
cognitive, or neuropsychological (including configured self-report data) 
measurements, reflecting some aspects of a disorder. 
• Factor analysis Statistical technique examining the underlying dimensions reflected by a set 
of item scores. 
• Mediator An intermediate variable, mediating the effect of the exposure on the outcome
• Incident cohort Individuals from the study population in Paper V with ADI-12 scores < 80th 
percentile. 
• Internal 
consistency 
The average inter-item correlation. 
• Persistent cohort Individuals from the study population in Paper V with ADI-12 scores > 80th 
percentile. 
• Sensitivity The proportion of true cases that are identified by a test. 
• Specificity The proportion of true non-cases that are identified by a test. 
• Test-retest 
reliability 
The coefficient quantifying the agreement between two test scores separated 
by a specified period of time. 
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4. BACKGROUND  
This dissertation addresses two of the most common mental ailments, namely 
anxiety and depression. For an understanding of these vaguely defined and multi-
factorial symptoms and disorders, a wide spectrum of research approaches is required. 
Various concepts of psychopathology and assessment methods illuminate different 
aspects of anxiety and depression, and the reciprocal relation between these 
constructs. Examination of the co-occurrence of anxiety and depression, as well as 
their co-morbidity with somatic illnesses elucidates the broad role of anxiety and 
depression within the field of health care. Likewise, studying associations with 
neurobiological and psychosocial factors will give a more comprehensive 
understanding of the mechanisms involved in the development of anxiety and 
depression.  
Hence, the studies of this dissertation address how anxiety and depression can 
be assessed by a simple questionnaire, how the relation between anxiety and 
depression can be viewed by two different approaches to psychopathology, how 
anxiety and depression are co-occurring with some somatic illnesses and symptoms, 
and finally how anxiety and depression are related to some neurobiological and 
psychosocial factors. These studies are based on the use of data from three Norwegian 
health surveys. Health surveys have a long tradition in Norway in the studies of major 
health problems such as tuberculosis and cardiovascular illnesses. Recently, mental 
disorders have received status as a major health problem in society, and, therefore, 
measurements of anxiety and depression have become a major goal of the national 
health surveys (1). 
 
4.1. ANXIETY, DEPRESSION AND PUBLIC HEALTH 
4.1.1. Prevalence 
Anxiety disorders and depression are among the most frequently occurring 
mental disorders in the general population. However, prevalence estimates vary 
markedly in different studies. In the Epidemiologic Catchment Area Study (ECA) (2) 
the 12-month prevalence of a major depressive episode was 5.8%, compared to 10.3% 
in the National Comorbidity Study (NCS) (3), and 7.3% in a recent study from Oslo, 
Norway (4). The 12-month prevalence of any anxiety disorder in ECA was 12.7%, 
and in NCS 17.2%. In the Oslo study the overall prevalence of anxiety disorders was 
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not reported, but the prevalence of the separate anxiety disorders were lower than in 
NCS. Although this may reflect real differences geographically or historically, the 
main explanation is probably differences in assessment instruments and their relation 
to different classification systems. ECA used the Diagnostic Interview Schedule (DIS) 
(5) which gave diagnoses according to the Diagnostic and Statistical Manual of 
Mental Disorders, third edition (DSM-III) (6). In contrast, the Composite 
International Diagnostic Interview (CIDI) (7) was used in NCS and the Oslo study, 
giving diagnoses according to DSM-III-R (8) and the International Classification of 
Diseases, version 10 (ICD-10) (9). The sampling procedures also differed; while ECA 
was a multi-site study, NCS included a nationally representative sample, and the Oslo 
study included a locally representative sample.  
The findings of a relatively high prevalence of mental disorders, e.g. 29% of 
any one-year DSM-III-R mental disorder in NCS, have questioned the clinical 
significance of the diagnoses achieved in such studies (10). This issue has recently 
been considered in a re-analysis of ECA and NCS (11), where clinical significant 
symptoms had to be related to self-reported use of health services, medication, or 
impairment. By this approach the prevalence of the anxiety disorders and major 
depression generally decreased, and the revision concluded with a one-year 
prevalence of any anxiety disorder of 11.8% and major depressive episode of 4.5%. 
The one-year prevalence of the anxiety disorders differed considerably, the most 
prevalent was simple phobias (4.3%), followed by posttraumatic stress disorder 
(3.6%), social phobia (3.2%), generalised anxiety disorder (2.8%), agoraphobia 
(2.1%), obsessive-compulsive disorder (2.1%), and panic disorder (1.4%). Dysthymic 
disorder (low-grade, chronic depression) and bipolar disorder (I/II) (recurrent 
depressive and manic/hypomanic episodes) had a one-year prevalence of 0.7% and 
1.7%, respectively. Since the one-year prevalence of having any of these mental 
disorders was 14.9%, the public health impact of depression and anxiety disorders 
should be evident.  
 
4.1.2. Impact on public health, costs and need for research 
Depression was ranked as the fourth most important specific cause of global 
disability-adjusted life years (DALY, sum of life years lost due to premature 
mortality, and years lived with disability adjusted for severity) by the Global Burden 
of Disease Study (GBD) (12) and was predicted to advance to the second most 
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important cause by year 2020 (13). The role of anxiety disorders was not addressed in 
the GBD, but analyses from the NCS estimated the annual costs of anxiety disorders 
(panic disorder, posttraumatic stress disorder, agoraphobia, social phobia, simple 
phobia and generalised anxiety disorder) to be 54 % of the total costs due to treatment 
for somatic illness, and 31 % of the costs due to treatment for mental illness (14). The 
total cost of affective disorders (major depression, dysthymia and bipolar disorder) 
was very similar to the total cost of anxiety disorders. 
Measures to prevent these widespread, deteriorating, and costly disorders 
should be of great interest to society. However, much is still unknown about the 
etiology and prevention of anxiety disorders and depression. Population-based 
epidemiological studies collecting comprehensive information on both mental and 
somatic health as well as characteristics of personal environment, lifestyle, use of 
health services, and biological measures, are warranted to identify modifiable risk 
factors. Such studies have not been abundant, but in Norway some have been 
performed during the last two decades. Data from three of these health surveys are the 
basis of the studies included in this dissertation. 
 
4.2. ASSESSMENT OF ANXIETY AND DEPRESSION 
Mental disorders are assessed by registration of subjective symptoms, 
behavioural patterns, and impairment during a specified period, either through 
interviews or questionnaires. However, there is a controversy about which features 
should characterise the constructs of anxiety and depression, and whether these 
conditions should be considered as categorical diagnoses or continuous phenomena. 
Both approaches, therefore, are used in this dissertation . However, before the 
assessment methods are presented, different approaches to the understanding of 
anxiety and depression will be reviewed. 
 
4.2.1. What is anxiety and depression? 
Anxiety is usually described as the emotion of fear involving feelings of 
tension, worry, apprehension, and dread for something considered dangerous in the 
future (15). Depression is associated with the emotion of sadness, in addition to 
feelings of sorrow, hopelessness, gloom, lack of energy, and anhedonia (16). These 
symptoms are sometimes considered as normal psychological responses, equivalent to 
physical pain, on a continuous scale from being absent to a maximum intensity. This 
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approach is often described as dimensional (17). In contrast, the categorical approach 
views anxiety and depression as discrete psychopathological entities, or disorders. 
Such disorders are classified as being present or not according to a threshold for 
specific diagnostic criteria (17). Figure 1 is illustrating the difference between the two 
approaches.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.2. The categorical approach 
From a public health and clinical point of view it is necessary to identify 
individuals suffering from anxiety disorders and depression in order to make 
decisions about planning of health services and treatment. Researchers also address 
anxiety and depression by the categorical approach in order to get a reliable 
description of their samples. The classification is based upon distinctive symptoms, 
such as panic or depressed mood, and their impact, most often on functional 
impairment, as well as their duration. The validity of categorical diagnoses can be 
Figure 1: Categorical versus dimensional approach to anxiety and depression. 
The categorical approach applies the rating scale score as a test for the disorder 
defined by a cut-off value, and in this example two different subjects with the 
same sum score have one versus two disorders. The dimensional approach 
applies the rating scale score to describe the contribution from both anxiety 
and depression. 
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settled by converging data from clinical, family, population–based, and laboratory 
studies (the Washington University criteria) (18, 19).  
A syndrome is defined by the presence of a set of co-occurring symptoms, and 
may be considered as a valid diagnosis if it has a predictable clinical course, treatment 
response, and pattern of familial aggregation (20). Accordingly, the current 
classification systems, DSM-IV (21) and ICD-10 (9), are meant to be atheoretical, 
solely describing the characteristic of the diagnoses, mainly without consideration of 
etiology or hierarchical organisation of the disorders. Moreover, in the expanding 
revision of DSM-III-R (8), which aimed to include all kinds of psychopathology, 
there was “no assumption that each mental disorder is a discrete entity with sharp 
boundaries (discontinuity) between it and other mental disorders” (p. xxii). 
In both ICD-10 and DSM-IV anxiety is classified as different anxiety 
disorders, while depression is mainly classified as unipolar or bipolar disorder with a 
variety of subtypes.  
 
4.2.3. The dimensional approach 
A limitation of the categorical approach is the need to define sharp, clear-cut 
thresholds between normality and pathology. Sub-threshold conditions of depression 
as well as of anxiety disorders have been found to have significant clinical impact in 
terms of functional impairment, mortality, treatment, and prognosis (22-27). 
However, simply lowering the diagnostic threshold does not solve the problem of 
categorisation (28). Thus, it has been suggested that anxiety and depression are 
dimensional phenomena with no thresholds between pathology and normality (29). 
Hence, the use of symptom scores opposed to categorical diagnoses has been 
proposed for research addressing anxiety and depression (17). 
 
4.2.3.1. Models for underlying dimensions 
By use of latent trait analyses of GHQ scores from primary care patients, 
Goldberg and colleagues (30) identified the highly correlated dimensions of anxiety 
and depression underlying the common mental illnesses presented in these patients. 
Later, Goldberg proposed a dimensional model for common mental disorders, 
including anxiety, depression and somatisation (31). Other similar models of non-
psychotic psychopathology have been developed, such as Krueger’s model (32) that 
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identified an externalising and an internalising dimension, the latter encompassing the 
anxious-misery and fear sub-dimensions.  
After having reviewed nearly 400 studies addressing symptoms of anxiety and 
depression among patients and non-patients, Clark and Watson (33) suggested a 
tripartite model. First, the model contains a common factor for anxiety and depression 
consisting of general distress or Negative Affect including both anxious and 
depressed mood, insomnia, and poor concentration. Second, a specific factor for 
anxiety, consisting of tension and anxious arousal manifested as shortness of breath, 
dizziness or light-headedness, and dry mouth was described. Third, the depression 
factor was described as anhedonia and absence of Positive Affect, i.e. loss of interest 
and feeling that nothing is interesting or enjoyable. However, subsequent testing of 
this model failed in confirming such a simple concept. Hence, Mineka, Watson and 
Clark (34) proposed an integrative hierarchical model of anxiety and depression, not 
very different from the original tripartite model, but where each individual anxiety 
disorder and depression had their own unique component that differentiated them 
from all the others. Later, Watson has suggested more specific factors for the various 
anxiety disorders (35). 
 
4.2.4. Assessment of anxiety and depression in epidemiological studies 
In epidemiological studies focusing mainly on mental health, standardised 
interviews performed by trained lay people have been the gold standard. As described 
in section 4.1.1., in the ECA, DIS was used, while CIDI was used in the NCS and the 
Oslo study. Such interviews are suitable for collecting comprehensive information as 
to a variety of mental symptoms, and yield categorical diagnoses according to the 
ICD-10 and DSM-IV classification systems. However, in large-scale health surveys 
the diagnostic information is mostly obtained from short questionnaires, resulting in a 
limited number of data on each topic.  
 
4.2.5. Rating scales 
Rating scales are widely used for clinical as well as scientific purposes. They 
yield scores that may be used as continuous measures (dimensional approach), or they 
may be used as diagnostic tests to identify cases by defined cut-off values (categorical 
approach). Several questionnaires that assess anxiety and depression are applicable in 
many settings due to their low cost. In epidemiologic studies the following 
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instruments are mostly used: Center for Epidemiological Studies of Depression Scale 
(CES-D) (36); Beck’s Depression Inventory (BDI) (37); Spielberger State-Trait 
Anxiety Inventory (STAI) (38); Hopkins Symptom Check List (HSCL) (39); General 
Health Questionnaire (GHQ) (40); and Hospital Anxiety and Depression Scale 
(HADS) (41). Some assess both anxiety and depression (HADS, HSCL, GHQ) while 
others assess only anxiety (STAI) or depression (CES-D; BDI).  
 
4.2.6. The Hospital Anxiety and Depression Scale (HADS) 
 Due to its briefness (14 items) and subscales for both anxiety and depression 
HADS is a feasible rating scale to be applied in health surveys. The subscales consist 
of seven items for anxiety (HADS-A) and seven for depression (HADS-D), each 
scored from 0 (not present) to 3 (maximally present) on a Likert scale formulated in 
readily understandable language (41). To increase acceptability and to preclude that 
individuals feel tested for mental disorders, symptoms of severe psychopathology are 
not included. HADS-A contains items mainly concerned with restlessness and worry, 
as in generalised anxiety disorder, plus one item on panic attacks. HADS-D focuses 
mainly on the reduced pleasure response aspect (anhedonia) of depression, as well as 
psychomotor retardation and depressed mood.  
The reported characteristics of a rating scale may vary depending on the 
sample on which it is applied as well as on the external validity criterion employed. 
Hence, to avoid such bias a number of studies addressing case-finding and other 
psychometric properties should be reviewed. The state of the art in doing so is the 
systematic review (42) hallmarked by the application of strategies, which are 
documented in the materials and methods section, to avoid bias in location and 
selection of studies (43, 44). Sources of such bias include limiting the search to one 
database, inclusion of studies published in English only, or not applying inclusion 
criteria (43).  
In a somewhat methodologically less stringent examination of studies 
applying HADS published until May 1996, Herrmann (45) concluded that “HADS is 
a reliable and valid instrument for assessing anxiety and depression in medical 
patients”. Hermann reported the following psychometric data on HADS (definitions 
of the psychometric measures, see section 3): Test-retest reliability after two weeks 
was high (r > 0.80 for both subscales), but decreased to 0.70 after six weeks. Internal 
consistency was reported from four studies, and varied from 0.80 to 0.93 for HADS-
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A, and from 0.81 to 0.90 for HADS-D. Factor analysis was reported from five studies 
giving most support for two separate dimensions, at least in the English and German 
versions, mainly corresponding to the two subscales. Discriminant validity was 
reported from 18 studies with an average of r = 0.63. In 17 studies of the English 
version the average sensitivity and specificity of both subscales at cut-off  > 8 were 
0.8 or higher. In further nine “international” HADS versions comparable or slightly 
poorer results were found, while specificity of less than 0.5 was observed in three 
studies of Asian and Australian patients. The external criteria, or gold standards, for 
anxiety disorders or depression varied in the studies. However, these were not stated 
explicitly in the review. Likewise, the efficiency of HADS as a casefinder at different 
cut-off scores demonstrated by Receiver Operating Characteristics curves (ROC 
curves, see section 6.4.2., “Paper I”) (46) was not reported. Finally, the concurrent 
validity of HADS was approved, however, no specific results were reported by 
Herrmann. 
 
4.3. COMORBIDITY 
The co-occurrence, or comorbidity, of two or more diseases is relatively 
common both in psychiatry and in somatic medicine, in particular in older age groups 
(47). Various combinations of diseases may occur simply by chance. However, the 
term comorbidity is usually applied when the risk (e.g. odds ratio) for a co-occurring 
disease is more than by chance (48). Some critics claim that comorbidity is simply an 
artefact of splitting nosological entities into separate classes. Hence, two disorders 
that have some common diagnostic criteria, are more prone to co-occur, which is 
called diagnostic comorbidity (49). Furthermore, when the co-occurring condition is a 
consequence of the other, e.g. when panic disorder is followed by agoraphobia, it has 
been referred as pathogenic comorbidity (49). As long as the diagnostic hierarchy 
with one main diagnosis introduced by Jaspers in 1913, was accepted, comorbidity 
was non-existing. The idea to make hierarchy-free diagnoses was suggested in 1984 
(50), and was accepted in DSM-III-R in 1987, after which comorbidity ensued as an 
important issue. However, due to lack of consensus as to definition, the reported 
extent of comorbidity varies across studies (51).  
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4.3.1. Comorbidity between anxiety and depression 
Varying degrees of comorbidity between anxiety disorders and depression 
have been reported in different studies. In NCS (52) the comorbidity between the 12 
month prevalence of major depressive disorder (MDD) and any anxiety disorder was 
51 %. In the international WHO Study on Psychological Disorders in Primary Health 
Care (53) the rates were somewhat lower. Among cases of depression 39% had an 
anxiety disorder, and among cases of anxiety disorder 44% had a depression. In a 
clinical sample panic disorder and generalised anxiety disorder were found to be more 
common in bipolar disorder than in MDD (54), while this pattern was not seen in a 
population-based study (55). 
Comorbidity between anxiety disorders and depression has several 
consequences including increased symptom severity (56), impaired treatment 
response to antidepressive medication (57), impaired recovery rate from depression, 
increased time to recovery, decreased time to relapse (58, 59) as well as increased risk 
for suicide (60).  
Studies addressing comorbidity have almost exclusively applied a categorical 
approach (61). Since the dimensional approach is seen as complementary to the 
categorical (62), it is paradoxical that the dimensional approach to anxiety and 
depression has hardly been applied when studying the causes or consequences of such 
comorbidity. In co-occurring anxiety and depression the contribution from each may 
vary from a minimum to a maximum of symptom load, resulting in an anxiety-
depression ratio varying from zero to infinite (figure 2).  
Although it is well known that anxiety and depression are highly correlated 
(34), a correlation coefficient alone cannot describe whether the relationship between 
the two is the same in the lower and upper parts of the symptom scales. The lower 
parts (i.e. few symptoms) are of special interest because sub-threshold conditions 
have been reported to be of clinical significance (22), and because most individuals 
have scores in that range.  
The high correlation between anxiety and depression does not necessarily 
mean that they are similarly associated with other mental or somatic conditions, or 
with various risk factors. However, in studies addressing depression, comorbid 
anxiety disorders or co-occurring anxiety symptoms are frequently not accounted for, 
and vice versa for studies addressing anxiety disorders. Hence, it is not known 
whether the findings are mainly “caused” by the anxiety or the depression component. 
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4.3.2. Comorbidity between anxiety and depression, and somatic disease   
The prevalence of anxiety disorders and depression among individuals 
reporting somatic illness in the general population (63) or among patients in general 
practice (64, 65), is higher than the prevalence among somatically healthy individuals. 
The hospital stay of patients with such comorbidity has been reported to be 
significantly longer than for somatic patients without co-occurring anxiety or 
depression (66). In an international study the economic consequences of depression 
were influenced to a greater extent by the presence of somatic comorbidity than by 
depressive symptom severity alone (67).  
The majority of studies have examined cardiovascular disease, such as 
myocardial infarction (68-73), stroke (74), and arterial stiffness (75), and found 
increased prevalence of depression. Increased prevalence of depression has been 
reported as well in diabetes (76, 77), Parkinson’s disease (78), rheumatoid arthritis 
(79), and back pain (80). Increased prevalence of anxiety has been reported among 
patients with peptic ulcer (81). Among patients with functional gastrointestinal 
complaints (82), cancer (83-85), HIV-infection (86-88), and multiple sclerosis (89) 
the prevalence of both anxiety and depression is increased.  
The mechanisms linking anxiety and/or depression with somatic disease are 
not known in part due to the presumed complexity of such mechanisms, as well as the 
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Figure 2: An illustration of how anxiety and depression as dimensional 
phenomena may co-occur in all possible combinations (codimensionality as a 
parallel to comorbidity). The Anxiety-Depresion ratio expresses the relative 
contribution from the anxiety and depression symptoms.  
Anxiety-Depression ratio 
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heterogeneity of both mental disorders and somatic diseases included in the various 
studies (90-92). In addition, there is a paucity of longitudinal studies and most of 
these have addressed depression only (47).  
Three theoretical explanations for these associations have received some 
support. First, anxiety/depression may cause or aggravate somatic disease, second, 
somatic disease may cause or aggravate anxiety/depression, or, third, there may be 
some common pathophysiological mechanisms for both anxiety/depression and 
somatic disease (92). Some studies suggest a reciprocal relationship between 
depression and somatic health problems (93, 94) merging the two first theoretical 
alternatives. Common pathophysiological mechanisms may involve the effect of 
hormonal dysfunction, nutritional deficiencies, toxic agents, or neurodegenerative or 
inflammatory processes. 
It is also possible that the observed comorbidity may be due to one or more 
uncontrolled confounding factors in the studies (95). These may include age or 
gender, as well as socioeconomic status, psychosocial factors or health behaviours 
(smoking, alcohol consumption, unhealthy dietary habits and lack of physical 
exercise). Finally, many studies have examined either anxiety or depression, and if 
they have included both, they usually have not accounted for the close association 
between the two. If the subjects studied have a depression with co-occurring anxiety 
(or vice versa) it may be hard to tease apart whether the association with a somatic 
disease is mainly due to the depression or the anxiety (20). We are aware of only one 
study (N=711) (96) addressing the occurrence of somatic illness in comorbid anxiety 
and depression. Hence, the patients with panic disorder and comorbid major 
depressive disorder were reported to have higher rates of somatic illness (peptic ulcer, 
angina pectoris, and thyroid disease) than patients with anxiety disorder without 
depression. However, the specific rates were not reported, nor tests of statistical 
difference between them.  
 
4.4. RISK FACTORS 
A risk factor may be defined as “An aspect of personal behaviour or life-style, 
an environmental exposure, or an inborn or inherited characteristic, that, on the basis 
of epidemiological evidence, is known to be associated with health-related 
condition(s) considered important to prevent” (97). However, the term is frequently 
 22 
inconsistently and imprecisely used (98), and should be differentiated into e.g. risk 
markers, determinants and modifiable risk factors (97).  
In the social sciences intermediate factors in a causal pathway from e.g. 
socioeconomic status (SES) to e.g. anxiety and/or depression, are often denoted 
“mediators” (99). However, to identify a mediator, a longitudinal study design with at 
least two follow-up points is necessary to establish the causal direction between 
various factors (100). In a cross-sectional study, or when there is only one follow-up, 
it might be difficult to decide whether a factor is a mediator or a confounder. Contrary 
to a mediator, a confounder should not be caused by the exposure (101), which is 
difficult to prove without three consecutive measurements as well.  
Specific risk factors may be difficult to identify when the validity of the 
outcome is questionable, e.g. due to extensive comorbidity (see section 4.3.1.) or 
overlapping criteria with other outcomes. In the search for risk factors in mental 
disorders, strong associations are therefore not to be expected. Alternatively, other 
phenotypes of neurophysiological, biochemical, endocrinological, neuroanatomical, 
cognitive, or neuropsychological (including configured self-report data) nature, called 
endophenotypes, have been suggested (102). 
Different theoretical approaches to mental disorders have emphasised their 
unique etiological models. Hence, research addressing biological, psychological, as 
well as social risk factors has been conducted. These different perspectives are, 
however, artificially separated, and an explicit integrated biopsychosocial model 
acknowledging the multifactorial diathesis of disease in general, and mental disorders 
in particular, was proposed by Engel (103) and has been implemented to a certain 
extent. Our knowledge of neurobiological and psychosocial risk factors is incomplete, 
as well as how they interplay in precipitating mental disorders (104). In the following 
sections some of these factors will be reviewed as to current status and unanswered 
questions. 
 
4.4.1. Biological factors 
4.4.1.1. Genetics 
A meta-analysis including twin studies of anxiety disorders has revealed a 
heritability between 30-40% (105), while another meta-analysis of major depressive 
disorder found 37% heritability (106). However, the limited reliability of life-time 
diagnosis in, for example, major depression (107) is likely to cause too low estimates 
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of the heritability due to overestimation of the individual specific environmental 
factors (108). The genetic factor in bipolar disorder is assumed to be even stronger 
than in major depression (109).  
There is some evidence for common etiologic factors for anxiety and 
depression. Female twin studies have shown that the genetic factors of MDD and 
generalised anxiety disorder seemed identical (110), while the association between the 
genetic factors of MDD and other anxiety disorders was modest (111). Obsessive 
compulsive disorder seemed to be genetically unrelated to depression or other anxiety 
disorders (112), but related to Tourette’s syndrome (113).   
Some studies have shown associations between a single nucleotide 
polymorphism in the promotor region of the serotonin transporter gene and 
neurotisism (114), anxiety (115) and depression (116), but others have not (117). 
Moreover, a study using functional magnetic resonance imaging demonstrated an 
association between this polymorphism and an increased response in amygdala, (the 
neurophysiological substrate for normal and abnormal fear behaviour) to fearful 
stimuli (118).  
 
4.4.1.2. Neurobiology 
Most studies examining neurobiological factors in mental disorders compare 
clinical samples to healthy controls. To measure such factors expensive and 
sometimes unpleasant or painful procedures are necessary, limiting the sample size 
and the chance of participation at follow-up assessments. Accordingly, in the paucity 
of longitudinal population-based studies, it may be difficult to decide whether the 
factors identified in cross-sectional association studies are determinants or only 
markers of the disorder. Hence, frequently short-cuts are made directly from clinical 
cross-sectional observations to randomised clinical trials (RCT).  
In mental disorders neurotransmission is compromised in various ways, which 
has lead to the development of drugs influencing receptors and transport mechanisms 
for neurotransmitters. Benzodiazepines binding to the gamma amino butyric acid – 
benzodiazepine receptor complex have a tranquillising effect on anxiety (119), while 
different drugs inhibiting the serotonin reuptake in the synapses have a relatively good 
effect on depression and anxiety as well (120). 
The hypothalamic-pituitary-adrenal (HPA) axis is affected in both anxiety and 
depression. Anxiety is characterised by hypocortisolemia, supersuppression after 
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dexamethasone, and increased number of glucocorticoid receptors. In contrast, 
depression is characterised by hypercortisolemia, non-suppression after 
dexamethasone and decreased glucocorticoid receptors (121).  
Abnormal regulation of sex-hormones (122), thyroid hormones (123, 124), 
and melatonin (125, 126) is observed in patients with anxiety disorder and depression. 
Elevated levels of cytokines, as seen in some infections and immunotherapy of cancer 
and hepatitis, may induce depression and possibly anxiety as well (127).  
 
4.4.1.3. B-vitamins and depression 
Deficiency of nutritional factors, such as fatty acids (128), tryptophan (129), 
folic acid, and cobalamin have all been associated with depression. The evidence for 
folic acid and cobalamin will be reviewed more closely in this section.  
Folate is a B-vitamin of major importance for methylation processes (one-
carbon metabolism) in the brain. By transferring a methyl group from 5-methyl-
tetrahydrofolate (5mTHF), the cobalamin dependent methionine synthetase converts 
homocysteine into methionine (figure 3). Folate deficiency may be caused by an 
inadequate dietary intake, increased metabolic demands due to cancer, or certain 
drugs (130), or due to a single nucleotide polymorphism of methylenetetrahydrofolate 
reductase gene (MTHFR 677C!T) reducing the availability of 5mTHF (131). 
Cobalamin deficiency may also be caused by an inadequate intake (e.g. among strict 
vegetarians) as well as gastrointestinal disease (in particular atrophic gastritis among 
elderly) (130). Low levels of both folate (132) and cobalamine (133) are associated 
with elevated levels of serum homocysteine . 
Four decades ago Victor Herbert (134) treated successfully his self-induced 
folate deficiency symptoms of insomnia, irritability, and impaired memory by folate 
supplementation. However, our understanding of the role of folate, and one-carbon 
metabolism in general, in mental disorders is still insufficient. Most studies on folate 
and depression are cross-sectional and compare folate status in depressed patients 
with the status in patients with other mental disorders or in healthy subjects. These 
studies suggest that low folate status is associated with depression, especially with 
more severe forms, prolonged episodes and weak treatment response (135). The 
limitations of these studies are related to lack of longitudinal design, small sample 
size, highly selected patients and lack of adequate control groups. Notably, two 
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population-based studies (136, 137) controlling for possible confounders 
demonstrated no association between folate status and depression.  
Indications that folate deficiency increases the risk for depression, have been 
obtained mainly from biochemical and in vitro studies, but also from a recent study of 
dietary habits (138). Folate metabolism is linked to biopterin-dependent 
neurotransmitter synthesis (139) (figure 4) and methylation of biogenic amines and 
phospholipids in the central nervous system (CNS) (140).  
Only two studies (141) have shown an association between serum total 
homocysteine and depression, while other studies have not (137, 142, 143). 
Homocysteine, or its metabolites, may have a direct excitotoxic effect on the N-
methyl-D-aspartate glutamate receptors in the CNS, or may inhibit the S-
adenosylmethionine (SAM)-dependent methylation via S-adenosylhomocysteine 
(140). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Components of one-carbon metabolism and central nervous system 
functions. SAM, S-adenosylmethionine; Hcy, homocysteine; Met, methionine; 
B12, cobalamin; MS, methionine synthetase; 5mTHF, 5-methyl-
tetrahydrofolate; 5,10mTHF, 5,10-methylene-tetrahydrofolate; THF, 
tetrahydrofolate; MTHFR, methylenetetrahydrofolate reductase 
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Some smaller clinical trials suggest that SAM is superior to placebo in the treatment 
of depression (144). 
 Investigations on a possible role of cobalamin status in neuropsychiatric 
disorders have been motivated by the central nervous system damage caused by overt 
or subtle cobalamin deficiency (145, 146). Data regarding the association between 
serum cobalamin levels and depression are ambiguous (137, 143, 147-149). Elevated 
levels of the cobalamin marker, methylmalonic acid, have been found among 
depressed physically disabled older women in a population-based study (137). 
Moreover, higher baseline serum cobalamin has been associated with a better 
outcome in treated depressed outpatients (150). Cobalamin is a co-factor in the 
methylation of homocysteine to methionine, which in turn affects the levels of both 
homocysteine and SAM figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MTHFR 677C!T affects MTHFR activity and thus folate distribution and 
homocysteine remethylation (131). Inconsistent results on the association between 
depression and the MTHFR 677C!T polymorphism have been obtained (151, 152). 
In case such a relation can be confirmed, it will support the hypothesis that altered 
folate status may precede the onset of depression. 
BH2
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Figur 4: The possible role of folate in neurotransmitter synthesis. 5-methyl-
tetrahydrofolate (5-MTHF) reduces dibiopterine (BH2) to tetrahydrobiopterine 
(BH4), which is a cofactor for tyrosine hydroxylase and tryptophan hydroxylase 
in their synthesis of dopamine and serotonin, respectively. 5,10 MTHF, 5,10-
methylene-tetrahydrofolate. 
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Despite our incomplete understanding of the relation between methylation and 
mood, several clinical trials examining the effect of folate in antidepressant treatment 
have been conducted. The results are promising, though the samples are small, and in 
only four of the studies were patients randomised to folate or placebo (153-156). The 
largest (n=127) and best designed study (154) showed a significant beneficial effect 
only in women. The lack of significance in men could be due to the small sample size 
or an insufficient dosage of folate. Still, we do not know which patients should be 
supplemented with folate, the duration of treatment, the dosage (135) or the safety of 
high dosage folate supplementation (157). 
In spite of the extensive comorbidity between depression and anxiety (52, 53), 
we have found no more than three studies (148, 158, 159) addressing the possibility of 
impaired one carbon metabolism in anxiety disorders. Only one of theses suggests 
such an association, namely between low cobalamin and anxiety (148). 
 
4.4.2. Psychosocial factors 
Environmental influences are strong and pervasive on mental health (160). 
Since World War II various kinds of stress have been addressed as determinants of 
anxiety and depression (161). Childhood adversities, such as loss of a parent, parental 
psychopathology, parental aggression, physical or sexual abuse, or life-threatening 
accidents, are associated with later anxiety and depression (162, 163). Likewise, 
adverse life events in adulthood, such as unemployment, homelessness, violence, 
breakdown of a relationship, loneliness, and lack of social support, have been 
observed to have similar effects on anxiety and depression (161, 164). Psychosocial 
factors have been associated with a worsened prognosis in bipolar disorder, however 
the relationship between such factors and bipolar disorder is more ambiguous (109).  
In the Islington study from London, some common environmental risk factors 
for developing both anxiety and depression in women were found (165). These were 
parental indifference and physical and sexual abuse in childhood. In adults, loss (of a 
person, a position or resources) and lack of social support predicted depression, while 
danger or threats (of a future loss, or a serious threat to life), predicted anxiety. The 
combination of loss and threat predicted comorbid anxiety and depression. A common 
feature of many of these adversities is their association with social inequalities (166), 
in that individuals belonging to the lower social classes have higher risk for being 
exposed to such unfortunate influences. 
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 4.4.2.1 Socioeconomic status 
Socioeconomic status (SES), which most often is characterised by length of 
completed education, household’s annual income, and/or occupation, has consistently 
been associated with poor somatic and mental health (166, 167). However, due to 
differences in study design, use of indicators for SES, and assessment of mental 
status, the relationship between SES and anxiety and depression is still ambiguous. 
Moreover, despite the role of psychosocial factors in both SES and mental health, the 
mechanisms causing this relationship are unknown. 
 
A meta-analysis 
In a recent meta-analysis Lorant et al found compelling evidence for 
socioeconomic inequalities in depression (168). Low-SES individuals had a 
significantly higher risk of being depressed (OR=1.81) compared to high-SES 
individuals in the 51 cross-sectional studies, where a dose-response relation was 
observed both for education and income. In the few longitudinal studies (n=7) similar 
socioeconomic inequalities in depression were observed: a slight association in the 
incidence studies (OR=1.24) and a moderate to strong association in the persistence 
studies (i.e. persistence of depression from baseline to follow-up) (OR=2.06). 
However, after excluding the studies not addressing education, the most frequently 
used SES indicator, the results of the studies on incidence (169, 170) and persistence 
(170-172) were inconsistent. The discrepancy may be due to differences in sample 
size and follow-up period between the studies. Moreover, only one of the studies that 
examined SES included education as the main predictor of depression (169).  
 
Differences in indicators of SES and anxiety and depression 
The indicators of SES usually vary from study to study, and despite being only 
moderately intercorrelated, such indicators are seldom addressed specifically. 
Likewise, the assessment of anxiety and depression varies between studies, however, 
according to Dohrenwend the use of different measures for mental health is welcomed 
in this field, because “…until diagnosis is less dependent on interviews, it is important 
to use a variety of methods…” (166).  
Although anxiety disorders are closely related to depression (52, 53), we are 
not aware of longitudinal studies of their relation to education.  
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Causation or selection? 
The association between SES and depression is not fully understood. In 
contrast to e.g. schizophrenia, there is most evidence that depression is a consequence, 
rather than a cause, of low SES, at least in women (168, 173). However, some studies 
(174, 175) support the selection theory; (176) that is, depression may be an obstacle to 
upward social mobility, and may promote downward social mobility.  
 
Mechanisms – mediators 
Assuming SES is a determinant, little is known about how SES influences the 
development of new cases or the maintenance of chronic cases of depression. The 
effect on depression of measures of SES other than education has been explained by 
work characteristics (SES measure: occupational grade) (177), health behaviours 
(SES measure: economic situation) (178), and psychosocial factors (SES measure: 
income) (170). In longitudinal studies the effect of education has mainly been 
explained by depressive symptoms at baseline (171, 172) and prior to baseline (172).  
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5. AIMS OF THE STUDY 
The inclusion of the Hospital Anxiety and Depression Scale (HADS) in two 
recent large scale Norwegian health surveys has enabled further epidemiological 
research addressing  anxiety and depression in an array of interesting health related 
questions. However, because the properties of HADS had been somewhat loosely 
evaluated, we felt the need to review its characteristics more thoroughly.  
The use of HADS made it possible to define various anxiety/depression 
categories by the combination of certain cut-off values of the two subscales. However, 
because HADS basically is a continuous measure of anxiety and depression symptom 
load, a dimensional approach to the HADS scores was obvious. Due to the paucity of 
research addressing the dimensional approach in co-occurring anxiety and depression, 
we wanted to use the HADS-A and HADS-D scores to compare a dimensional and 
categorical approach to anxiety and depression.  
 Despite the increased focus on co-occurring anxiety and depression during the 
last two decades, anxiety and depression are usually addressed separately in studies 
relating them to other somatic diseases or complaints. Hence, we wanted to compare 
the associations, or comorbidity, between various anxiety/depression combinations 
and somatic health problems. 
 Combining HADS data with results from blood sample analyses gave 
opportunity for analyses as to biological markers and determinants of anxiety or 
depression. Affiliation to Locus of Homocysteine and Related Vitamins at the 
University of Bergen made it possible to investigate the role of anxiety and depression 
in disturbed folate metabolism. 
 There is a paucity of longitudinal studies addressing the association between 
socioeconomic status (SES) and depression. Moreover, anxiety, separately or 
comorbid with depression, has got even less research attention than depression. The 
combination of the two health studies of Nord-Trøndelag County, HUNT 1 (1984-86) 
and HUNT 2 (1995-97) made it possible to design a cohort study with a follow-up 
period of 11 years examining the role of SES, measured by educational level, as a 
predictor for anxiety and depression. 
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The specific aims of this dissertation are: 
 
1. To review the literature and to update information regarding: 
A. the factor structure, discriminant validity and the internal consistency of 
HADS. (Paper I) 
B. the case finding performance of HADS for anxiety disorders and 
depression. (Paper I) 
C. to what extent HADS agrees with other self-rating instruments 
(concurrent validity). (Paper I) 
 
2. To examine the relation between HADS anxiety and depression scores in the 
general population. (Paper II) 
 
3. To examine how co-occurring anxiety and depression is associated with 
impairment due to chronic mental health problems according to the dimensional 
approach compared to the categorical one. (Paper II) 
 
4. To investigate the associations between comorbid anxiety disorders and 
depression (in contrast to the pure conditions) and somatic diseases and 
symptoms. (Paper III) 
 
5. To examine whether key components of the folate metabolism are associated with 
anxiety disorders and/or depression. (Paper IV)  
 
6. To examine whether low education is a predictor of new and chronic cases of 
anxiety disorder, depression and comorbid disorder, (Paper V) 
 
7. and if so, whether these relationships may be explained by somatic illness, use of 
health services, health behaviours, psychosocial status, and sociodemographic or 
work characteristics. (Paper V) 
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6. MATERIALS AND METHODS 
 
6.1. DATA SOURCES 
6.1.1. The literature review (Paper I) 
The Medline (179), ISI (180), and PsycINFO (181) databases were searched 
until May 2000. All papers containing the terms “Hospital” and “Anxiety” and 
“Depression”, or “HAD”, or “HADS” in the title or abstract were identified. This 
procedure identified 1403 abstracts which were inspected in order to ascertain 
whether they contained information about the psychometrics or case-finding abilities 
of HADS. The abstracts indicated 747 studies for closer review for relevant issues, 
and based on this examination 71 papers were identified for the review. Only studies 
where diagnoses were made by a structured interview were considered for sensitivity 
and specificity measures. 
 
6.1.2. The other studies (Paper II-V)  
The three health surveys were performed by the National Health Screening 
Service (SHUS), today a part of The Norwegian Institute of Public Health, in 
collaboration with HUNT Research Centre and the administration of Nord-Trøndelag 
County (HUNT 1 and HUNT 2); the Faculty of Medicine, the Norwegian University 
of Science and Technology (NTNU) (HUNT 2); the University of Bergen (HUSK); 
and regional health services (all surveys). All surveys were carried out in a two-stage 
sequence: First, all individuals in the source populations were invited to participate by 
a posted letter including the first questionnaire (Appendix I, III, V). The invitation file 
was created from periodically updated census data from Statistics Norway. At 
attendance the questionnaire was handed over to the survey staff who checked the 
questionnaire for completeness. The participants then underwent a brief physical 
examination, which was performed by two teams visiting each municipality of the 
county. All clinical examinations were performed indoors at comfortable room 
temperature. The team surveying the largest municipalities used more extensive 
standard office facilities; the other team working in the smaller municipalities used a 
large, well-equipped trailer with efficient temperature regulation and other modern 
facilities. In HUNT 1 a chest x-ray was taken as well, and in HUNT 2 and HUSK 
blood samples were drawn and stored. The participants were given a second 
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questionnaire (Appendix II, IV, VI) which they could fill in and deliver on the spot or 
bring home for completion before returning it by prepaid mail. 
 
6.1.2.1. The Nord-Trøndelag Health Study 1984-86 (HUNT 1)  
HUNT 1 (182) was the first health study in Nord-Trøndelag County, primarily 
designed to cover four areas, i.e. on hypertension, diabetes, lung diseases and quality 
of life. All 87,285 inhabitants > 20 years were invited to take part, of these 74,599 
individuals participated, yielding a participation rate of 88%.  
 
6.1.2.2. The Nord-Trøndelag Health Study 1995-97 (HUNT 2)  
HUNT 2 (1) was both a follow-up of HUNT 1, with identical or similar 
questions and assessments of hypertension, diabetes and quality of life, but in addition 
HUNT 2 was much more comprehensive collecting more data on each participant 
covering an extensive range of topics. Of 92,100 eligible individuals aged 20-89 
years, 65,648 (71%) participated.  
 
6.1.2.3. The Hordaland Health Study 1997-99 (HUSK)  
In HUSK all individuals in Hordaland county born 1953-57 (N=29,400) were 
invited. A total of 8,598 men and 9,983 women participated, yielding a participation 
rate of 57% for men and 70% for women. The study also included 2,291 men and 
2,558 women born 1950-51 and 1,868 men and 2,470 women born 1925-27, who had 
participated in an earlier study in 1992-93 (the homocysteine cohort). Participation 
rates in these groups were 73%, 81%, 79%, and 76%, respectively.  
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6.2. STUDY POPULATIONS 
This dissertation includes four study populations, those in Paper II and III 
were almost identical: 
 
Paper II: The study population was sampled from HUNT 2: Among the 65,648 
participants those with both valid HADS-A and HADS-D ratings (N = 61,216; 47% 
males) were selected.  
 
Paper III: The study population was sampled from HUNT 2: Among the 
65,648 participants the 60,869 individuals who had valid ratings of HADS as well as 
of the somatic variables in question were selected. 
 
Paper IV: The study population was sampled from the homocysteine cohort in 
HUSK consisting of 7,072 participants (77% of those invited). 
 
Paper V: Individuals participating in both HUNT 1 (baseline) and HUNT 2 
(follow-up) with valid scores of mental distress (Anxiety-Depression Index-12, ADI-
12, see section 6.3.1.2.) at baseline, and valid information on educational level were 
selected (N=36,150). The sample was further divided into two cohorts by the 80th 
percentile of ADI-12 at baseline: The incident cohort (N=29,463) was selected by 
ADI-12 < the 80th percentile; the persistent cohort (N=6,687) was selected by ADI-12 
> the 80th percentile. The selection procedure is illustrated in figure 5. 
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Figure 5:The selection procedure for the study population in Paper V.  
    a Anxiety-Depression Index-12, see section 6.3.2. 
    b Deceased or moved out of the county during the follow-up period. 
Eligible for HUNT 1 (1984-86)
age 20-69 years
N=71,991
Attended HUNT 1:
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With valid ADI-12a score
N=51,295
Incident cohort
N=29,463
ADI-12 score < 80th percentile:
N=41,036
ADI-12 score > 80th percentile:
N=10,259
Persistent cohort
N=6,687
7,548 not attending
13,148 without valid ADI-12 a score
5,040 1,670
5,490
977
89
1,516
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32
Not eligibleb for HUNT 2
Not attending HUNT 2
Not valid HADS scores
Not valid information on
education
Attending both HUNT 1 and 2
N=30,506
Attending both HUNT 1 and 2
N=7,073
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6.3. VARIABLES 
6.3.1. The Hospital Anxiety and Depression Scale (HADS) (All papers)  
HADS is described in section 4.2.6. and the examination of its psychometric 
and case-finding properties is the objective of Paper I. However, its application in the 
other studies will be described here.  
When applied as continuous measures the anxiety and depression subscales 
(HADS-A and HADS-D) were used without consideration to each other in the 
analyses (Paper II). However, when defining anxiety-depression categories, the other 
scale was most often taken into consideration (Paper II-V). Hence, “pure” anxiety 
disorder was defined as HADS-A > 8 restricting HADS-D < 8, and vice versa. To 
evaluate the influence of the other subscale score even in the < 8 range, it was 
included as a covariate in a set of the analyses as well (Paper II and V). Comorbid 
anxiety disorder and depression (or only “comorbid disorder”) was defined by scores 
> 8 for both HADS-A and HADS-D. To illustrate the impact of not considering the 
other subscale a set of analyses was performed on anxiety disorder and on depression, 
respectively, without restrictions of the other subscale (Paper II and V). The 
differences in the resulting estimates in analyses wit or without consideration of the 
other subscale, is illustrated in figure 8 and in figure 4 in Paper II. The relation 
between anxiety and depression symptoms was expressed by the ratio between 
HADS-A and HADS-D, the Anxiety-Depression ratio, as illustrated in figure 2 and in 
figure 1 in Paper II.  
While anxiety and depression were the outcome in most analyses, in Paper II 
they were treated as exposure variables. 
 
6.3.2. The Anxiety Depression Index 12 (ADI-12) (Paper V) 
In HUNT 1 there was no direct measure of anxiety and depression included. In 
order to get an evaluation of these symptoms, the Anxiety-Depression Index (ADI-12) 
was composed out of 12 questions in HUNT 1 addressing different aspects of anxiety, 
depression, life satisfaction, and personality (Appendix I, II). Individuals having 
answered at least eight of the 12 questions were given valid ADI-12 scores. These 
were calculated as the mean of the z-scores of the 12 ADI questions, which had been 
weighted by their correlation with the one factor extracted from a principal 
component analysis. In a follow-up study of 6,380 participants four years after HUNT 
1 where these 12 questions were repeated, the ADI-12 scores predicted 67% of the 
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variance of the Hopkins Symptom Checklist (SCL-25) scores (183). ADI-12 was, 
therefore, considered a valid measure to divide the cohort in HUNT 1into a mentally 
healthy sample (the incident cohort) by ADI-12 score < the 80th percentile and a 
sample with more symptoms of mental distress (the persistent cohort) by ADI-12 
score > the 80th percentile. ADI-12 was also used to adjust for mental distress level at 
baseline within each of the two cohorts. 
 
6.3.3. Impairment due to chronic health problems (Paper II-III) 
In HUNT 1 and 2 (Questionnaire 1, Appendix I, III) the participants were 
asked whether they had any chronic (lasting at least one year) physical or mental 
disease or injuries that impaired their daily life functioning. Subjects checking “no” (n 
= 56,992) were categorised as not being impaired. Those who checked “yes” were 
further required in the questionnaire to rank their impairment into “little”, “moderate” 
or “much” due to impairment of either movement, reduced sight, reduced hearing, 
somatic disease, or mental health problems. Subjects checking “moderate” or “much” 
due to mental health problems in HUNT 2 (Paper II) were categorised as being 
impaired due to mental health problems. Those who checked “little” were categorised 
as not being impaired. Impairment due to chronic somatic illness in HUNT 1 (Paper 
V) was categorised by an identical procedure. 
 
6.3.4. Educational level (Paper III and V) 
In paper V the level of education was the main variable of exposure. 
Considering that not all participants had finished their education at the time of HUNT 
1, we composed a common educational level variable for HUNT 1 and HUNT 2, by 
choosing the highest level from the two if there was a discrepancy. Although 
educational level was divided into eight categories in HUNT 1 and five in HUNT 2 
(Appendix  II, III) we could combine the categories into three common levels: 
Primary school (< 10 years), high school (10-12 years) and college or university (> 12 
years). When information of education was missing at HUNT 1 the reported level 
from HUNT 2 was substituted, and vice versa. Further, a variable that identified 
individuals reporting a higher level of education at HUNT 2 than at HUNT 1 (from 
primary to high school, or from high school to college or university) was used to 
examine the relation between level of mental distress at HUNT 1 and additional 
educational attainment during the follow-up period. 
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As a proxy for socioeconomic status (SES) the educational level was included 
as a covariate to adjust for possible confounding in paper IV. There were six 
educational categories in HUSK (Appendix V), which were combined to three main 
categories (< 10; 10-12; > 12 years) similar to the categories used in paper V. 
 
6.3.5. Somatic health and health behaviours (Paper III) 
In the HUNT 2 questionnaire (Appendix III) somatic diseases were defined as: 
“Do you have or have you ever had the following disease?”. Several somatic diseases 
were addressed in the questionnaire. However, the aim of the study was not to make 
an exhaustive examination of them all, but rather to illustrate the associations between 
comorbid anxiety/depression and somatic health problems. Hence, these five were 
included in the paper: myocardial infarction, stroke, diabetes, migraine, and 
fibromyalgia. Some other somatic symptoms, health behaviours, and measurements 
were included as well. Musculoskeletal symptoms were reported as pain and/or 
stiffness in muscles of at least 3 months duration in the last year, and cardiovascular 
symptoms implied report of palpitations or breathlessness the last year. Impairment 
due to somatic illness was entirely based on the subjective reports of the respondents 
(see section 6.3.3.). Smoking was defined as daily consumption of any number of 
cigarettes. Low physical activity was defined as neither easy nor hard leisure time 
physical activity. Alcohol problems (Appendix IV) implied positive response to at 
least one of the five items of the CAGE screening instrument (184). High Body Mass 
Index (BMI) was defined as > 30kg/m2. Hypertension was defined as systolic blood-
pressure > 140 mmHg and/or diastolic blood-pressure > 90 mmHg, based on the mean 
of the second and the third measurement at the HUNT 2 examination.  
 
6.3.6. Variables related to folate metabolism (Paper IV) 
Plasma total homocysteine (tHcy) was analysed by High Performance Liquid 
Chromatography (HPLC) and fluorescence detection (185) and divided into four 
categories (< 9.0 µmol/L [reference], 9.0 - 11.9 µmol/L, 12.0-14.9 µmol/L, > 15.0 
µmol/L) (186), which corresponded approximately to the 0-30th, 30th-5th , 75th-90th and 
90th-100th percentiles.  
Plasma folate was determined by a Lactobacillus casei microbiological assay 
(187) and divided into four categories corresponding to the 0-10th, 10th-25th, 25th-70th 
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and 70th-100th percentiles: < 3.80 nmol/L, 3.80-4.99 nmol/L, 5.00-8.49 nmol/L, > 8.50 
nmol/L (reference).  
Plasma cobalamin was determined by a L. leichmannii microbiological assay 
(188) and divided into four categories similar to the folate percentiles: < 230.0 
pmol/L, 230.0-279.9 pmol/L, 280.0-414.9 pmol/L, > 415.0 pmol/L (reference). Both 
the folate and cobalamin assays were adapted to a microtiter plate formate and carried 
out by a robotic workstation (Micro-lab AT plus 2; Hamilton Bonaduz).  
Genotyping of the methylenetetrahydrofolate reductase (MTHFR) 677C!T 
polymorphism into the CC, CT and TT variants was performed by a real-time 
polymerase chain reaction (PCR) (189). 
 
6.3.7. Potential mediators for the education – anxiety/depression association  
         (Paper V) 
 HUNT 1 included self-reported information on somatic health, use of health 
services, health behaviours, psychosocial factors, and sociodemographic and work 
characteristics (Appendix I, II). These characteristics might be assumed to be 
consequences of educational level or SES, and if associated with anxiety or 
depression at follow-up, they would be intermediate variables, or mediators. 
However, they might be assumed as confounders as well (100), and, therefore, they 
were denoted “potential mediators”. No matter what, we included them in the 
analyses to examine their effect on the associations. 
At baseline, current or former diabetes, myocardial infarction, angina pectoris 
and stroke were reported. The three latter were combined to denote cardiovascular 
disease. Daily impairment due to chronic physical illness or injury was dichotomised 
into “Not impaired” and “Impaired”. Use of analgesics was defined as daily or weekly 
use during the last month. Having visited a general practitioner or other physician 
during the last 12 months and having been hospitalised during the last five years, were 
the two measures for use of health services. Problems with falling asleep or other 
sleep disturbances frequently or almost every night were characterised as “Sleep 
problems”. Calculation of Body Mass Index was based on data from the clinical 
examinations and categorised by two cut-offs, > 25kg/m2 and > 30kg/m2. Physical 
exercise was defined as at least weekly practising. Daily smoking was compared to 
less frequent smoking/not smoking. High alcohol consumption was defined as use of 
alcohol ten of the 14 last days. Psychosocial factors included whether the respondents 
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felt lonely, or had available social support in case of long-lasting illness requiring bed 
rest. Sociodemographic characteristics included whether they were living alone and/or 
were separated or divorced. Work characteristics included dichotomised variables as 
to whether the respondents considered their job to be stressful, whether the job 
allowed influence on the planning of one’s work, whether they were satisfied with 
their job, and whether they were unemployed.  
 
 6.3.8. Age (Paper II-V) 
Age was somewhat differently categorised in the various studies: In paper II 
and III age (20-89 years) was categorised into seven ten-year groups, and in paper V 
into three HUNT 1 age groups (20-34, 35-49, 50-69 years). In paper IV the age 
groups of the homocysteine cohort (46-49 70-74 years) were kept unchanged.  
 
6.3.9. Other covariates (Paper IV) 
Smoking status in HUSK was dichotomised separating daily smokers from 
non-smokers similarly to the procedure for the smoking variable in HUNT 1 and 
HUNT 2.  
Coffee consumption was tricotomised into the following categories: 0, 1-5, > 5 
cups per day. 
Physical exercise was categorised somewhat differently in HUSK than in 
HUNT 2, namely at least one hour easy or some hard exercise weekly outside job. 
Body Mass Index was divided into the following categories: < 20.0, 20.0-24.9, 
25.0-29.9, > 30 kg/m2.  
As in HUNT 1 and 2 somatic diseases were asked for in the HUSK 
questionnaire (Appendix V) by the standard formulation: “Do you have or have you 
ever had the following disease?”. Individuals checking “Yes” for myocardial 
infarction, angina pectoris, or stroke were categorised as having cardiovascular 
disease.  
In the HUSK questionnaire the respondents were asked whether they had 
taken any medicines or vitamin supplements “yesterday”, and if “Yes”, they were 
asked to write down their names (Appendix V). All individuals who were taking any 
B-vitamin supplement, tranquilliser or antidepressant, were categorised as their 
respective users. These variables were added as covariates to the multivariate models 
estimating the association between the folate-related compounds and anxiety or 
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depression. Use of B-vitamin supplements was additionally examined as a “predictor” 
for anxiety or depression.  
 
6.4. STATISTICAL ANALYSES 
6.4.1. General considerations 
To adjust for possible confounding we chose statistical multivariate 
approaches allowing for simultaneous adjustment of several covariates. The choice of 
statistical methods was also influenced by our approach to anxiety and depression, 
which mainly was categorical defining anxiety disorder, depression and comorbid 
disorder by certain cut-off values of HADS-A and HADS-D scores (see section 
6.3.1.).  
The categorical approach was considered to be the more appropriate when 
studying possible risk factors (Paper IV-V) for two reasons: First, we were interested 
in clinically relevant outcomes and, second, we would give priority to an effect 
measure that could be easily interpreted. However, considering the possible 
confounding effect of co-occurring depression when addressing anxiety, and vice 
versa, “pure” anxiety or “pure” depression and combined categories were explicitly 
defined (see section 6.3.1). The effect measure from the categorical approach 
applying logistic regression models was odds ratio (OR) with a corresponding 95% 
confidence interval for being a case when increasing the value of the explanatory 
variable by one unit, or when having a value of the explanatory variable (indicator 
variable) compared to its reference value . The representation of covariates as 
indicator variables was used to allow for assessment of non-linear dose-response 
relationships while a linear (1 df) representation was used to test for linear trends 
(Paper IV and V). In general, adjustments for age and gender were included in all 
models. Likewise, interaction terms were added separately to all models to evaluate 
effect modification of age and gender. In all analyses, except those in paper III, binary 
logistic regression models were applied. In contrast to binary, multinomial regression 
models allowed the outcome variable to have more than two values. The 
interpretation of the ORs was similar to binary logistic regression.  
When studying the relation between anxiety and depression (Paper II) a 
dimensional approach was also applied, which implied exploration of the whole range 
of scores. For that purpose we used generalised logistic regression, which is based on 
the generalised additive model (GAM) (190). GAM is helpful when exploring the 
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dose-response relation between a continuous measure, e.g. HADS scores, and a 
categorical outcome measure adjusting for covariates. The outcome is presented as a 
plot (“GAM curves”) of ORs on a log scale where the reference value (OR = 1.00) 
corresponds to the mean value of the explanatory variable.  
The precision of the OR estimates in the logistic regression analyses was 
expressed with 95% confidence intervals. A two-sided p-value < 0.05 was chosen to 
indicate statistical significance. The statistical analyses were conducted using the 
software package of S-Plus 6.0 (GAM-curves) and SPSS 11.0-11.5 (all other 
analyses). 
 
6.4.2. Analyses applied in the separate papers 
Paper I. In studies reporting pairs of sensitivity and specificity at several cut-
off values of HADS-A and HADS-D, Receiver Operating Characteristics (ROC) 
curves were plotted by us. ROC curves may guide the decision of the cut-off score 
that yields the optimal balance between sensitivity and specificity (46). The ROC 
method produces an overall measure of the efficiency of the test defined by the Area 
Under the Curve (AUC). Approximations of AUC were calculated by summarising 
the areas of trapeziums occurring between two sequential cut-off points on the curve 
(the trapezium rule) (191). An AUC value of 0.50 is reflecting a test that is unable to 
discriminate between cases and non-cases, while a value of 1.00, means perfect 
sensitivity and specificity at all cut-off values. In order to summarise the findings, 
optimal cut-off values as well as sensitivity and specificity from each study were 
weighted by their respective numbers of subjects, and means were calculated. 
 
Paper II. Associations between anxiety and depression as dimensional 
quantities and impairment due to chronic mental health problems were examined by a 
dose-response approach (GAM-curves) adjusting for age and gender. The “effect” of 
anxiety on impairment was evaluated in individuals with HADS-D scores < 8 and > 8, 
respectively. Likewise, the dose-response “effect” of depression was evaluated in the 
corresponding anxiety categories. ORs (95% CI) for impairment due to chronic 
mental health problems were estimated for five different anxiety/depression 
categories (see section 6.3.1.), compared to a non-anxiety/depression category, using 
logistic regression models adjusting for age and gender. To examine the effect of co-
occurring below-threshold depressive symptoms (HADS-D < 8) in pure anxiety 
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disorder, and vice versa, two models adjusting for HADS-D and HADS-A scores, 
respectively, were added.  
 
Paper III. Logistic regression analysis was used to estimate ORs between the 
somatic health variables and the categories of anxiety and depression.  
 
Paper IV. Logistic regression analyses were used to estimate ORs for being a 
case comparing each category to the reference category of the metabolites and the 
MTHFR polymorphism. Two logistic regression models were used, one with 
adjustment for age and gender (Model 1) and one with additional adjustments for 
smoking status and educational level (Model 2). The effects of other possible 
confounders, such as coffee consumption, physical exercise, Body Mass Index, and 
self-reported cardiovascular disease, were examined by adding these one by one to 
model 2. Possible effect modification of B-vitamin supplementation or tranquilliser or 
antidepressant use was evaluated by stratification. To examine whether use of B-
vitamin supplements was associated with anxiety or depression logistic regression 
analyses were used to estimate the OR for being a case comparing non-users with 
users, after adjusting for age, gender, smoking status and educational level. GAM-
curves adjusted for age, gender, smoking status, and educational level were used to 
provide graphical representations of the dose-response relations of plasma folate, 
cobalamin, and tHcy to anxiety or depression. 
 
Paper V. Logistic regression analyses were used to estimate ORs for being a 
case of the various anxiety/depression categories at follow-up, comparing the two 
lower educational levels separately to the highest. Most analyses were performed 
separately for the incident and persistent cohorts. Two logistic regression models were 
used, one with adjustment for age and gender (Model 1) and one with additional 
adjustment for mental distress (ADI-12 score) at baseline (Model 2). The latter aimed 
to adjust for the variation in ADI-12 score within the cohorts. To examine whether co-
occurring low-score depression symptoms (HADS < 8) in anxiety disorder would 
influence the association between educational level and anxiety disorder, the HADS-
D score was added to the model, and vice versa regarding low-score anxiety 
symptoms (HADS-A < 8) in depression. Moreover, to evaluate possible effect 
modification of age and gender, product terms between these variables and 
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educational level were added separately to Model 2. The effect of the potential 
mediators was examined by logistic regression analyses performed in three steps. 
First, all the mediator variables were added one by one separately to Model 2 for all 
the three anxiety/depression outcome variables. Second, those mediators reducing the 
OR for being a case at the lowest versus the highest educational level with at least 
5%, were included in the analyses to evaluate the combined effect of all the 
mediators. However, to examine the individual effect of the identified mediators in 
the combination, each variable was added to the model after the other(s) were already 
in. Third, the mediators still reducing the OR were included in the final model. One 
aspect of the selection hypothesis was tested by examining whether a high mental 
distress (ADI-12) score at baseline was associated with subsequent less educational 
attainment during the follow-up period in the youngest age group. Hence, a logistic 
regression analysis adjusting for age and gender, which estimated the OR for an 
unchanged educational level at follow-up for individuals in the high-ADI-12 group 
compared to the low ADI-12 group was performed as well. Contrary, the causation 
hypothesis could be supported if lower educational attainment during the 
observational period was associated with anxiety/depression at follow-up. Hence, a 
logistic regression analysis adjusting for age, gender, and ADI-12 score was 
performed, estimating the OR for being a case at follow-up among those with 
unchanged educational level between baseline and follow-up compared to those with 
an increased level. 
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7.  RESULTS OF THE PAPERS 
7.1. PAPER I: The validity of the Hospital Anxiety and Depression Scale. An updated 
literature review . 
After a review of 747 papers found by a literature search in MEDLINE, ISI 
and PsychINFO we examined published reports on HADS regarding factor structure, 
discriminant validity, and the internal consistency, how HADS performed as a case-
finder for anxiety disorders and depression, and how HADS agreed with other self-
rating instruments used to rate anxiety and depression. 
 HADS performed as a bidimensional test, although the factors were not 
absolutely consistent with the subscales of anxiety and depression. Among the 19 
studies reporting factor analysis of HADS, eleven studies (total N=14,588) achieved a 
two-factor structure, five studies (total N=3,459) a three-factor structure and two 
studies (total N=235) a four-factor structure. Two studies from the general population 
both reported a two-factor structure (total N= 6,017). One of these found that the two-
factor solution was stable across different age groups from the general population and 
in different clinical samples. The other found the same two-factor structure for both 
males and females. 
21 studies reported the Pearson correlation coefficient between HADS-A and 
HADS-D (mean 0.56). In seven studies of non-patient samples the correlations varied 
between 0.49 and 0.74 (mean 0.59). In 12 studies of somatic patient samples the 
correlations varied between 0.40 and 0.64 (mean 0.55). The two studies of psychiatric 
patients both achieved a correlation of 0.56.  
 Cronbach’s coefficient alpha of internal consistency was reported in 15 
studies and varied for HADS-A from 0.68 to 0.93 (mean 0.83), and for HADS-D 
from 0.67 to 0.90 (mean 0.82). 
 In most studies an optimal balance between sensitivity and specificity was 
achieved when caseness was defined by a score of 8 or above on both HADS-A and 
HADS-D. The weighted means of cut-offs were 8.01 for HADS-A and 8.04 for 
HADS-D. The sensitivity and specificity for HADS-A were 0.79 and 0.83, 
respectively, and for HADS-D 0.76 and 0.83, respectively, which was similar to the 
sensitivity and specificity achieved by the GHQ. Figure 6, which is taken from the 
paper of elRufaie and Absood (192), illustrates how ROC curves for HADS-D and 
HADS-A demonstrated the screening properties at various cut-off values. In that 
study AUC was calculated to 0.86 for both subscales. Correlations between HADS 
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and other commonly used questionnaires (Beck’s Depression Inventory, GHQ, 
Clinical Anxiety Scale, Spielberger’s State-Trait Anxiety Inventory, Symptom Check 
List-90, Montgomery Asberg Depression Rating Scale) were in the range 0.49 - 0.83.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.2. PAPER II: A dimensional versus a categorical approach to co-
occurring anxiety and depression: The HUNT study 
  Data from 61,216 individuals aged 20 to 89 years in HUNT 2 with valid 
ratings of HADS were analysed to explore the occurrence of anxiety and depression 
as codimensions and to examine how co-occurring anxiety and depression was 
associated with impairment in a dimensional approach compared to a categorical one.  
 We found that mean anxiety scores in general exceeded mean depression 
scores in both genders, however, less markedly by increasing age, which was 
demonstrated by the mean AD ratio (figure 1 in paper II). In general, women achieved 
higher anxiety scores, and marginally lower depression scores than men. The relation 
between anxiety and depression scores was close to linear.  
 The dimensional approach revealed a dose-response relation between anxiety 
symptoms and impairment in the high-score as well as in the low-score depression 
categories. A similar relation was seen between depression symptoms and impairment 
in the anxiety categories.  
Figure 6: Receiver Operating Characteristics (ROC) curves showing the case-finding 
properties of HADS-D and HADS-A in a sample of 217 primary care patients (192). 
Numbers in circles are cut-off values (>).The external criteria were anxiety disorders and 
major depression according to DSM-III (Clinical Interview Schedule). 
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 The categorical approach demonstrated that all the anxiety/depression 
categories were associated with chronic subjective impairment, more in younger than 
older age groups. The two anxiety categories were more strongly associated with 
impairment than the depression categories and the comorbid category more than the 
others. 
 The dimensional approach demonstrated the impact of co-occurring symptoms 
in the entire range of scores, even in the lower part. This finding indicates that the 
categorical analyses should be performed and interpreted with caution. Our results 
showed that depression without any anxiety restriction was more than twice as 
strongly associated with impairment as pure depression. Hence, ignoring the degree of 
co-occurring anxiety would induce a significant bias. Even in pure depression the co-
occurring sub-threshold anxiety symptoms contributed as much as the depression 
itself to the association with impairment.  
 
7.3. PAPER III: Anxiety and depression in individuals with somatic 
health problems. The Nord-Trøndelag Health Study (HUNT) 
 To examine the relationship between anxiety disorders and 
depression and various somatic health problems in the general population 
we used data from 60,869 individuals aged 20-89 years in HUNT 2.  
Among those reporting somatic health problems, about one-third also had 
anxiety disorder and/or depression. Subjective impairment due to somatic symptoms 
as well as myocardial infarction, diabetes, migraine, fibromyalgia, musculoskeletal 
symptoms, cardiovascular symptoms, smoking, and low physical activity were all 
more strongly associated with comorbid anxiety disorder and depression than with 
pure anxiety disorder and pure depression, in both genders. The strongest associations 
were seen for cardiovascular symptoms, fibromyalgia, musculoskeletal symptoms, 
and impairment due to somatic symptoms. There were, however, some few 
exceptions: Stroke and high BMI were more strongly associated with pure depression 
than the comorbid condition, and alcohol problems were more strongly associated 
with pure anxiety disorder. High BMI and little physical exercise were more strongly 
associated with pure depression than pure anxiety, while the opposite was seen for 
musculoskeletal symptoms, smoking, alcohol problems, and cardiovascular 
symptoms. 
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7.4. PAPER IV: Folate, cobalamin, homocysteine and the MTHFR 677C→T 
polymorphism in anxiety and depression. The Hordaland Homocysteine study. 
 We investigated the association between key components of folate 
metabolism and anxiety disorders and depression in a cohort of 7,072 subjects.  
 The strongest relationship was observed between the TT MTHFR genotype 
and depression, and the association was present for both cut-off levels of depression 
(HADS-D > 8: OR = 1.69 [95% CI 1.09-2.62]; HADS-D > 11: OR=2.75 [95% CI 
1.20 - 6.32]). Significant associations were observed between hyperhomocysteinemia 
(plasma total homocysteine > 15.0 µmol/L) and depression (OR = 1.90 [95% CI 1.11-
3.25]) and between the lowest level of cobalamin (< 230.0 pmol/L) and depression 
with high cut-off (HADS-D > 11) (OR=2.39 [95% CI 1.07 - 5.36]). Borderline 
significant associations were found between depression and low folate levels (< 3.80 
nmol/L) (OR=3.05 [95% CI 0.96- 9.65]) among middle-aged women. No significant 
relations were seen between anxiety disorder, or comorbid anxiety disorder and 
depression, and tHcy, folate, cobalamin or MTHFR genotype. 
 
7.5. PAPER V: Education as predictor for anxiety and depression. A 
population-based cohort study. 
In a study of 36,150 individuals aged 20-69 years from HUNT 1 we examined 
whether educational level in those with low and high levels of mental distress at 
baseline was associated with anxiety and depression after a follow up period of 11 
years, assessed in HUNT 2. We also wanted to identify mediators if significant 
associations were found. 
There was a strong association between ADI-12 scores at baseline and HADS 
categories at follow-up (figure 7). 
Educational level was inversely associated with depression and comorbid 
disorder at follow-up, in both the incident and persistent cohorts, and, among younger 
women with anxiety disorder in the incident cohort. A significant gradient (p < 
0.001), demonstrated by the trend tests, was found from the highest to the lowest 
educational level. The associations were only modestly affected by the potential 
mediators (table 1). Adjusting for HADS-D and HADS-A scores at follow-up in the 
analyses of anxiety disorder and depression, respectively, resulted in a markedly 
reduction in the ORs for the lowest educational level for anxiety disorder in the 
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incident cohort. The other outcome categories were less affected. An illustration of 
the ORs for being a case at follow-up among individuals in the lowest compared to 
the highest educational group is presented in figure 8. 
A high mental distress (ADI-12) score at baseline was inversely but weakly 
associated with unchanged educational level during the follow-up period. Additional 
educational attainment during the observation period was not significantly associated 
with anxiety/depression at follow-up.  
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Figure 7: Dose-response relationships between ADI-score at baseline and HADS 
categories at follow-up 11 years later. The ORs that constitue the curves are 
estimated by a generalised additive model (GAM), which has adjusted for age and 
gender. Dotted lines represent pointwise 95% confidence intervals. 
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Figure 8: Risk (OR) for being a case of various categories of anxiety disorder and 
depression at follow-up among individuals in the lowest educational group 
compared to the highest educational group. Comorbid, HADS-A > 8 and HADS-D 
> 8; Unrestricted, HADS-A > 8 or HADS-D > 8; Restricted, HADS-A > 8 and 
HADS-D < 8, or HADS-D > 8 and HADS-A < 8; Adjusted, Restricted adjusted by 
HADS-D or HADS-A score. 
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Table 1: Adjusteda ORs for being a case in the lowest (primary school) educational 
group compared to the highest (college/university) before and after introduction of the 
various identified mediatorsb in the models.  
 
 Model without 
mediators 
Model with identified 
mediators 
 Identified mediators OR 95% CI OR 95% CI 
INCIDENT COHORT     
 Anxiety disorder: 
Daily smoking 
1.34 1.16-1.55 1.28 1.11-1.49 
 Depression: 
Low physical activity 
1.86 1.54-2.25 1.81 1.49-2.19 
 Comorbid disorder: 
Daily smoking, low physical activity 
1.97 1.59-2.44 1.88 1.51-2.33 
PERSISTENT COHORT     
 Anxiety disorder: 
Daily smoking, impaired due to 
somatic disease, use of analgesics, 
unemployment 
1.17 0.92-1.50 1.15 0.89-1.48 
 Depression: 
Lack of social support 
1.80 1.32-2.44 1.75 1.29-2.38 
 Comorbid disorder: 
Daily smoking, use of analgesics 
1.69 1.33-2.15 1.62 1.28-2.07 
 
a Before introduction of the mediators, the models were adjusted for age, gender and 
ADI-12 score, the latter due to its variation within each cohort.  
b Mediators reducing the risk for being a case at the lowest educational level 
compared to the highest with at least 5 percent (mediators that did not contribute to a 
reduction in OR when introduced into the model after the other mediators, were 
excluded) 
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8. GENERAL DISCUSSION 
The scope of this dissertation covers several areas of investigation. The 
common feature is, however, how anxiety and depression can be examined in 
epidemiological studies. Such observational studies have limitations as to design and 
potential biases in terms of systematic errors regarding selection of participants, 
information obtained, and confounding factors. These limitations will be discussed in 
the following sections. Further, the findings from our studies will be compared to 
those of others, and discussed in more detail.  
 
8.1. METHODOLOGICAL CONSIDERATIONS 
8.1.1. Study design 
In analytic epidemiology, aiming to test hypotheses, a longitudinal study 
design is necessary to observe the influence of exposures on health over time. Cross-
sectional health surveys are, however, designed for more descriptive purposes such as 
estimating prevalence of different health related problems. All but one of our studies 
had a cross-sectional design, nevertheless, their aims were beyond solely prevalence 
estimates. By examining associations between anxiety and depression, and other 
measures, new hypotheses could be generated, which might be subject for later testing 
in longitudinal studies. However, in cross-sectional studies an element of longitudinal 
information may be achieved by collecting information retrospectively, which was 
done in all the current surveys. Moreover, in studies examining the effects of genetic 
factors by DNA analyses (Paper IV) a cross-sectional design would be appropriate 
because such factors are not modified by environmental influence.  
By combining data from consecutive health surveys in the same population a 
longitudinal design can be achieved, which was done by linking the data sets from 
HUNT 1 and HUNT 2, (Paper V). However, in order to evaluate the incidence of the 
outcome to be studied at follow-up, the occurrence of the same variable, or a proxy 
for it, must be known at baseline. The questionnaire used in HUNT 1 did not contain 
the HADS items, nevertheless, there were items on various aspects of relevance to 
mental health. Hence, it was possible to establish an index for mental distress, ADI-12 
(see section 6.3.2). The ADI-12 score was used primarily to define a cohort that was 
mainly mentally healthy (incident cohort) at baseline by excluding the upper quintile 
of ADI-12 scores. The upper quintile (persistent cohort) was examined  to address the 
chronicity of mental distress. Self-report of educational level at both baseline and 
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follow-up enabled analyses of educational attainment during the observational period 
as well.  
 
8.1.2. Selection bias 
When the association between the two factors to be examined is different in 
the participants and the non-participants, the selection of participants has resulted in a 
systematic error, or a selection bias (101). Information about differences between 
participants and non-participants is helpful when considering such bias, and such 
information will be discussed in this section.  
In HUNT 1 and 2 there was a characteristic pattern as to participation rates (1): 
the younger and older age groups were under-represented, and among the younger 
and middle aged groups (up to 50 years in HUNT 1 and 60 years in HUNT 2) men 
were under-represented (figure 9). Further, the proportion of missing data for various 
variables increased in older age. The proportions missing varied between the different 
variables, possibly due to differences in how easily the questions and their 
corresponding answer alternatives could be understood. In the homocysteine cohort of 
HUSK the participation rates were lowest in the youngest age group (46-49 years) and 
among men.  
In 1997 a 2.5% random sample of non-participants (n=685) in HUNT 2 were 
selected shortly after the data collection for a non-participant study (193). Non-
participants were contacted and asked to give their reasons for not participating (table 
2). Information was obtained from 291 individuals (42%). In the youngest age group 
(20-44 years) the most common reasons were having moved out of the county (31%), 
lack of time (22%), or they had forgotten the invitation, or had no reason (19%). 
Among the oldest (> 70 years), reasons included being under the care of a 
physician/hospital (thus, no need to participate in a health study) (29%), having 
moved out of the county (21%), or being immobilised by disease (21%). Generally, 
the participation rate was better in HUNT 1 than in HUNT 2  (figure 9).  
In the cohort study of participants in HUNT 1 re-examined in HUNT 2 (Paper 
V), the baseline differences between participants and non-participants in HUNT 2 
(20-69 years at baseline) were examined (table 3). The non-participant group included 
significantly more men, more individuals in the youngest and oldest age groups, as 
well as people with less education and higher ADI-12 scores. Non-participants had 
significantly more unfavourable characteristics with regard to somatic health, health 
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behaviours, and sociodemographic characteristics, with the exception of a lower 
proportion reporting a stressful job and having little influence on the planning of their 
work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Reasons for non-participation in HUNT 2 (193) 
 20-44 years 45-69 years >70 years  Total 
Reasons for non-participation n (%) n (%) n (%)  n (%) 
Follow-up by physician/hospital 11 (5.8) 10 (13.7) 8 (28.6)  29 (10.0) 
Long waiting at screening site 8 (4.2) 4 (5.5) 0 (0.0)  12 (4.1) 
Busy at job 42 (22.1) 18 (24.7) 2 (7.1)  62 (21.3) 
Immobilised by disease 16 (8.4) 6 (8.2) 6 (21.4)  28 (9.6) 
Moved, or long time absent 59 (31.1) 10 (13.7) 6 (21.4)  75 (25.8) 
Forgot/no reason/other 36 (18.9) 21 (28.8) 3 (10.7)  60 (20.6) 
Unnecessary/unwilling 18 (9.5) 4 (5.5) 3 (10.7)  25 (8.6) 
Total 190 (100.0) 73 (100.0) 28 (99.9)  291 (100.0) 
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Figure 9: Participation rates in various age and gender groups in HUNT 1 and 
HUNT 2 (1). 
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Table 3: A comparison between attendees a and nonattendees b in HUNT 1 and HUNT 2. 
 
 Attended HUNT 1 
and HUNT 2 
Attended HUNT 1 but 
not HUNT 2 
 n (%) c n (%) d 
Men 17,706 (47.1) 7,866 (57.3)** 
20-34 years 10,757 (28.6) 4,582 (33.4)** 
35-49 years 13,211 (35.2) 3,131 (22.8)** 
50-69 years 13,611 (36.2) 6,003 (43.8)** 
Primary school 16,059 (42.9) 7,275 (54.5)** 
High school 15,536 (41.5) 4,521 (33.9)** 
College/university 5,863 (15.7) 1,554 (11.6)** 
ADI-12 score e > the 80th percentile 30,506 (81.2) 10,530 (76.8)** 
Cardiovascular disease f 972 (2.6) 1,031 (7.5)** 
Diabetes 368 (1.0) 399 (2.9)** 
Impaired due to somatic disease 2,265 (6.9) 1,399 (12.1)** 
Use of analgesics 2,800 (7.7) 1,397 (10.1)** 
Visit to a physician, last year 28,739 (76.5) 10,347 (75.)4* 
Hospital admission, last five years 12,394 (33.1) 4,777 (34.9)** 
Low physical activity 14,798 (40.0) 5,700 (42.6)** 
Sleep problems 2,277 (6.1) 1,130 (8.4)** 
BMI > 25 kg/m2 16,119 (42.9) 6,192 (45.3)** 
BMI > 30 kg/m2 3,249 (8.7) 1,560 (11.4)** 
Daily smoking 12,686 (34.3) 5,986 (44.6)** 
High alcohol consumption g 1,081 (2.9) 491 (3.7)** 
Separated or divorced 1,131 (3.0) 693 (5.1)** 
Living alone 2,556 (6.9) 1,771 (13.1)** 
Lack of social support 6,330 (17.0) 2,782 (20.5)** 
Loneliness 2,005 (5.4) 1,062 (7.8)** 
Stressful job 15,766 (49.2) 4,668 (48.7) ns 
Low job control 10,673 (33.2) 3,112 (32.3) ns 
Job dissatisfaction 1,232 (3.6) 591 (5.4)** 
Unemployment 2,393 (7.0) 1,091 (9.1)** 
 
ns non-significant difference between attendees and non-attendees 
* p < 0.05 for the difference between attendees and non-attendees 
** p < 0.001 for the difference between attendees and non-attendees  
a Participated in HUNT 1 and  HUNT 2 (age 20-69 years at HUNT 1) 
b Participated in HUNT 1, but not in  HUNT 2 (age 20-69 years at HUNT 1) 
c % within the attendees 
d % within the nonattendees 
e Anxiety-Depression Index-12 score measured at HUNT 1 
f Self-reported present or previous angina pectoris, myocardial infarction, or stroke 
g Use of alcohol at least ten of the last 14 days 
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There is some evidence that the non-participants could be divided into two 
main groups; (I) men in the younger age groups who were too busy to participate, and 
(II) elderly individuals of both genders with poor health. Both groups possibly had 
less favourable health behaviours, psychosocial status, and sociodemographic work 
characteristics. Non-participants in another Norwegian health survey have been 
reported to have a higher prevalence of mental disorders (194), the same was also 
found in an analysis of non-participants in the ECA (195) and in the Swedish Survey 
of Living Conditions (196), but not in a health survey of the elderly in Australia 
(197). Hence, the mental and somatic health status in our study populations probably 
was better than the true health status in the total population of same age groups. 
Likewise, the risk factors we examined in Paper IV and V were probably more 
prevalent in the total population. These differences do not necessarily imply that the 
findings in our studies would be different with a higher participation rate. However, 
the “under-representation” of both the risk factors and outcomes (HADS 
anxiety/depression) in question, could have attenuated the associations. 
 
8.1.3. Information bias  
Information regarding exposure or outcome may be subject to information bias 
resulting in systematic error (101). Such information bias is often called 
misclassification if the variable is measured categorically, and the error leads to a 
person being placed in an incorrect category. If the misclassification of an exposure 
variable is related to the outcome, or the misclassification of an outcome variable is 
related to the exposure, the misclassification is differential. Otherwise, the 
misclassification is non-differential. Differential misclassification will either 
strengthen or attenuate the association studied, while non-differential 
misclassification always will have an attenuating effect. 
In studies where most of the information collected is self-reported, there will 
always be some degree of non-differential misclassification. This can be illustrated by 
comparing data from HUNT 1 with HUNT 2 in individuals participating in both 
surveys (the study population in Paper V). In HUNT 2, 12% of the individuals 
reported a higher educational level than in HUNT 1 (from primary school to high 
school, or from high school to college or university). However, another 5% of the 
individuals reported a lower educational level, which must be due to misclassification. 
There were probably misclassified individuals among those reporting a higher 
 57
educational level as well. Hence, the estimated associations between educational level 
and the anxiety and depression categories at follow-up in Paper V were probably 
attenuated, as were the associations between additional educational attainment during 
the observational period and anxiety/depression level at baseline or 
anxiety/depression categories at follow-up. Similar non-differential misclassifications 
probably also occurred for other self-reported variables, due to inaccurate checking of 
answer options, impaired memory, or misreading. Some of the residual confounding 
might be due to such information bias.  
The use of HADS as a screening instrument for DSM-IV or ICD-10 diagnoses 
of anxiety disorders or major depressive disorder may be viewed as another source of 
non-differential misclassification. Using a cut-off of > 8 for both sub-scales will most 
often result in sensitivities and specificities of approximately 0.8. In a population with 
a prevalence of any anxiety disorder of 10%, only 31% of the HADS-A identified 
cases would have such an disorder (table 4). If the prevalence of major depressive 
disorder was 5%, only 17% of the HADS-D identified cases would be correctly 
classified. However, simple rating scales are not expected to have any better positive 
predictive value in populations with a relatively low prevalence of the disorder in 
question. In section 8.2.1. the question as to what HADS really is measuring is 
discussed. Generally, dimensional rating scales not covering the whole syndrome of 
the disorder, but rather some core feature of it, may be as appropriate as conventional 
categorical diagnoses in analytic epidemiological research (102). The estimated 
associations reported in the various papers of this thesis support the notion that cases 
identified by HADS-D cover some central aspects of depression.  
Finally, differential misclassification may have occurred in the studies as well. 
Information from individuals reporting high levels of anxiety or depression might be 
biased. A high anxiety score might be associated with a stronger awareness, 
sensitivity, and worry about somatic symptoms such as pains, palpitations, and 
gastrointestinal, or respiratory symptoms. In Paper III such information bias might 
have resulted in too strong associations between somatic health problems and anxiety 
disorder or comorbid disorder (198). Accordingly, anxiety disorder was not associated 
with the physically measured health problems (high BMI and hypertension), or two of 
the more definite organic diagnoses reported (myocardial infarction and diabetes). 
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8.1.4. Confounding 
 Confounding implies that the effect of an exposure is mixed together with the 
effect of another variable, leading to bias (101). Hence, the confounder must be 
imbalanced between the exposure groups to be compared (i.e. associated with the 
exposure), and associated with the outcome (either as a cause or as a proxy for the 
cause of the outcome). However, the confounder should not be an effect of the 
exposure or the outcome.  
 The effect of a specific confounder can be prevented by selecting individuals 
to a study with restricted values on that variable. Epidemiological studies, however, 
usually aim to select representative population samples, without making such 
restrictions. Hence, in observational studies attempts are made to reduce the effect of 
selected confounders by stratification or by use of various multivariate statistical 
techniques (e.g. regression models). The challenge is, nevertheless, to identify the 
appropriate confounders. Some characteristics, such as age and gender, are well 
known to confound associations between a variety of exposures and outcomes. Hence, 
they are almost routinely adjusted for in observational studies, including the studies of 
this dissertation. Life-style factors, or health behaviours, such as smoking, alcohol 
Table 4: HADS as a screening test in a hypothetical population (N=1000) with a prevalence of 
any anxiety disorder of 10% and major depressive disorder of 5%, given that both HADS-A 
and HADS-D cut-offs of > 8 result in sensitivities and specificities of 0.8.  
 
 Anxiety disorder Major depressive disorder 
Test result Cases Non-
cases 
Total PPV NPV Cases Non-
cases
Total PPV NPV
Positive (n) 80 180 260 0.31  40 190 230 0.17  
Negative (n) 20 720 740  0.97 10 760 380  0.99 
Total (n) 100 900 1000   50 950 1000   
Sensitivity 0.80     0.80     
Specificity  0.80     0.80    
 
PPV  Positive predictive value (proportion of true cases among the test-positive subjects) 
NPV  Negative predictive value (proportion of true non-cases among the test-negative  
subjects) 
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intake, and coffee consumption, as well as physical exercise, are often associated with 
both other exposures under investigation and various diseases or health problem 
outcomes. In our studies these variables were included as confounders in the 
regression analyses in the “risk factor studies” (Papers IV and V). However, as 
defined above, a confounder should not be caused by the exposure or the outcome. To 
rule out such a possibility, a longitudinal design with measurements of the variables 
involved at a minimum of three different times with adequately intervals, is required 
(100). What comes first, low educational level or smoking? In studies addressing 
human behaviour and social phenomena, the sequence of factors is not always 
obvious. Hence, factors associated with both exposure and outcome are often 
considered as mediating the effect of the exposure, rather than confounding it (99, 
100). This problem is addressed in Paper V where the covariates are referred to as 
“potential mediators” suggesting that they might just as well act as intermediate 
variables as confounders. The covariates did, however, not markedly influence the 
association between educational level and anxiety or depression, simplifying the 
interpretation regarding the main results. In that study the covariates were reported at 
baseline, and could therefore not have been caused by the outcome assessed at follow-
up. In the cross-sectional study in Paper IV, however, the health behaviours 
considered as confounders and adjusted for in the analyses (smoking status, coffee-
consumption, and physical exercise), might be the consequence, rather than the cause 
of the outcome (HADS anxiety and depression). If so, some of the associations should 
be minimally stronger (more deviation from the null hypothesis) than reported 
because the adjustments had a minor attenuating effect.  
 In paper II and V the HADS scores were included in some additional analyses 
as covariates (HADS-D when anxiety was the exposure [Paper II] or outcome [Paper 
V], and HADS-A when depression was the exposure or outcome). The general 
prerequisite that a confounder should be associated with both the exposure and the 
outcome, was fulfilled (an association between anxiety and depression, and an 
association between anxiety or depression, and impairment, or educational level). 
However, as illustrated in figure 10, when anxiety or depression is “caused” by the 
exposure or the outcome (indicated by “Yes” in the figure), they are doubtful 
confounders. It is likely that anxiety leads to depression, probably mediated by 
impairment (199, 200). Anxiety disorders due to depression are less probable (200). 
The main finding of Paper V was that low educational level predicted depression (and 
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possibly anxiety disorder), but not the other way round . Hence, the adjustments were 
solely suggestive, and intended not to rule out true confounding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.2. DISCUSSION OF SPECIFIC RESULTS 
8.2.1. Assessment of anxiety and depression (Paper I and II) 
The use of HADS in the current three health surveys will be mainly discussed 
regarding its characteristics as a rating scale reviewed in Paper I, but also as to what 
constructs of anxiety and depression it is reflecting (Paper II). 
Our systematic review of HADS essentially confirmed the findings in 
Herrmann’s paper (45). The majority of studies that applied factor analyses, including 
the largest one with a general population sample, concluded that a two-factor solution 
achieved the better fit. Hence, there is evidence that HADS really is measuring two 
different, though correlated, underlying factors or dimensions of mental distress, 
probably closely related to some core features of anxiety and depression. The 
Figure 10: The role of anxiety and depression as possible confounders in the 
associations addressed in Paper II and V. A confounder must not be caused by 
the exposure or the outcome (indicated by “Yes” or “No”), hence, only in the 
association between depression and impairment due to chronic mental 
problems anxiety may possibly act as a confounder (right top panel). 
a Impairment is probably a predictor of depression (see section 8.2.2.2.) 
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identified factors were not completely consistent with the subscales, however, in a 
factor analysis of HUNT 2 (201) the two factors were identical with the subscales in 
most age and gender strata. The mean correlation between the subscales in our review 
(r = 0.56) was somewhat lower than in Herrmann’s (r = 0.63), but similar to HUNT 2 
(r = 0.55) (201). Other self-report measures of anxiety and depression have been 
correlated with coefficients in the 0.45 to 0.75 range (16). Some authors (202) have 
argued that the correlation between any valid and reliable measure of anxiety and 
depression should be at the 0.70 level, not because of shared symptoms between 
anxiety and depression, but because of a common causal factor. However, other 
authors (16) have claimed that a low correlation between the two measures of anxiety 
and depression is a hallmark of good discriminant validity of a bidimensional test.  
The properties of HADS as a screening test for anxiety disorders or major 
depressive disorder were similar in our and Herrmann’s review. Zigmond and 
Snaith’s original recommendations of a cut-off value of scores > 8 for both subscales 
to identify “possible” cases (41) were confirmed as the cut-off resulting in an optimal 
balance between sensitivity and specificity of approximately 0.8. A similar result was 
achieved in a recent Norwegian study of primary care patients (N=1781) examining 
the screening properties of HADS against DSM-IV major depressive disorder 
(measured by the General Anxiety Screening Questionnaire – GASQ) and generalised 
anxiety disorder (measured by the Depression Screening Questionnaire – DSQ) 
(Ingrid Østby-Deglum, personal communication, 2004). Receiver Operating 
Characteristics (ROC) curves resulted in a very good Area Under Curves (AUC) of 
0.93 and 0.89 for HADS-A and HADS-D, respectively. However, the usefulness of a 
test in a specific population is dependent on the actual prevalence of the condition to 
be identified. As illustrated in section 8.1.3., the positive predictive value is only 17% 
if the prevalence of the disorder is 5%, and 31% if the prevalence is 10%. Hence, the 
properties of HADS as a case finder of anxiety disorders or major depressive disorder 
as defined by ICD-10 or DSM-IV in health surveys of the general population, is 
questionable. Other brief self-report rating scales assessing anxiety and depression do 
not, however, exhibit better case-finding properties (see section 7.1). Still, in studies 
addressing risk factors, some core features of anxiety disorders or depression (variants 
of endophenotypes) may be just as, or even more appropriate outcomes, than the 
whole syndromes (see section 4.4.). 
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Considering the content of the various items in the two subscales (face 
validity) gives a clue of what HADS is measuring: The items of HADS-A are mainly 
reflecting restlessness and worry, as in generalised anxiety disorder, while the items 
of HADS-D are concerned with the reduced pleasure response (anhedonia), which is 
but one of several core diagnostic criteria of major depressive episode in both ICD-10 
and DSM-IV. Anhedonia is by some authors (16, 203) considered to be the most 
characteristic feature of depression, while it has been difficult to identify such a 
common feature for the anxiety disorders (34) Mineka et al). Possibly HADS-A is 
reflecting generalised anxiety disorder more specifically, or mental distress more 
generally. In HUNT 2 there were seven questions addressing general mental distress; 
the CONOR Mental Health Index (CONOR-MHI) (Appendix III), the first seven 
question in the section “Hvorledes føler du deg?”). Correlation coefficients corrected 
for attenuation between CONOR-MHI and HADS-A and HADS-D were 0.91 and 
0.76, respectively (204) supporting the notion that HADS-A is assessing mental 
distress more generally.  
In contrast to other epidemiological studies (205) there was no female, but 
rather a minor male preponderance of depression in HUNT 2 (206) (and HUSK). 
Hence, HADS-D may possibly reflect a gender non-specific depression component. 
Accordingly, in NCS there were only minimal gender differences in depression when 
cases with “somatic” depression were excluded, while the prevalence of the latter 
category was twice as high in women than in men (207). The somatic component of 
depression, consisting of disturbances of sleep, appetite, and weight, were not 
included in HADS in order to avoid diagnostic comorbidity when used in patients 
with somatic illness (41). This feature is specific for HADS and may explain some of 
the similarity in prevalence between genders.  
Even if anxiety and depression may be best characterised and understood as 
dimensional disorders, which were supported by Paper II, a categorical approach was 
applied in the current studies addressing comorbidity with somatic health problems 
(Paper III) and risk factors (Paper IV and V). In epidemiological studies, both 
descriptive and analytical, the outcome usually is a disease entity that can be 
classified as being present or not, which is the prerequisite for quantities such as 
prevalence, incidence, persistence, sensitivity, specificity, and various measures 
assessing risk. The challenge when using a rating scale like HADS is, however, to 
define appropriate cut-off points for anxiety and depression categories. By elevating 
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the cut-off for caseness the specificity and the PPV would increase, and thus reduce 
the number of false positives. Hence, in Paper IV analyses with cut-off of > 11 on 
both HADS sub-scales were performed resulting in stronger associations compared to 
when cut-offs > 8 were used. However, elevating the cut-off value reduces number of 
cases, and thereby the statistical power.  
Another challenge of categorisation is how to manage co-occurring anxiety 
and depression. For example, in the group with HADS-A > 8 there were individuals 
with HADS-D scores in the whole range of the distribution, and vice versa among 
those with HADS-D > 8 (figure 11). By classifying all cases with scores > 8 on both 
subscales in a comorbid disorder category, the anxiety disorder and depression 
categories were made relatively “pure”. However, as illustrated in figure 11, there 
were still considerable co-occurring symptoms (bars to the left of the dotted lines in 
the figure) that probably are of some clinical significance (Paper II). With this 
categorisation the prevalence of anxiety disorder was 11.5%, of depression 4.8%, and 
comorbid disorder 5.2% in the homocysteine cohort (Paper IV), which was very close 
to the revised prevalence estimates from ECA and NCS (comorbidity was not 
addressed in the revised study) (11) (see section 4.1.1.).  
Despite the domineering role of the categorical approach in the current studies, 
the dimensional approach proved to be appropriate when examining the (probable) 
consequences of anxiety or depression, demonstrated by a precise indication of the 
dose-response relationship between HADS-A or HADS-D scores and reported 
impairment due to chronic mental problems (Paper II). Hence, these two approaches 
are not contradictory, but can rather be viewed as complementary (62). 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Distribution of depression symptoms (HADS-D scores) in the anxiety 
disorder category (HADS-A >8) (left panel), and distribution of anxiety symptoms 
(HADS-A scores) in the depression category (HADS-D >8) (right panel). 
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8.2.2. Comorbidity (Paper II and III) 
In the introduction to the HADS questionnaire the respondents were invited to 
report their feelings during the last week, thus yielding point prevalence estimates of 
anxiety disorder and depression and their comorbidity. However, the associations 
between various measures of anxiety and depression, categorical or dimensional, and 
impairment due to chronic mental health problems reported in Paper II, were strong. 
Assumed that these chronic health problems were reflected by the HADS-scores,  this 
finding indicates that the reported symptoms of anxiety and depression may have been 
long lasting. The period for report of the various health problems was life time for 
alcohol problems and diagnosed diseases, the last year for impairment due to somatic 
health problems, symptoms of cardiovascular and musculoskeletal symptoms, and 
physical exercise, and current for smoking. Hence, the estimates of comorbidity 
between the various anxiety and depression categories and health problems might 
differ according to the different time periods covered. Such potential patterns were, 
however, not possible to investigate in these data. 
 
8.2.2.1. Anxiety and depression (Paper II) 
Comorbidity defined by the categorical approach was a frequent finding in 
HUNT 2. Among 9,493 cases of anxiety disorder 3,639 (38%) had a depression as 
well, and among the 6,671 cases of depression 3,032 (55%) had an anxiety disorder. 
These figures are higher than those reported in NCS (see section 4.3.1.), which 
probably is due to different methods of measuring anxiety disorders and depression, 
and a wider age range in HUNT 2 than in NCS. The pattern regarding the 
preponderance of comorbid anxiety disorder in depression compared to the opposite, 
was, however, seen in both studies.  
When viewing the co-occurrence of anxiety and depression as the ratio 
between HADS-A and HADS-D scores (AD-ratio) a very distinct pattern appeared 
(figure 1 in Paper II). The generally higher mean AD-ratio level in women reflects the 
discrepancy in gender differences between HADS-A and HADS-D, with higher 
HADS-A levels in women, but (minimally) higher HADS-D levels in men. The 
decreasing AD-ratio with increasing age in both genders similarly reflects the 
discrepancy in age trends between HADS-A and HADS-D, with a continuous increase 
in HADS-D with increasing age, but a more stable, though somewhat lowered levels 
of HADS-A in the older age groups (figure 12). Assuming no historical effects, the 
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age distribution of the AD-ratio may reflect the temporal pattern with anxiety 
disorders preceding depression, which is observed in other studies as well (52). Such 
a pattern is observed already in childhood (figure 13) (200). The fact that anxiety 
predicts depression does not necessarily imply that anxiety causes depression. The 
association could be due to common risk factors causing anxiety first, then depression 
(see section 4.4.1.1 and 4.4.2.). However, the chronic course and major impairment 
associated with many of the anxiety disorders are suggested to increase the risk for 
depression (199, 208, 209).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The presence of a continuous measure of anxiety or depression achieved by a 
rating scale does not necessarily infer that they should be regarded as dimensional 
disorders. If lower levels of e.g. anxiety was hardly associated with any impairment, 
while there was a sudden increase in impairment over a certain level of symptoms, 
that could indicate a natural threshold above which symptom levels cause impairment 
and become clinical relevant. However, we found no such break points when 
examining the symptom continuum of anxiety or depression related to impairment. 
Others have found similar gradients when examining various sub-threshold categories 
of anxiety and depression (22, 26, 27, 210), but we are not aware of any studies 
having examined these relationships with a generalised additive model, which gives 
point-wise estimates along the symptom scales. 
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Figure 12: Age and gender distribution of mean HADS-A and HADS-D 
scores in HUNT 2. 
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The close relationship between anxiety/depression and impairment is 
supported by other studies addressing the impact on public health and costs (see 
section 4.1.2.). Moreover, findings from the Australian National Survey of Mental 
Health and Well-Being suggest that the combination of affective (depression and 
dysthymia) and anxiety disorders was more predictive of disability and service 
utilisation than any other combinations of mental disorders (211). Consistently with 
our results, a systematic review concluded that there was some evidence that anxiety 
disorders have a worse outcome than depressions (212). 
The possible moderating effect of age on the association between 
anxiety/depression and impairment was somewhat surprising, and we have not found 
any studies addressing this issue. This is probably due to smaller sample sizes and 
narrower age ranges in most previous studies. A possible explanation of our finding is 
an increase in competent emotion regulation across the life span (213-215).  
The close relationship between anxiety and depression symptoms throughout 
the whole scale, combined with the strong dose-response relationships between 
anxiety or depression and impairment, suggests that the use of the categorical 
approach has some limitations, in particular when not considering the co-occurrence 
of anxiety and depression symptoms. 
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Figure 13: Cumulative incidence of anxiety and depression in childhood, 
adolescence, and early adulthood (200). 
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8.2.2.2. Somatic health problems (Paper III) 
 Comorbidity between various somatic health problems and the 
anxiety/depression categories was common in HUNT 2, an expected finding on the 
basis of the review of relevant studies (section 4.3.2.). In our study comorbid anxiety 
disorder and depression was positively associated with all the somatic health problem 
outcomes, except hypertension, and the associations were in general stronger than 
those between pure anxiety disorder or pure depression and somatic health problems. 
Hence, despite the predominant attention to depression in this field, as revealed in our 
review of the literature (section 4.3.2.), anxiety disorders may play a more prominent 
role than previously assumed. The role of anxiety is probably different from that of 
depression as to the question of cause or consequence, and what kind of somatic 
health problem to be examined. Accordingly, anxiety symptoms and disorders have in 
particular been associated with gastrointestinal symptoms (82, 216) and diseases (81, 
216), associations that have also been found in HUNT 2 (217, 218). While some 
authors suggest that gastrointestinal complaints solely reflect an unspecific 
concomitant vegetative disturbance common to anxiety (82), others propose that 
anxiety related stress has a deteriorating influence on somatic health via the 
hypothalamic-pituitary-adrenal (219, 220) axis. Hence, generalised anxiety disorder, 
which may be assumed to be a marker of chronic stress, has demonstrated a dose-
response relationship with gastric ulcer (81). However, as suggested in section 8.1.3., 
a high anxiety score might also be related to a stronger awareness, sensitivity, and 
worry about bodily symptoms, resulting in stronger associations between somatic 
health problems and anxiety disorder alone or comorbid with depression (198).  
Somatic comorbidity has been associated with late, in contrast to early life 
onset depression (221). In HUNT 2 the prevalence of depression increased with age in 
both genders (206). However, the increased risk for depression in older age groups 
was mainly explained by impairment due to somatic illness or disabilities as well as 
somatic diagnoses and symptoms (222) (figure 13). While late onset depression has 
been associated with neurobiological brain changes in particular (90), early onset 
depression has been associated with anxiety (221). In a study of patients with 
secondary depression (N=401) those who were secondary to other mental disorders, 
had an earlier onset of their depression, were more often suicidal, had less treatment 
response and higher relapse rate, and had more often family members with alcohol 
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problems compared to patients with depression secondary to somatic illness, who 
more often had memory problems (223).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hence, it is possible that depression most often is secondary to somatic illness. 
In the analyses from HUNT 2 (222) impairment due to somatic illness or disability 
was the main predictor of late life depression, indicating that depression might be a 
psychological reaction to physical impairment. Common pathophysiological factors 
for both the somatic disease and the depression, such as nutrient deficiency or toxic 
agents, can, however, not be ruled out. Likewise, cytokines from inflammatory 
processes may induce depression (127). The role of anxiety disorders in most somatic 
diseases still remains equivocal, mainly due to the paucity of studies considering co-
occurring anxiety in depression. Accordingly, in Stordal and colleagues’ study from 
HUNT 2 (222) depression was defined as HADS-D > 8 without considering the co-
occurring HADS-A scores, which were considerable in the older age groups as 
demonstrated in Paper II.  
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Figure 13: Crude and adjusted ORs for having depression in various age and 
gender groups is HUNT 2 (222). Adjustments were made for impairment due 
to somatic disease/disabilities, sociodemographic characteristics, health 
behaviours, somatic diagnoses, somatic symptoms, and physical measurements 
in a logistic regression analysis. 
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8.2.3. Risk factors (Paper IV and V) 
Both the biological (Paper IV) and the social (Paper V) risk factors addressed 
seemed to be more related to depression than to anxiety disorder. By considering the 
age distribution of mean HADS-A versus mean HADS-D (figure 12) there might be 
some indication that anxiety is less influenced by various factors accumulating 
throughout life than depression. However, the anxiety/depression outcome categories 
represented not only new cases in Paper V (incident and persistent cohorts) and in 
Paper IV.  
 
8.2.3.1. Folate metabolism (Paper IV) 
The strongest association was found between the MTHFR 677C!T 
polymorphism and depression, and this was the first study addressing this relation in a 
large population sample. The results from two smaller case-control studies, (152) 
(N=32) and (151) (N=71), are contradictory. Having applied DSM-III-R or DSM-IV 
criteria for major depressive disorder, these studies differed from our study also 
regarding diagnostic criteria for depression.  
Another common polymorphism in the MTHFR is the 1298A→C substitution 
(224). The 1298CC variant also affects enzyme activity and homocysteine levels, but 
to a lesser degree than the TT variant of the 677C→T polymorphism (225). Some 
data suggest that heterozygosity for this polymorphism combined with heterozygosity 
for the MTHFR 677C→T polymorphism is associated with increased risk of neural 
tube defects (226) and increased (227) or decreased (228, 229) risk of cancer diseases. 
Its association with psychiatric disorders has previously not been reported. Hence, we 
made an additional analysis of the MTHFR 1298A→C polymorphism in our sample 
to examine a possible association with anxiety and depression. Contrary to the 
analyses of the MTHFR 677C→T polymorphism (Paper IV), we found no association 
between the CC variant of the 1298A→C polymorphism and depression. We also 
investigated the combined effect of the MTHFR 677C→T and 1298A→C 
polymorphisms, but neither of the combinations were associated with increased risk 
for anxiety disorder or depression (data not shown). 
Our findings of only weak associations between plasma levels of folate and 
depression, contrasted somewhat to earlier findings of impaired folate status in 
depressed patients (230). However, those findings are mainly from clinical case-
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control studies that are more prone to selection bias than a population-based study. 
Nevertheless, there might have been a selection bias (see section 8.1.2.) in our sample 
as well, due to a possible better folate status and less severe depression in participants 
versus non-participants.  
None of the other folate related factors were associated with anxiety disorder. 
Hence, out data suggest that impaired folate metabolism is related to the sub-group of 
depression without comorbid anxiety. Depression may be a more secondary 
phenomenon than anxiety and, thus, is influenced by more risk factors (see section 
8.2.2.1. and 8.2.2.2.). Moreover, if HADS-A is more an indicator of general mental 
distress than HADS-D (see section 8.2.1.), associations with specific risk factors, such 
as those related to folate metabolism, might be less probable.  
Although the design of the study of Paper IV was cross-sectional, the 
association between the MTHFR 677C!T polymorphism is suggestive of a causal 
relationship between impaired folate metabolism and depression. The associations 
between deficiency of folate or cobalamin and depression could be due to depression 
related impaired dietary habits. However, the MTHFR 677C!T polymorphism is not 
affected by mental status or environmental factors. 
 
8.2.3.2. Educational level (Paper V) 
 During a follow-up period of 11 years significant gradients from the lowest to 
the highest educational level were observed in the association with depression, with or 
without comorbid anxiety disorder, in both the incident and the persistent cohorts. A 
similar association was seen with anxiety disorder among the youngest women in the 
incident cohort. 
Our findings for depression are in accordance with the results of Kaplan et al 
(170) who followed 4,864 individuals for nine years. The ORs for being depressed at 
follow-up in the lowest compared to the highest educational groups were 1.6 (95% CI: 
1.2-2.1) in both the incident and the persistent cohort. However, findings from the 
three other longitudinal studies were inconsistent with our results: After a 15 years 
follow-up period Eaton et al (169) did not find such an association in their incident 
cohort (N=693). In a persistent cohort (N=2,223) Bracke (171) reported an association 
between low educational level and depression after three years follow-up in men only, 
but after adjustment for baseline depression severity, the association was not present. 
Likewise, Sargeant et al (172) estimated a significant effect of low educational level 
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on depression after one year in a persistent cohort (N=423), however after 
adjustments for the number and length of former depressive episodes and symptom 
severity at baseline, the association was no longer significant. In our study 
adjustments for mental distress level at baseline (ADI-12 score) were performed in 
both cohorts, without influencing the associations markedly.These inconsistent 
findings may be due to differences in assessment of depression. Kaplan et al. used the 
Human Population Laboratory Depression Index (231), while the samples of Sargeant 
et al and Eaton et al were from the ECA using DSM-III criteria for major depression, 
and Bracke used a modified version of the global depression scale in the Health and 
Daily Living Form (232). The inconsistencies might as well be due to differences in 
sample size, sample characteristics, observational time, and/or covariates included in 
the analyses.  
 Educational level was just as strongly associated with pure depression as 
depression comorbid with anxiety disorder (comorbid disorder) in both cohorts. This 
finding along with the limited effect of educational level on pure anxiety disorder 
indicates that educational level mainly affects depression and to a lesser degree 
anxiety. The markedly attenuating effect of adjusting for even low-score depression 
(HADS-D at follow-up) on the association between educational level and anxiety 
disorder supports this notion.   
 By studying a mentally healthy cohort at baseline (incident cohort) the effect 
of educational level on anxiety and depression could be examined without the 
possible confounding effect of mental distress. The participants in the persistent 
cohort (high mental distress level at baseline) had lower educational levels at baseline 
compared to the incident cohort (table 1 and 2 in Paper V), and the association 
between educational level and depression at follow-up, therefore, could be biased by 
baseline mental distress. However, neither stratification nor adjustments with ADI-12 
score within the strata did mainly influence the associations between educational level 
and depression. In other words, in both cohorts educational level independently 
predicted depression during the observational period of 11 years.  
The selection theory (176) claims that health problems may be an obstacle to 
upward and promote downward social mobility, would be supported if a high level of 
mental distress at baseline was associated with a lack of additional educational 
attainment during the observational period. However, the opposite was surprisingly 
found, namely that a high, compared to a low level of mental distress at baseline was 
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modestly associated with additional educational attainment. A possible interpretation 
is that individuals with a high level of mental distress at baseline actually have 
delayed their education. Moreover, there were no effects of additional educational 
attainment on the anxiety/depression outcome categories (HADS) at follow-up. 
Hence, the factor(s) inherent to lower educational level that predicts depression is 
probably established relatively early in life, which might be a vulnerable personality 
trait or belonging to a lower social class. Hence, to test the theories of causation and 
selection theories properly, an inter-generational (233) or inter-ethnicity (173) study 
design is recommended  
Length of education is the most frequently used measure of SES, probably 
because it is a robust variable that does not change much during adult life and is easy 
to categorise, contrary to households’ annual income and occupation. Opposed to 
income, which reflects material resources, education may reflect personal resources, 
such as knowledge and competence. Moreover, education probably influences 
important choices in early adult life and might even serve as a “vaccination” against 
the effect of later adverse incidents. Accordingly, contrary to educational level, the 
effect of income on depression at follow up disappeared after adjusting for other 
psychosocial variables in the study of Kaplan et al (170). In a natural experiment 
moving parts of a population out of poverty, the raise in income did not affect 
symptoms of anxiety and depression in children (234). 
In our analyses the associations between educational level and depression 
were only modestly influenced by adjustments for a variety of covariates including 
somatic illness, use of health services, health behaviours, psychosocial status, and 
sociodemographic and work characteristics. Hence, our study did not add new 
information as to the mechanisms of the observed associations. Other authors have 
made efforts to reveal potential mechanisms as well, but mainly addressing other 
indicators of SES than education. In a cross-sectional study (177) using occupational 
grade as a proxy for SES, work characteristics, including skill discretion and decision 
authority, explained most of the SES-depression gradient. Physical disease has been 
suggested (166), but was not found to play a mediating role in a study using economic 
situation as the measure of SES (178). Health behaviours have been proposed (235) as 
possible mediators, and adjusting for smoking, alcohol consumption, physical 
activity, and Body Mass Index reduced the SES (economic hardship)-depression 
association in a longitudinal study (178). However, psychological functioning was 
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assessed only at follow-up, and the different behaviours were not evaluated 
separately. Personality traits such as optimism, coping style, personal control, and 
sense of mastery have been suggested to influence the SES-health relation (167). 
Moreover, social support has been associated with higher SES and less depression 
(236), partly as a mediator, partly as a moderator (or effect modifier) buffering the 
effect of low SES on depression.  
A comprehensive concept that integrate vulnerability factors such as genetic 
predisposition, developmental experiences, health behaviours, and physiological 
responses to acute and, in particular, chronic stress, called “allostatic load”, has been 
proposed by McEwen (220). Allostatic load is meant to reflect the resulting “wear and 
tear” of an elevated physiologic activation due to the many events of daily life and is 
suggested to be related to SES (237), anxiety, and depression (162).  
A low social position is suggested to cause feelings of shame, social anxiety, 
and depression (238) more directly. The health gradients associated with SES have 
mainly been independent of average income in the population, but rather to the range 
of inequalities in income (239), indicating the significance of social hierarchy for 
health. Social anxiety is characterised by a fear of being devaluated and ridiculed, 
which may be more pronounced among individuals belonging to lower social classes. 
Depression has been suggested as well to be an adaptation in response to situations 
dominated by others where the consequences of opposition could be harmful (240), 
equivalent to the lower position in the social hierarchy.  
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9. CONCLUSIONS AND INTEGRATION OF THE FINDINGS 
 
The issues in this dissertation cover a broad scope, which hopefully has 
illustrated the complex aspects of anxiety and depression in both mental and somatic 
health issues. Although HADS is a brief self-rating instrument, our systematic review 
showed that HADS performed well in assessing some core aspects of these mental 
syndromes (Paper I). To simplify our main findings and our interpretation of these in 
light of previously reported studies, an illustration will be presented for each paper. 
Finally, an attempt will be made to merge the findings in an integrated model (figure 
14).  
 
1. The basic model states that anxiety and depression are related, and that they are 
influenced by genetic and environmental (non-genetic) factors. Certain genetically 
determined personality traits may influence what environmental factors that an 
individual will  be exposed to as well (104, 108, 241).  
 
2. In Paper II the strong relationship between anxiety, depression and impairment is 
best described by the dimensional approach. We suggest a causal relationship 
from anxiety to depression, at least among younger adults, and in agreement with 
findings from other studies.  
  
3. Paper III demonstrates an extensive comorbidity between somatic disease and 
various combinations of anxiety and depression. Most evidence is for depression 
as a consequence of somatic disease, which probably is the most important 
determinant of depression in older age. However, the relationship between 
somatic diseases and anxiety is less clear.   
 
4. Paper IV contributes further evidence that impaired folate metabolism may be a 
determinant of depression, but probably not of anxiety. A genetic vulnerability 
(the MTHFR 677C!T polymorphism) combined with low folate intake probably 
gives the highest risk for depression.  
 
5. In Paper V low educational level is suggested to be a determinant for depression, 
and to a smaller degree for anxiety. Low educational level may be considered as a 
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proxy for some vulnerability associated with living conditions in the lower social 
strata, or less personal or network resources which can buffer the effect of stress. 
Factors related to somatic health, use of health services, health behaviours, 
psychosocial status, or sociodemographic or work characteristics explained only a 
small part of the observed association between low educational level and 
depression. 
 
6. Finally, the integrated model converges our findings with those of others. 
Findings from studies suggesting that low education is related to somatic illness 
(167) and low folate intake (242), and that impaired folate metabolism is 
associated with somatic illness (243-249), are included in order to complete the 
model. Although the model is by no means comprehensive, it illustrates the 
complexity of the relationship between anxiety and depression, and biological and 
psychosocial factors. Furthermore, in such a complex network of associations, the 
various subtypes of anxiety and depression may show different associations. The 
model is in accordance with the biopsychosocial model of mental disorders (103). 
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Figure 14: Models of the relation between anxiety and depression including the findings from the 
papers in the dissertation. The final model (right bottom panel) attempts to integrate these findings 
and results from other studies as well. 
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10. IMPLICATIONS AND RECOMMENDATIONS FOR FURTHER 
RESEARCH 
 
Generally. Anxiety and depression are common and costly public health 
problems. As demonstrated in this dissertation, much is still unknown regarding 
causes and efficient preventive measures. Hence, increased resources not only for the 
treatment of mental disorders, but for research as well, are welcomed. Large scale, 
representative epidemiological studies that include information regarding various 
biopsychosocial aspects are needed to study these complex phenomena. According to 
their relative impact on public health, items addressing mental health problems have 
been under-represented in general health surveys in Norway.  
Assessment. For both clinical and research purposes HADS can be 
recommended as an efficient screening tool to identify possible anxiety disorder and 
depression. In the health services further assessment of the screen-positive subjects 
must, however, be made in order to ascertain clinically significant cases. In 
epidemiological studies supplementary scales that might identify other subtypes of 
anxiety and depression, suitable for both a categorical and a dimensional approach, 
could be included. Some measure of clinical significance related to symptom scores 
should be included, such as impairment, use of health services, and medication.  
Comorbidity. It is a challenge for clinicians as well as researchers to identify 
the extensive co-occurrence of anxiety, depression, and somatic health problems, and 
consider the deteriorating effect of such comorbidity. However, while much is known 
of the co-occurrence of various mental disorders and somatic diseases, less is known 
about the possible mechanisms of this phenomenon. Most probably there are different 
mechanisms for different variants of comorbidity. A longitudinal design is necessary 
to settle the temporal relationship between the disorders. To avoid information bias, 
somatic disease should be ascertained by objective measures or information from a 
physician or a hospital.  
Risk factors. There is still not irrefutible evidence that folate should be 
recommended in prevention and treatment of depression. However, folate and 
cobalamin are both inexpensive and non-toxic agents, which might be supplemented 
in patients with a deficiency of those vitamins and perhaps in patients with a treatment 
restistent depression.  
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Whether a generally increased level of education in the population, which 
actually has taken place after World War II, would prevent depression, is highly 
questionable. Most probably the education-depression gradient reflects social 
inequalities in general, which rather should be addressed, a challenge that is more a 
political than a health care issue.   
Cohort studies with comprehensive measurements at baseline and regular 
follow-ups will be of great value in further examination of risk factors. One such 
study, the Mother and Child Study (Den Norske Mor & Barn Undersøkelsen) (250) by 
the Norwegian Institute of Public Health, has by February 2004 recruited 35,000 
pregnant women who will be followed up several times during the pre-, peri- and 
neonatal period. The relationship between folate metabolism and mental health, in 
particular pregnancy related depression, may be examined. Detailed information 
regarding dietary habits and intake of vitamin supplements is collected, as well as 
blood samples and assessment of anxiety and depression at both baseline and follow-
up. The children will be followed up during their childhood enabling examination of 
developmental aspects of their mental health. Such aspects will be addressed in 
another cohort study as well, the Bergen Child Study (Barn i Bergen) (251). 
Preliminary results regarding the relation between neurodevelopmental (attention 
deficit and hyperactivity, obsessive compulsive symptoms, language problems, 
autism, and clumsy motor behaviour) and emotional problems (anxiety and 
depression) have already been presented (252).  
It may also be possible to link data from health surveys to various other data 
sources, such as  the Norwegian Medical Birth Registry, the Cancer Registry of 
Norway, and Statistics Norway. Linkage to bio banks will enable examination of 
genetic risk factors, such as single nucleotide polymorphisms, and other biological 
markers.   
Statistical methods. Due to the complex network of mediators, moderators, 
and independent, overlapping, and proxy risk factors (100) associated with anxiety 
and depression, statistical techniques that can model such intricate relationships are 
recommended. While conventional regression models are useful, other techniques 
such as generalised linear latent and mixed models (GLLAMM) (253) including 
structural equation modelling (SEM) (254), may better attend to the complexity of 
these relationships.  
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is for men aged 20-69 
years, but it contains all the 
relevant items for the other 
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APPENDIX V: 
 
HUSK 
 
QUESTIONNAIRE 1 
12. ARBEID
Tok du noen slags medisiner I GÅR?...............................
Hvis NEI, kan du gå til avsnitt 12.
Hvis JA, besvar følgende:
Hvilke medisiner tok du I GÅR, og hva var grunnen til at du tok
medisinen (diagnose, sykdom, symtom, helseeffekt)?
Sett svarene inn i skjemaet nedenfor, en linje for hver medisin.
Kryss av for ja om du bruker medisinen daglig eller nesten daglig.
Dersom det ikke er nok plass her, kan du fortsette på eget ark som legges ved.
Oppgi antall egne barn (eventuelt 0) av hvert kjønn:
Antall gutter Antall jenter
11. BRUK AV MEDISINER
NEI
Personlig innbydelse
HELSEUNDERSØKELSEN 
I HORDALAND 1997-99
IE
 3
21
58
01
 (ID
.
N
R
.1
.9
7)-
 30
.00
0- 
Be
ye
r-
H
ec
os
 9
.9
7
SP02B
Hvor ofte i løpet av de siste 4 ukene
har du hatt mye overskudd? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
Hvor ofte i løpet av de siste 4 ukene
har du følt deg nedfor og trist? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
I løpet av de siste 4 ukene, hvor mye av tiden har din fysiske
helse eller følelsesmessige problemer påvirket din sosiale
omgang(som det å besøke venner, slekt)? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
Stort sett, vil du si at din helse er:
Utmerket Meget god God Nokså god Dårlig
1 2 3 4 5
Med medisiner mener vi her alle slags medisiner, både:
• med og uten resept, naturmedisin, vitaminer og mineraler
• medisin som svelges, inhaleres eller injiseres, stikkpiller,
salver, kremer eller dråper.
Navn på medisinen
(ett navn pr. linje):
Grunn til bruk av medisinen
I GÅR var:
Daglig
JA      NEI
Hvor lenge har du praktisert
i dette yrket i ditt liv? ...........................
Besvares av dem som har hatt inntektsgivende arbeid i minst 100 timer det siste året:
Beskriv virksomheten på det arbeidsstedet der du utførte
inntektsgivende arbeid i lengst tid de siste 12 mnd. (Skriv f.eks.
jordbruk, barneavd. på sykehus, snekkeravd. på skipsverft e.l.).
Virksomhet:
Antall år i yrket
Hvilket yrke/tittel har eller hadde du på dette arbeidsstedet?
(Skriv f.eks. kornbonde, anestesisykepleier, snekker e.l.)
Yrke:
Har du noen av de følgende yrker (heltid eller deltid)?
Sett kryss for hvert spørsmål.
Sjåfør ................................................................................
Bonde/gårdbruker.............................................................
Fisker................................................................................
NEIJA
Har du tidligere i ditt llv (ikke i dag) hatt inntektsgivende
arbeid som:
Bilmekaniker/biloppretter ..................................................
Frisør ................................................................................
NEIJA
13. SAMLIV
Har du noen gang hatt regelmessig samliv uten pre-
vensjon i ett år eller mer uten at det har ført til graviditet?...
Med prevensjon menes også mer usikre metoder
som avbrutt samleie, «sikre perioder» etc.
NEIJA
Hvis denne helseundersøkelsen viser at du bør undersøkes
nærmere, hvilken allmennpraktiserende lege/kommunelege
ønsker
Ikke skriv i disse rutene
14. ETTERUNDERSØKELSE
Takk for utfyllingen!
Nok en gang:         Velkommen til undersøkelsen
1
2
3
4
5
6
1
2
3
4
5
6
1
2
3
4
5
6
Adresse endring
JA
Har du noen gang spontanabortert (ufrivillig mistet fosteret)
etter at graviditet var sikkert påvist?
Hvis JA:
Antall ganger
Følgende spørsmål besvares bare hvis du har vært gravid:
Oppgi antall måneder det tok med regelmessig samliv
uten prevensjon (eller evt. amming), til du ble gravid:
Siste svangerskap ....................
Nest siste svangerskap.............
Tredje siste svangerskap ..........
USIKKER JANEI
mnd. uten prevensjon
mnd. uten prevensjon
mnd. uten prevensjon
De følgende spørsmål besvares bare av kvinner
Nei/ubetydelig I noen grad I betydelig grad Vet ikke
1. EGEN HELSE 4. MUSKEL- OG SKJELETTPLAGER
Hvordan er helsen din nå? (Sett bare ett kryss)
Dårlig Ikke helt god God Svært god
Har du, eller har du hatt:
Hjerteinfarkt.....................................................
Angina pectoris (hjertekrampe).......................
Hjerneslag/hjerneblødning ..............................
Astma ..............................................................
Diabetes (sukkersyke).....................................
Multippel sklerose ...........................................
Har du de siste to ukene følt deg:
Nervøs og urolig? ............
Plaget av angst?..............
Trygg og rolig?.................
Irritabel? ..........................
Glad og optimistisk?........
Nedfor/deprimert? ...........
Ensom? ...........................
Nei
Med «hvite fingre» mener vi plager i form av at en eller
flere fingre blir hvite og at man samtidig mister følelsen
i dem når det er kaldt. Har du slike plager?.....................
Har en eller flere av foreldre eller søsken
hatt hjerteinfarkt (sår på hjertet) eller
angina pectoris (hjertekrampe)? ..............................
Har en eller flere foreldre/søsken hatt:
Hjerteinfarkt før de fylte 60 år?.................................
Hjerneslag/hjerneblødning før de fylte 70 år? ..........
Har du i løpet av det siste året vært plaget med
smerter og/eller stivhet i muskler og ledd som
har vart i minst 3 måneder sammenhengende?..............
Hvis NEI, gå til avsnitt 5.
Hvis JA, svar på følgende:
Hvor har du hatt disse plagene?
Nakke ...............................................................................
Skuldre (aksler) ................................................................
Albuer ...............................................................................
Håndledd/hender..............................................................
Bryst, mage ......................................................................
Øvre del av ryggen ...........................................................
Korsryggen .......................................................................
Hofter................................................................................
Knær.................................................................................
Ankler, føtter .....................................................................
Hvor lenge har plagene vart sammenhengende?
Svar for det området hvor plagene har vart lengst.
Hvis under 1 år, oppgi antall måneder............Antall mnd.
Hvis 1 år eller mer, oppgi antall år ......................Antall år
Har du noen gang det siste året hatt eksem
(rød, kløende, sår og sprukken hud):
På hendene? ....................................................................
I ansiktet? .........................................................................
Andre steder på kroppen?................................................ Har plagene redusert din arbeidsevne det siste året?
Gjelder også hjemmearbeidende. Sett bare ett kryss.
Har du vært sykmeldt p.g.a. disse
plagene det siste året? ..............................................
Har plagene ført til redusert aktivitet i fritiden? ......
1 2 3 4
1 2 3 4
Litt
En god
del
Svært
mye
Bruker du medisin mot høyt blodtrykk?
Nå Før, men ikke nå Aldri brukt
1 2 3
1 2 3 4
T i m e r  p r . u k e
NEI
Alder første
gang
JA
NEIJA
NEIJA
NEIJA
I løpet av de siste 4 ukene, har du hatt noen av de
følgende problemer i ditt arbeid eller i andre av dine
daglige gjøremål på grunn av din fysiske helse?
Du har utrettet mindre enn du hadde ønsket ....................
Du har vært hindret i å utføre visse typer
arbeid eller gjøremål .........................................................
NEIJA
I løpet av de siste 4 ukene, har du hatt noen av de
følgende problemer i ditt arbeid eller i andre av dine
daglige gjøremål p.g.a. følelsesmessige problemer?
(Som f.eks. å være deprimert eller engstelig)
Du har utrettet mindre enn du hadde ønsket ....................
Du har utført arbeidet eller andre gjøremål
mindre grundig enn vanlig ................................................
NEIJA
I løpet av de siste 4 ukene, hvor mye har
smerter påvirket ditt vanlige arbeid?
(Gjelder både i og utenfor hjemmet) Sett bare ett kryss.
Ikke i det hele tatt .............................................................
Litt.....................................................................................
En del ...............................................................................
Mye...................................................................................
Svært mye ........................................................................
JA
Hvor ofte i løpet av de siste 4 ukene
har du følt deg rolig og harmonisk? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
NEIJA
NEI
VET
IKKEJA
NEI
Ikke i
arbeidJA
NEIJA
år
år
år
år
år
år
3. SYKDOM I FAMILIEN
2. HVORDAN FØLER DU DEG?
Hvilken utdanning er den høyeste du har fullført?
Sett bare ett kryss.
Mindre enn 7 år grunnskole..............................................
Grunnskole 7-10 år, framhaldsskole,
folkehøgskole....................................................................
Realskole,  middelskole, yrkesskole,
1-2 årig videregående skole .............................................
Artium, øk.gymnas, allmennfaglig retning
i videregående skole ........................................................
Høgskole/universitet, mindre enn 4 år ..............................
Høgskole/universitet, 4 år eller mer ..................................
De neste spørsmålene handler om hvordan du ser på
din egen helse. Hvis du er usikker på hva du skal svare,
vennligst svar så godt du kan.
Er din helse slik at den begrenser deg i utførelsen
av disse aktivitetene NÅ? 
Hvor mange kopper kaffe/te drikker du daglig?
Sett 0 hvis du ikke drikker kaffe/te daglig.
A n t a l l  k o p p e r  d a g l i g
Kokekaffe       Annen kaffe             Te
Er du total avholdsmann/-kvinne?....................................
Hvor mange ganger i måneden drikker du
vanligvis alkohol? Regn ikke med lettøl.
Sett 0 hvis mindre enn 1 gang i mnd.............Antall ganger
Hvor mange glass øl, vin eller brennevin
drikker du VANLIGVIS i løpet av to uker?
Regn ikke med lettøl. Sett 0 hvis du ikke drikker alkohol.
NEIJA
NEI
6. KAFFE / TE / ALKOHOL
5. MOSJON
Eksempler:
Avkryssing: Tall: Bokstaver:
1
2
3
4
5
Glass
øl
Glass
vin
Glass
brennevin
9. UTDANNING
Hvor lenge er du vanligvis daglig
tilstede i røykfylt rom?.............................Antall hele timer
Sett 0 hvis du ikke oppholder deg i røykfylt rom.
Røyker du selv:
Sigaretter daglig? .............................................................
Sigarer/sigarillos daglig? ..................................................
Pipe daglig?......................................................................
Aldri røykt daglig ....................
Hvordan har din fysiske aktivitet i fritiden vært
det siste året?
Tenk deg et ukentlig gjennomsnitt for året.
Arbeidsvei regnes som fritid. Besvar begge spørsmålene.
Dette gjelder din interesse
for å endre helsevaner.
Røykespørsmålet besvares
bare av dem som røyker.
Har du de siste 12 mnd. forsøkt å:
Om 5 år, tror du at du har
endret vaner på noen av
disse områdene?.............................
Anslå din høyeste og laveste vekt
i løpet av de siste 5 år. (Hele kg)
(Se bort fra vekt under svangerskap)
NEIJA NEIJA NEIJA
NEIJA NEIJA NEIJA
8. ENDRING AV HELSEVANER
10. HELSE OG TRIVSEL
7. RØYKING
1 2 3 4
Høyeste
vekt
Spise
sunnere
Trimme
mer
Slutte
å røyke
Laveste
vekt
Hvis du har røykt daglig tidligere, hvor
lenge er det siden du sluttet?..............................Antall år
Hvis du røyker daglig nå eller har røykt tidligere:
Hvor mange sigaretter røyker eller 
røykte du vanligvis daglig? ......................Antall sigaretter
Hvor gammel var du da du begynte 
å røyke daglig? ..................................................Alder i år
Hvor mange år til sammen har 
du røykt daglig? ..................................................Antall år
(Sett kryss)
JA
Under 1 1-2 3 og merLett aktivitet
(ikke svett/andpusten) .....
Hard fysisk aktivitet
(svett/andpusten) ............
Ingen
S
Det utfylte skjemaet vil bli lest av en maskin. Bruk blå eller sort farge ved utfylling. Det er viktig at du går fram slik:
• i de små boksene setter du kryss for det svaret som passer best for deg
• i de store boksene skriver du tall eller blokkbokstaver – NB! innenfor rammen for boksen.
pørreskjemaet er en viktig del av helseundersøkelsen. Vennligst fyll ut skjemaet på forhånd og ta det med til helseundersøkelsen. Dersom
enkelte spørsmål er uklare, lar du dem stå ubesvart til du møter fram, og drøfter dem med personalet som gjennomfører undersøkelsen.
Alle svar vil bli behandlet strengt fortrolig.
x
Moderate aktiviteter som å flytte bord, støvsuge, gå
en tur eller drive med hagearbeid:
Ja, begrenser Ja, begrenser Nei, begrenser meg
meg mye meg litt ikke i det hele tatt
Gå opp trappen flere etasjer:
Ja, begrenser Ja, begrenser Nei, begrenser meg
meg mye meg litt ikke i det hele tatt
1
2
3
4
5
1
2
3
4
5
6
Med vennligh hilsen
Statens helseundersøkelser Kommunehelsetjenesten  Helseundersøkelsen i Hordaland
Nei/ubetydelig I noen grad I betydelig grad Vet ikke
1. EGEN HELSE 4. MUSKEL- OG SKJELETTPLAGER
Hvordan er helsen din nå? (Sett bare ett kryss)
Dårlig Ikke helt god God Svært god
Har du, eller har du hatt:
Hjerteinfarkt.....................................................
Angina pectoris (hjertekrampe).......................
Hjerneslag/hjerneblødning ..............................
Astma ..............................................................
Diabetes (sukkersyke).....................................
Multippel sklerose ...........................................
Har du de siste to ukene følt deg:
Nervøs og urolig? ............
Plaget av angst?..............
Trygg og rolig?.................
Irritabel? ..........................
Glad og optimistisk?........
Nedfor/deprimert? ...........
Ensom? ...........................
Nei
Med «hvite fingre» mener vi plager i form av at en eller
flere fingre blir hvite og at man samtidig mister følelsen
i dem når det er kaldt. Har du slike plager?.....................
Har en eller flere av foreldre eller søsken
hatt hjerteinfarkt (sår på hjertet) eller
angina pectoris (hjertekrampe)? ..............................
Har en eller flere foreldre/søsken hatt:
Hjerteinfarkt før de fylte 60 år?.................................
Hjerneslag/hjerneblødning før de fylte 70 år? ..........
Har du i løpet av det siste året vært plaget med
smerter og/eller stivhet i muskler og ledd som
har vart i minst 3 måneder sammenhengende?..............
Hvis NEI, gå til avsnitt 5.
Hvis JA, svar på følgende:
Hvor har du hatt disse plagene?
Nakke ...............................................................................
Skuldre (aksler) ................................................................
Albuer ...............................................................................
Håndledd/hender..............................................................
Bryst, mage ......................................................................
Øvre del av ryggen ...........................................................
Korsryggen .......................................................................
Hofter................................................................................
Knær.................................................................................
Ankler, føtter .....................................................................
Hvor lenge har plagene vart sammenhengende?
Svar for det området hvor plagene har vart lengst.
Hvis under 1 år, oppgi antall måneder............Antall mnd.
Hvis 1 år eller mer, oppgi antall år ......................Antall år
Har du noen gang det siste året hatt eksem
(rød, kløende, sår og sprukken hud):
På hendene? ....................................................................
I ansiktet? .........................................................................
Andre steder på kroppen?................................................ Har plagene redusert din arbeidsevne det siste året?
Gjelder også hjemmearbeidende. Sett bare ett kryss.
Har du vært sykmeldt p.g.a. disse
plagene det siste året? ..............................................
Har plagene ført til redusert aktivitet i fritiden? ......
1 2 3 4
1 2 3 4
Litt
En god
del
Svært
mye
Bruker du medisin mot høyt blodtrykk?
Nå Før, men ikke nå Aldri brukt
1 2 3
1 2 3 4
T i m e r  p r . u k e
NEI
Alder første
gang
JA
NEIJA
NEIJA
NEIJA
I løpet av de siste 4 ukene, har du hatt noen av de
følgende problemer i ditt arbeid eller i andre av dine
daglige gjøremål på grunn av din fysiske helse?
Du har utrettet mindre enn du hadde ønsket ....................
Du har vært hindret i å utføre visse typer
arbeid eller gjøremål .........................................................
NEIJA
I løpet av de siste 4 ukene, har du hatt noen av de
følgende problemer i ditt arbeid eller i andre av dine
daglige gjøremål p.g.a. følelsesmessige problemer?
(Som f.eks. å være deprimert eller engstelig)
Du har utrettet mindre enn du hadde ønsket ....................
Du har utført arbeidet eller andre gjøremål
mindre grundig enn vanlig ................................................
NEIJA
I løpet av de siste 4 ukene, hvor mye har
smerter påvirket ditt vanlige arbeid?
(Gjelder både i og utenfor hjemmet) Sett bare ett kryss.
Ikke i det hele tatt .............................................................
Litt.....................................................................................
En del ...............................................................................
Mye...................................................................................
Svært mye ........................................................................
JA
Hvor ofte i løpet av de siste 4 ukene
har du følt deg rolig og harmonisk? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
NEIJA
NEI
VET
IKKEJA
NEI
Ikke i
arbeidJA
NEIJA
år
år
år
år
år
år
3. SYKDOM I FAMILIEN
2. HVORDAN FØLER DU DEG?
Hvilken utdanning er den høyeste du har fullført?
Sett bare ett kryss.
Mindre enn 7 år grunnskole..............................................
Grunnskole 7-10 år, framhaldsskole,
folkehøgskole....................................................................
Realskole,  middelskole, yrkesskole,
1-2 årig videregående skole .............................................
Artium, øk.gymnas, allmennfaglig retning
i videregående skole ........................................................
Høgskole/universitet, mindre enn 4 år ..............................
Høgskole/universitet, 4 år eller mer ..................................
De neste spørsmålene handler om hvordan du ser på
din egen helse. Hvis du er usikker på hva du skal svare,
vennligst svar så godt du kan.
Er din helse slik at den begrenser deg i utførelsen
av disse aktivitetene NÅ? 
Hvor mange kopper kaffe/te drikker du daglig?
Sett 0 hvis du ikke drikker kaffe/te daglig.
A n t a l l  k o p p e r  d a g l i g
Kokekaffe       Annen kaffe             Te
Er du total avholdsmann/-kvinne?....................................
Hvor mange ganger i måneden drikker du
vanligvis alkohol? Regn ikke med lettøl.
Sett 0 hvis mindre enn 1 gang i mnd.............Antall ganger
Hvor mange glass øl, vin eller brennevin
drikker du VANLIGVIS i løpet av to uker?
Regn ikke med lettøl. Sett 0 hvis du ikke drikker alkohol.
NEIJA
NEI
6. KAFFE / TE / ALKOHOL
5. MOSJON
Eksempler:
Avkryssing: Tall: Bokstaver:
1
2
3
4
5
Glass
øl
Glass
vin
Glass
brennevin
9. UTDANNING
Hvor lenge er du vanligvis daglig
tilstede i røykfylt rom?.............................Antall hele timer
Sett 0 hvis du ikke oppholder deg i røykfylt rom.
Røyker du selv:
Sigaretter daglig? .............................................................
Sigarer/sigarillos daglig? ..................................................
Pipe daglig?......................................................................
Aldri røykt daglig ....................
Hvordan har din fysiske aktivitet i fritiden vært
det siste året?
Tenk deg et ukentlig gjennomsnitt for året.
Arbeidsvei regnes som fritid. Besvar begge spørsmålene.
Dette gjelder din interesse
for å endre helsevaner.
Røykespørsmålet besvares
bare av dem som røyker.
Har du de siste 12 mnd. forsøkt å:
Om 5 år, tror du at du har
endret vaner på noen av
disse områdene?.............................
Anslå din høyeste og laveste vekt
i løpet av de siste 5 år. (Hele kg)
(Se bort fra vekt under svangerskap)
NEIJA NEIJA NEIJA
NEIJA NEIJA NEIJA
8. ENDRING AV HELSEVANER
10. HELSE OG TRIVSEL
7. RØYKING
1 2 3 4
Høyeste
vekt
Spise
sunnere
Trimme
mer
Slutte
å røyke
Laveste
vekt
Hvis du har røykt daglig tidligere, hvor
lenge er det siden du sluttet?..............................Antall år
Hvis du røyker daglig nå eller har røykt tidligere:
Hvor mange sigaretter røyker eller 
røykte du vanligvis daglig? ......................Antall sigaretter
Hvor gammel var du da du begynte 
å røyke daglig? ..................................................Alder i år
Hvor mange år til sammen har 
du røykt daglig? ..................................................Antall år
(Sett kryss)
JA
Under 1 1-2 3 og merLett aktivitet
(ikke svett/andpusten) .....
Hard fysisk aktivitet
(svett/andpusten) ............
Ingen
S
Det utfylte skjemaet vil bli lest av en maskin. Bruk blå eller sort farge ved utfylling. Det er viktig at du går fram slik:
• i de små boksene setter du kryss for det svaret som passer best for deg
• i de store boksene skriver du tall eller blokkbokstaver – NB! innenfor rammen for boksen.
pørreskjemaet er en viktig del av helseundersøkelsen. Vennligst fyll ut skjemaet på forhånd og ta det med til helseundersøkelsen. Dersom
enkelte spørsmål er uklare, lar du dem stå ubesvart til du møter fram, og drøfter dem med personalet som gjennomfører undersøkelsen.
Alle svar vil bli behandlet strengt fortrolig.
x
Moderate aktiviteter som å flytte bord, støvsuge, gå
en tur eller drive med hagearbeid:
Ja, begrenser Ja, begrenser Nei, begrenser meg
meg mye meg litt ikke i det hele tatt
Gå opp trappen flere etasjer:
Ja, begrenser Ja, begrenser Nei, begrenser meg
meg mye meg litt ikke i det hele tatt
1
2
3
4
5
1
2
3
4
5
6
Med vennligh hilsen
Statens helseundersøkelser Kommunehelsetjenesten  Helseundersøkelsen i Hordaland
12. ARBEID
Tok du noen slags medisiner I GÅR?...............................
Hvis NEI, kan du gå til avsnitt 12.
Hvis JA, besvar følgende:
Hvilke medisiner tok du I GÅR, og hva var grunnen til at du tok
medisinen (diagnose, sykdom, symtom, helseeffekt)?
Sett svarene inn i skjemaet nedenfor, en linje for hver medisin.
Kryss av for ja om du bruker medisinen daglig eller nesten daglig.
Dersom det ikke er nok plass her, kan du fortsette på eget ark som legges ved.
Oppgi antall egne barn (eventuelt 0) av hvert kjønn:
Antall gutter Antall jenter
11. BRUK AV MEDISINER
NEI
Personlig innbydelse
HELSEUNDERSØKELSEN 
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Hvor ofte i løpet av de siste 4 ukene
har du hatt mye overskudd? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
Hvor ofte i løpet av de siste 4 ukene
har du følt deg nedfor og trist? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
I løpet av de siste 4 ukene, hvor mye av tiden har din fysiske
helse eller følelsesmessige problemer påvirket din sosiale
omgang(som det å besøke venner, slekt)? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
Stort sett, vil du si at din helse er:
Utmerket Meget god God Nokså god Dårlig
1 2 3 4 5
Med medisiner mener vi her alle slags medisiner, både:
• med og uten resept, naturmedisin, vitaminer og mineraler
• medisin som svelges, inhaleres eller injiseres, stikkpiller,
salver, kremer eller dråper.
Navn på medisinen
(ett navn pr. linje):
Grunn til bruk av medisinen
I GÅR var:
Daglig
JA      NEI
Hvor lenge har du praktisert
i dette yrket i ditt liv? ...........................
Besvares av dem som har hatt inntektsgivende arbeid i minst 100 timer det siste året:
Beskriv virksomheten på det arbeidsstedet der du utførte
inntektsgivende arbeid i lengst tid de siste 12 mnd. (Skriv f.eks.
jordbruk, barneavd. på sykehus, snekkeravd. på skipsverft e.l.).
Virksomhet:
Antall år i yrket
Hvilket yrke/tittel har eller hadde du på dette arbeidsstedet?
(Skriv f.eks. kornbonde, anestesisykepleier, snekker e.l.)
Yrke:
Har du noen av de følgende yrker (heltid eller deltid)?
Sett kryss for hvert spørsmål.
Sjåfør ................................................................................
Bonde/gårdbruker.............................................................
Fisker................................................................................
NEIJA
Har du tidligere i ditt llv (ikke i dag) hatt inntektsgivende
arbeid som:
Bilmekaniker/biloppretter ..................................................
Frisør ................................................................................
NEIJA
13. SAMLIV
Har du noen gang hatt regelmessig samliv uten pre-
vensjon i ett år eller mer uten at det har ført til graviditet?...
Med prevensjon menes også mer usikre metoder
som avbrutt samleie, «sikre perioder» etc.
NEIJA
Hvis denne helseundersøkelsen viser at du bør undersøkes
nærmere, hvilken allmennpraktiserende lege/kommunelege
ønsker
Ikke skriv i disse rutene
14. ETTERUNDERSØKELSE
Takk for utfyllingen!
Nok en gang:         Velkommen til undersøkelsen
1
2
3
4
5
6
1
2
3
4
5
6
1
2
3
4
5
6
Adresse endring
JA
Har du noen gang spontanabortert (ufrivillig mistet fosteret)
etter at graviditet var sikkert påvist?
Hvis JA:
Antall ganger
Følgende spørsmål besvares bare hvis du har vært gravid:
Oppgi antall måneder det tok med regelmessig samliv
uten prevensjon (eller evt. amming), til du ble gravid:
Siste svangerskap ....................
Nest siste svangerskap.............
Tredje siste svangerskap ..........
USIKKER JANEI
mnd. uten prevensjon
mnd. uten prevensjon
mnd. uten prevensjon
De følgende spørsmål besvares bare av kvinner
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX VI: 
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QUESTIONNAIRE 2 
FOR THE 
HOMOCYSTEINE 
COHORT 
TRIVSEL OG HELSE
Her kommer noen spørsmål om hvordan du føler deg.
For hvert spørsmål setter du kryss for ett av de fire svarene
som beskriver dine følelser den siste uken. Ikke tenk for lenge
på svaret - de spontane svarene er best.
Jeg føler meg nervøs og urolig
Mesteparten av tiden
Fra tid til annen
Mye av tiden
Ikke i det hele tatt
Jeg gleder meg fortsatt over ting, slik jeg pleide før
Avgjort like mye
Ikke fullt så mye
Bare lite grann
Ikke i det hele tatt
Jeg har en urofølelse, som om noe forferdelig vil skje
Ja, og noe svært ille
Ja, ikke så veldig ille
Litt, bekymrer meg lite
Ikke i det hele tatt
Jeg kan le og se det morsomme i situasjoner
Like mye som før
Ikke like mye som før
Avgjort ikke som før
Ikke i det hele tatt
Jeg har hodet fullt av bekymringer
Veldig ofte
Ganske ofte
Av og til
En gang i blant
Jeg er i godt humør
Aldri
Noen ganger
Ganske ofte
For det meste
Jeg kan sitte i fred og ro og kjenne meg avslappet
Ja, helt klart
Vanligvis
Ikke så ofte
Ikke i det hele tatt
Jeg føler meg som om alt går langsommere
Nesten hele tiden
Svært ofte
Fra tid til annen
Ikke i det hele tatt
Jeg føler meg urolig, som om jeg har sommerfulgler i magen
Ikke i det hele tatt
Fra tid til annen
Ganske ofte
Svært ofte
Jeg bryr meg ikke lenger om hvordan jeg ser ut
Ja, jeg har sluttet å bry meg
Ikke som jeg burde
Kan hende ikke nok
Bryr meg som før
Jeg er rastløs, som om jeg stadig må være aktiv
Uten tvil svært mye
Ganske mye
Ikke så veldig mye
Ikke i det hele tatt
Jeg ser med glede frem til hendelser og ting
Like mye som før
Heller mindre enn før
Avgjort mindre enn før
Nesten ikke i det hele tatt
Jeg kan plutselig få en følelse av panikk
Uten tvil svært ofte
Ganske ofte
Ikke så veldig ofte
Ikke i det hele tatt
Jeg kan glede meg over gode bøker, radio og TV
Ofte
Fra tid til annen
Ikke så ofte
Svært sjelden
HELSEUNDERSØKELSEN 
I HORDALAND 1997-99
15
.0
00
- B
ey
e
r-
H
ec
os
  -
 0
3.
98
Dato for utfylling av skjema
DAG MÅNED ÅR
Eksempler:
Avkryssing: Tall: Bokstaver:
Det utfylte skjemaet vil bli lest av en maskin. Bruk blå eller sort farge ved utfylling.
Det er viktig at du går frem slik:
• i de små boksene setter du kryss for det svaret som passer best for deg
• i de store boksene skriver du tall eller blokkbokstaver –
NB! innenfor rammen for boksene.
Takk for at du har tatt deg tid til å komme til en ny helseundersøkelse i Hordaland. Dere som inviteres nå, deltok også  i 1992-93.
Den gang fikk vi verdifulle resultater som har gitt viktig ny kunnskap. For å øke vår forståelse av forhold som påvirker risikoen
for hjerte- og karsykdom er det viktig å kartlegge både fysiske (f.eks. blodkolesterol) og psykososiale (f.eks. sosial støtte)
faktorer. Vi ser frem til din deltakelse også i denne helseundersøkelsen. Mer informasjon om årets undersøkelse finner du i
HUSK brosjyren og i eget informasjonsskriv.
Alle svar vil bli behandlet strengt fortrolig.
x
Vennlig hilsen
Helseundersøkelsen i Hordaland 1997–99. Statens helseundersøkelser - Universitetet i Bergen - Kommunehelsetjenesten
SYMPTOMER PÅ HJERTE- OG KARSYKDOM
INNTEKT
SINNSSTEMNING
Har du noen gang siden 1992 hatt store smerter i brystet som
varte i mer enn 30 minutter?
Bruker du nitroglyserin?
NEI
Dersom JA, angi år
Hvis JA, hvor ofte?
92 93 94 95 96 97 98 99
NEIJA
Får du smerter i ett eller begge ben når du går?
NEIJA
Hender det at denne smerten begynner mens du står stille
eller sitter?
NEIJA
Får du slike smerter i bena når du går fort eller i oppoverbakke?
NEIJA
Får du slike smerter i bena når du går i vanlig fart på flat mark?
NEIJA
Hender det at smertene forsvinner mens du går?
Hva gjør du hvis smertene i bena kommer mens du går?
NEIJA
Daglig, eller nesten daglig ..................................................
1–3 ganger pr. uke ..............................................................
1–3 ganger pr. måned.........................................................
Sjeldnere enn 1 gang pr. måned.........................................
Får du smerter eller ubehag i brystet når du:
går i bakker, trapper eller fort på flat mark?........................
går i vanlig takt på flat mark?..............................................
I hvilken del av benet kjenner du smerter?
bare legger .........................................................................
bare lår................................................................................
både legger og lår...............................................................
Går aldri fort eller i oppoverbakke.......................................
Stopper eller saktner farten ................................................
Fortsetter som før ...............................................................
Hva skjer dersom du stopper opp?
Smertene vedvarer .............................................................
Smertene opphører.............................................................
Hvor lang tid tar det før smertene i bena eventuelt opphører?
10 minutter eller mindre ......................................................
Mer enn 10 minutter............................................................
Har du vanligvis:
hoste om morgenen?..........................................................
oppspytt fra brystet om morgenen?....................................
Dersom du får smerter eller vondt i brystet ved gange,
pleier du da å:
stoppe?...............................................................................
saktne farten?.....................................................................
fortsette i samme fart?........................................................
Dersom du stopper, eller saktner farten, forsvinner
brystsmertene da?
Hvis JA, hvor lang tid tar det før de forsvinner?
10 minutter eller mindre ......................................................
Mer enn 10 minutter............................................................
Her kommer noen ord for ulike følelser. Les hvert ord og merk av det
svaret som passer best for hvordan du vanligvis kjenner deg, altså
hvordan du i gjennomsnitt føler deg.
Sett ett kryss for hver sinnsstemning.
Ingen inntekt ................................................................................
Kr. 100 – 49.900...........................................................................
Kr. 50.000 – 99.900......................................................................
Kr. 100.000 – 149.900..................................................................
Kr. 150.000 – 199.900..................................................................
Kr. 200.000 – 299.900..................................................................
Kr. 300.000 – 399.900..................................................................
Kr. 400.000 – 499.900..................................................................
Kr. 500.000 – eller mer ................................................................
Hva er for tiden husholdningens årsinntekt (lønn og pensjon)
før skatt?
interessert...................................
irritabel.........................................
uvennlig .......................................
nedtrykt........................................
årvåken........................................
entusiastisk .................................
opprømt .......................................
skamfull .......................................
stolt ..............................................
opprørt .........................................
inspirert........................................
skjelven........................................
sterk.............................................
nervøs..........................................
aktiv .............................................
full av skyldfølelse........................
bestemt........................................
redd .............................................
skremt..........................................
oppmerksom/konsentrert.............
Svært lite Litt Middels En del MyeJeg er vanligvis:
Takk enda en gang for at du har tatt deg tid til å fylle ut dette skjemaet!
Ditt bidrag vil være viktig for forståelsen av hvordan ulike forhold kan virke inn på helse og sykdom.
Vennlig hilsen 
Helseundersøkelsen i Hordaland 97-99
Statens Helseundersøkelser
NEIJA
NEIJA
NEIJA
Lårhalsbrudd ................................................
Brudd ved håndledd/underarm.....................
Nakkesleng (whiplash) .................................
Skade som førte til sykehusinnleggelse .......
NEIJA
Høysnue? .............................................................................
Kronisk bronkitt? ..................................................................
Benskjørhet (osteoporose)? .................................................
Fibromyalgi/fibrositt/kronisk smertesykdom? .......................
NEIJA
Blir du kortpustet når du skynder deg (går fort) på flat mark,
eller går opp en liten bakke?
Hvis NEI, gå til neste avsnitt. Hvis JA, fortsett med de neste 
spørsmålene.
NEIJA
Blir du kortpustet når du spaserer på flat mark
sammen med mennesker på din egen alder?
Har du noen gang hatt følgende sykdommer?
Sett kryss for hvert spørsmål. Oppgi også alderen for hendelsen. Hvis
det har skjedd flere ganger, hvor gammel var du siste gang?
Har du eller har du hatt: Kryss JA eller NEI for hvert spørsmål.
Hender det at du må stoppe for å få igjen pusten
mens du spaserer i ditt eget tempo på flat mark?
Får du pustevansker i forbindelse med stell og
påkledning?
Har du hatt hjerneslag, blodpropp, hjerteinfarkt, hjerte-/eller
karoperasjoner i 1992 eller senere?
For hvilke av sykdomsepisodene var du innlagt på
sykehus?
Hadde du store lammelser og/eller talevansker?
Hvis NEI, ber vi deg gå til neste avsnitt. Hvis JA, ber vi deg
besvare disse spørsmålene.
Hjerneslag/Hjernedrypp .......................
Hjerteinfarkt...........................................
Blodpropp i lunge ..................................
Blodpropp i legg/lår ...............................
Operasjon på halsåren..........................
Hjerteoperasjon.....................................
Operasjon på hovedpulsåren ................
Operasjon på blodårer i legg/lår............
(ikke åreknuter)
NEI
Har du pustevansker når du ligger stille,
f.eks. i sengen?
Bruker du ekstra puter om natten p.g.a. pustevansker?
JA
Plagsomt tørre øyne - har du hatt denne følelsen
daglig i mer enn 3 måneder?
Tørrhet i munnen - har du hatt denne følelsen
daglig i mer enn 3 måneder?
Har du vært behandlet/operert for snorking/pustepauser?
Har du vært innlagt på sykehus siden 1992 av andre 
grunner enn hjerte-karsykdom?
Dersom JA, hvilke(t) år
Har du ofte følelsen av sand på øynene?
Må du ofte drikke for å kunne svelge tørr mat?
HJERTE- OG KARSYKDOM SIDEN 1992
SØVN
KONTAKT MED ANDRE MENNESKER
92 93 94 95 96 97 98 99
Kreft......................................................
Ulykke/skade.........................................
Annet.....................................................
angi grunn...........
92 93 94 95 96 97 98 99
Hjerneslag/Hjernedrypp .......................
Hjerteinfarkt...........................................
Blodpropp i legg/lår ...............................
92 93 94 95 96 97 98 99
Dersom du har hatt hjerneslag eller hjernedrypp:
Lammelser
Talevansker
arm
ben
ansikt
Hvor lenge varte disse plagene?
Mindre enn 1 døgn
1 døgn til 1 måned
Mer enn 1 måned
ANNEN SYKDOM
SKAL BARE BESVARES AV KVINNER
Alder siste
gang
Har du merket følgende besvær siste 3 måneder?
Tenk på alle (barn, foreldre, søsken, ektefelle, samboer eller kjæreste, naboer, venner, kolleger eller andre du kjenner) når du besvarer
følgende spørsmål:
Jeg har noen jeg bryr meg om, som jeg kan snakke med om mine
personlige problemer
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Det er mennesker i livet mitt som jeg bryr meg om, men som
misliker hverandre
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Det finnes en person i livet mitt som trenger min hjelp, men jeg
vet ikke hvordan jeg kan hjelpe
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Det finnes en viktig person i livet mitt som ønsker å støtte meg,
men som ofte sårer meg i stedet
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Det finnes mennesker som jeg må være sammen med nesten
daglig som ofte hakker på meg
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Det finnes personer som gjør livet mitt vanskelig fordi de 
ønsker for mye omsorg fra meg
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Jeg har noen jeg bryr meg om, som forventer mer av meg enn
jeg kan klare
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
NEIJA
NEIJA
P-pille (også minipille) ...........................................
Hormonspiral...........................................................
Østrogen (tabletter eller plaster) .............................
Østrogen (krem eller stikkpiller) ..............................
Nå Før Aldri
Det finnes minst én person som ville kunne låne meg penger
for en kortere tid
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Jeg synes at jeg har nok kontakt med mennesker som bryr seg
om meg
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Jeg føler meg ofte ensom
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Jeg synes det er vanskelig å snakke med mennesker jeg ikke
har møtt før
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Jeg føler meg ensom selv når jeg er sammen med andre
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Jeg føler ofte at andre ikke forstår meg og min situasjon
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Jeg føler at andre bryr seg om meg
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Gode venner
Føler du at du har nok gode venner?
Hvor mange gode venner har du? Regn med de du kan snakke for-
trolig med og som kan gi deg hjelp når du trenger det?
Tell ikke med de du bor sammen med, men ta med andre slektninger.
NEIJA
Aldri, eller noen få ganger i året...................................................
1-3 ganger i måneden..................................................................
Omtrent en gang i uken ...............................................................
Mer enn en gang i uken ...............................................................
Hvor ofte tar du del i foreningsvirksomhet som f.eks. idrettslag,
politiske lag, religiøse eller andre foreninger?
Bruker du eller har du brukt:
Snorking (ifølge andre) ....................................................
Pustepauser under søvn (ifølge andre) ...........................
Trett/søvning på arbeid eller i fritiden...............................
Behov for å kjempe mot søvnen for å holde deg våken....
Hvordan synes du at du sover totalt sett?
Veldig bra............................................................................
Ganske bra .........................................................................
Verken bra eller dårlig.........................................................
Ganske dårlig......................................................................
Veldig dårlig ........................................................................
Aldri
Sjelden
Noen ganger
pr. år
Iblant
Noen ganger
pr. mnd.
For det meste
Flere ganger
pr. uke Alltid
Lårhalsbrudd ................................................
Brudd ved håndledd/underarm.....................
Nakkesleng (whiplash) .................................
Skade som førte til sykehusinnleggelse .......
NEIJA
Høysnue? .............................................................................
Kronisk bronkitt? ..................................................................
Benskjørhet (osteoporose)? .................................................
Fibromyalgi/fibrositt/kronisk smertesykdom? .......................
NEIJA
Blir du kortpustet når du skynder deg (går fort) på flat mark,
eller går opp en liten bakke?
Hvis NEI, gå til neste avsnitt. Hvis JA, fortsett med de neste 
spørsmålene.
NEIJA
Blir du kortpustet når du spaserer på flat mark
sammen med mennesker på din egen alder?
Har du noen gang hatt følgende sykdommer?
Sett kryss for hvert spørsmål. Oppgi også alderen for hendelsen. Hvis
det har skjedd flere ganger, hvor gammel var du siste gang?
Har du eller har du hatt: Kryss JA eller NEI for hvert spørsmål.
Hender det at du må stoppe for å få igjen pusten
mens du spaserer i ditt eget tempo på flat mark?
Får du pustevansker i forbindelse med stell og
påkledning?
Har du hatt hjerneslag, blodpropp, hjerteinfarkt, hjerte-/eller
karoperasjoner i 1992 eller senere?
For hvilke av sykdomsepisodene var du innlagt på
sykehus?
Hadde du store lammelser og/eller talevansker?
Hvis NEI, ber vi deg gå til neste avsnitt. Hvis JA, ber vi deg
besvare disse spørsmålene.
Hjerneslag/Hjernedrypp .......................
Hjerteinfarkt...........................................
Blodpropp i lunge ..................................
Blodpropp i legg/lår ...............................
Operasjon på halsåren..........................
Hjerteoperasjon.....................................
Operasjon på hovedpulsåren ................
Operasjon på blodårer i legg/lår............
(ikke åreknuter)
NEI
Har du pustevansker når du ligger stille,
f.eks. i sengen?
Bruker du ekstra puter om natten p.g.a. pustevansker?
JA
Plagsomt tørre øyne - har du hatt denne følelsen
daglig i mer enn 3 måneder?
Tørrhet i munnen - har du hatt denne følelsen
daglig i mer enn 3 måneder?
Har du vært behandlet/operert for snorking/pustepauser?
Har du vært innlagt på sykehus siden 1992 av andre 
grunner enn hjerte-karsykdom?
Dersom JA, hvilke(t) år
Har du ofte følelsen av sand på øynene?
Må du ofte drikke for å kunne svelge tørr mat?
HJERTE- OG KARSYKDOM SIDEN 1992
SØVN
KONTAKT MED ANDRE MENNESKER
92 93 94 95 96 97 98 99
Kreft......................................................
Ulykke/skade.........................................
Annet.....................................................
angi grunn...........
92 93 94 95 96 97 98 99
Hjerneslag/Hjernedrypp .......................
Hjerteinfarkt...........................................
Blodpropp i legg/lår ...............................
92 93 94 95 96 97 98 99
Dersom du har hatt hjerneslag eller hjernedrypp:
Lammelser
Talevansker
arm
ben
ansikt
Hvor lenge varte disse plagene?
Mindre enn 1 døgn
1 døgn til 1 måned
Mer enn 1 måned
ANNEN SYKDOM
SKAL BARE BESVARES AV KVINNER
Alder siste
gang
Har du merket følgende besvær siste 3 måneder?
Tenk på alle (barn, foreldre, søsken, ektefelle, samboer eller kjæreste, naboer, venner, kolleger eller andre du kjenner) når du besvarer
følgende spørsmål:
Jeg har noen jeg bryr meg om, som jeg kan snakke med om mine
personlige problemer
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Det er mennesker i livet mitt som jeg bryr meg om, men som
misliker hverandre
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Det finnes en person i livet mitt som trenger min hjelp, men jeg
vet ikke hvordan jeg kan hjelpe
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Det finnes en viktig person i livet mitt som ønsker å støtte meg,
men som ofte sårer meg i stedet
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Det finnes mennesker som jeg må være sammen med nesten
daglig som ofte hakker på meg
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Det finnes personer som gjør livet mitt vanskelig fordi de 
ønsker for mye omsorg fra meg
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Jeg har noen jeg bryr meg om, som forventer mer av meg enn
jeg kan klare
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
NEIJA
NEIJA
P-pille (også minipille) ...........................................
Hormonspiral...........................................................
Østrogen (tabletter eller plaster) .............................
Østrogen (krem eller stikkpiller) ..............................
Nå Før Aldri
Det finnes minst én person som ville kunne låne meg penger
for en kortere tid
Stemmer helt
Stemmer ikke særlig
Stemmer ganske bra
Stemmer slett ikke
Jeg synes at jeg har nok kontakt med mennesker som bryr seg
om meg
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Jeg føler meg ofte ensom
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Jeg synes det er vanskelig å snakke med mennesker jeg ikke
har møtt før
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Jeg føler meg ensom selv når jeg er sammen med andre
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Jeg føler ofte at andre ikke forstår meg og min situasjon
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Jeg føler at andre bryr seg om meg
I svært stor grad
I ganske stor grad 
I noen grad
I liten grad
Ikke i det hele tatt
Gode venner
Føler du at du har nok gode venner?
Hvor mange gode venner har du? Regn med de du kan snakke for-
trolig med og som kan gi deg hjelp når du trenger det?
Tell ikke med de du bor sammen med, men ta med andre slektninger.
NEIJA
Aldri, eller noen få ganger i året...................................................
1-3 ganger i måneden..................................................................
Omtrent en gang i uken ...............................................................
Mer enn en gang i uken ...............................................................
Hvor ofte tar du del i foreningsvirksomhet som f.eks. idrettslag,
politiske lag, religiøse eller andre foreninger?
Bruker du eller har du brukt:
Snorking (ifølge andre) ....................................................
Pustepauser under søvn (ifølge andre) ...........................
Trett/søvning på arbeid eller i fritiden...............................
Behov for å kjempe mot søvnen for å holde deg våken....
Hvordan synes du at du sover totalt sett?
Veldig bra............................................................................
Ganske bra .........................................................................
Verken bra eller dårlig.........................................................
Ganske dårlig......................................................................
Veldig dårlig ........................................................................
Aldri
Sjelden
Noen ganger
pr. år
Iblant
Noen ganger
pr. mnd.
For det meste
Flere ganger
pr. uke Alltid
TRIVSEL OG HELSE
Her kommer noen spørsmål om hvordan du føler deg.
For hvert spørsmål setter du kryss for ett av de fire svarene
som beskriver dine følelser den siste uken. Ikke tenk for lenge
på svaret - de spontane svarene er best.
Jeg føler meg nervøs og urolig
Mesteparten av tiden
Fra tid til annen
Mye av tiden
Ikke i det hele tatt
Jeg gleder meg fortsatt over ting, slik jeg pleide før
Avgjort like mye
Ikke fullt så mye
Bare lite grann
Ikke i det hele tatt
Jeg har en urofølelse, som om noe forferdelig vil skje
Ja, og noe svært ille
Ja, ikke så veldig ille
Litt, bekymrer meg lite
Ikke i det hele tatt
Jeg kan le og se det morsomme i situasjoner
Like mye som før
Ikke like mye som før
Avgjort ikke som før
Ikke i det hele tatt
Jeg har hodet fullt av bekymringer
Veldig ofte
Ganske ofte
Av og til
En gang i blant
Jeg er i godt humør
Aldri
Noen ganger
Ganske ofte
For det meste
Jeg kan sitte i fred og ro og kjenne meg avslappet
Ja, helt klart
Vanligvis
Ikke så ofte
Ikke i det hele tatt
Jeg føler meg som om alt går langsommere
Nesten hele tiden
Svært ofte
Fra tid til annen
Ikke i det hele tatt
Jeg føler meg urolig, som om jeg har sommerfulgler i magen
Ikke i det hele tatt
Fra tid til annen
Ganske ofte
Svært ofte
Jeg bryr meg ikke lenger om hvordan jeg ser ut
Ja, jeg har sluttet å bry meg
Ikke som jeg burde
Kan hende ikke nok
Bryr meg som før
Jeg er rastløs, som om jeg stadig må være aktiv
Uten tvil svært mye
Ganske mye
Ikke så veldig mye
Ikke i det hele tatt
Jeg ser med glede frem til hendelser og ting
Like mye som før
Heller mindre enn før
Avgjort mindre enn før
Nesten ikke i det hele tatt
Jeg kan plutselig få en følelse av panikk
Uten tvil svært ofte
Ganske ofte
Ikke så veldig ofte
Ikke i det hele tatt
Jeg kan glede meg over gode bøker, radio og TV
Ofte
Fra tid til annen
Ikke så ofte
Svært sjelden
HELSEUNDERSØKELSEN 
I HORDALAND 1997-99
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Dato for utfylling av skjema
DAG MÅNED ÅR
Eksempler:
Avkryssing: Tall: Bokstaver:
Det utfylte skjemaet vil bli lest av en maskin. Bruk blå eller sort farge ved utfylling.
Det er viktig at du går frem slik:
• i de små boksene setter du kryss for det svaret som passer best for deg
• i de store boksene skriver du tall eller blokkbokstaver –
NB! innenfor rammen for boksene.
Takk for at du har tatt deg tid til å komme til en ny helseundersøkelse i Hordaland. Dere som inviteres nå, deltok også  i 1992-93.
Den gang fikk vi verdifulle resultater som har gitt viktig ny kunnskap. For å øke vår forståelse av forhold som påvirker risikoen
for hjerte- og karsykdom er det viktig å kartlegge både fysiske (f.eks. blodkolesterol) og psykososiale (f.eks. sosial støtte)
faktorer. Vi ser frem til din deltakelse også i denne helseundersøkelsen. Mer informasjon om årets undersøkelse finner du i
HUSK brosjyren og i eget informasjonsskriv.
Alle svar vil bli behandlet strengt fortrolig.
x
Vennlig hilsen
Helseundersøkelsen i Hordaland 1997–99. Statens helseundersøkelser - Universitetet i Bergen - Kommunehelsetjenesten
SYMPTOMER PÅ HJERTE- OG KARSYKDOM
INNTEKT
SINNSSTEMNING
Har du noen gang siden 1992 hatt store smerter i brystet som
varte i mer enn 30 minutter?
Bruker du nitroglyserin?
NEI
Dersom JA, angi år
Hvis JA, hvor ofte?
92 93 94 95 96 97 98 99
NEIJA
Får du smerter i ett eller begge ben når du går?
NEIJA
Hender det at denne smerten begynner mens du står stille
eller sitter?
NEIJA
Får du slike smerter i bena når du går fort eller i oppoverbakke?
NEIJA
Får du slike smerter i bena når du går i vanlig fart på flat mark?
NEIJA
Hender det at smertene forsvinner mens du går?
Hva gjør du hvis smertene i bena kommer mens du går?
NEIJA
Daglig, eller nesten daglig ..................................................
1–3 ganger pr. uke ..............................................................
1–3 ganger pr. måned.........................................................
Sjeldnere enn 1 gang pr. måned.........................................
Får du smerter eller ubehag i brystet når du:
går i bakker, trapper eller fort på flat mark?........................
går i vanlig takt på flat mark?..............................................
I hvilken del av benet kjenner du smerter?
bare legger .........................................................................
bare lår................................................................................
både legger og lår...............................................................
Går aldri fort eller i oppoverbakke.......................................
Stopper eller saktner farten ................................................
Fortsetter som før ...............................................................
Hva skjer dersom du stopper opp?
Smertene vedvarer .............................................................
Smertene opphører.............................................................
Hvor lang tid tar det før smertene i bena eventuelt opphører?
10 minutter eller mindre ......................................................
Mer enn 10 minutter............................................................
Har du vanligvis:
hoste om morgenen?..........................................................
oppspytt fra brystet om morgenen?....................................
Dersom du får smerter eller vondt i brystet ved gange,
pleier du da å:
stoppe?...............................................................................
saktne farten?.....................................................................
fortsette i samme fart?........................................................
Dersom du stopper, eller saktner farten, forsvinner
brystsmertene da?
Hvis JA, hvor lang tid tar det før de forsvinner?
10 minutter eller mindre ......................................................
Mer enn 10 minutter............................................................
Her kommer noen ord for ulike følelser. Les hvert ord og merk av det
svaret som passer best for hvordan du vanligvis kjenner deg, altså
hvordan du i gjennomsnitt føler deg.
Sett ett kryss for hver sinnsstemning.
Ingen inntekt ................................................................................
Kr. 100 – 49.900...........................................................................
Kr. 50.000 – 99.900......................................................................
Kr. 100.000 – 149.900..................................................................
Kr. 150.000 – 199.900..................................................................
Kr. 200.000 – 299.900..................................................................
Kr. 300.000 – 399.900..................................................................
Kr. 400.000 – 499.900..................................................................
Kr. 500.000 – eller mer ................................................................
Hva er for tiden husholdningens årsinntekt (lønn og pensjon)
før skatt?
interessert...................................
irritabel.........................................
uvennlig .......................................
nedtrykt........................................
årvåken........................................
entusiastisk .................................
opprømt .......................................
skamfull .......................................
stolt ..............................................
opprørt .........................................
inspirert........................................
skjelven........................................
sterk.............................................
nervøs..........................................
aktiv .............................................
full av skyldfølelse........................
bestemt........................................
redd .............................................
skremt..........................................
oppmerksom/konsentrert.............
Svært lite Litt Middels En del MyeJeg er vanligvis:
Takk enda en gang for at du har tatt deg tid til å fylle ut dette skjemaet!
Ditt bidrag vil være viktig for forståelsen av hvordan ulike forhold kan virke inn på helse og sykdom.
Vennlig hilsen 
Helseundersøkelsen i Hordaland 97-99
Statens Helseundersøkelser
NEIJA
NEIJA
NEIJA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PAPER I 
Review
The validity of the Hospital Anxiety and Depression Scale
An updated literature review
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Abstract
Objective: To review the literature of the validity of the
Hospital Anxiety and Depression Scale (HADS). Method: A
review of the 747 identified papers that used HADS was
performed to address the following questions: (I) How are the
factor structure, discriminant validity and the internal consistency
of HADS? (II) How does HADS perform as a case finder for
anxiety disorders and depression? (III) How does HADS agree
with other self-rating instruments used to rate anxiety and
depression? Results: Most factor analyses demonstrated a two-
factor solution in good accordance with the HADS subscales for
Anxiety (HADS-A) and Depression (HADS-D), respectively. The
correlations between the two subscales varied from .40 to
.74 (mean .56). Cronbach’s alpha for HADS-A varied from .68 to
.93 (mean .83) and for HADS-D from .67 to .90 (mean .82). In
most studies an optimal balance between sensitivity and specificity
was achieved when caseness was defined by a score of 8 or above
on both HADS-A and HADS-D. The sensitivity and specificity for
both HADS-A and HADS-D of approximately 0.80 were very
similar to the sensitivity and specificity achieved by the General
Health Questionnaire (GHQ). Correlations between HADS and
other commonly used questionnaires were in the range .49 to .83.
Conclusions: HADS was found to perform well in assessing the
symptom severity and caseness of anxiety disorders and
depression in both somatic, psychiatric and primary care patients
and in the general population. D 2002 Elsevier Science Inc.
All rights reserved.
Keywords: Anxiety; Depression; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of results; Sensitivity and specificity
Introduction
To make cost-effective screening of mental disorders
feasible, several brief questionnaires assessing a limited set
of symptoms have been developed. The Hospital Anxiety
and Depression Scale (HADS) [1] was developed by
Zigmond and Snaith in 1983 to identify caseness (possible
and probable) of anxiety disorders and depression among
patients in nonpsychiatric hospital clinics. It was divided
into an Anxiety subscale (HADS-A) and a Depression
subscale (HADS-D) both containing seven intermingled
items. To prevent ‘noise’ from somatic disorders on the
scores, all symptoms of anxiety or depression relating also
to physical disorder, such as dizziness, headaches, insom-
nia, anergia and fatigue, were excluded. Symptoms relating
to serious mental disorders were also excluded, since such
symptoms were less common in patients attending a non-
psychiatric hospital clinic. The authors [1] also intended to
‘‘define carefully and distinguish between the concepts of
anxiety and depression.’’
HADS has been used extensively, and we identified 747
papers that referred to HADS in Medline, ISI and PsycINFO
indexed journals by May 2000.
The evaluation of psychometric properties and dia-
gnostic efficacy of questionnaires is often inadequate [2].
To our knowledge, there has been only one review of the
literature addressing these issues in HADS [3]. Based on
approximately 200 papers on HADS in approximately
35,000 individuals in various patient populations, Herr-
mann concluded in 1996 that ‘‘HADS is a reliable and
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valid instrument for assessing anxiety and depression in
medical patients.’’
Since Herrmann’s review the number of ‘HADS-papers’
that have been published has increased almost fourfold.
These papers also include samples from the general popu-
lation, which Herrmann’s review did not. Another reason for
conducting an updated review of HADS-related papers was
to achieve more information about the following issues: (I)
How is the factor structure, discriminant validity and the
internal consistency of HADS? (II) How does HADS
perform as a case finder for anxiety disorders and depres-
sion? (III) To what extent does HADS agree with other self-
rating instruments (concurrent validity)?
Method
A search in the Medline, ISI and PsycINFO databases
was performed in May 2000. All papers containing the
terms ‘Hospital’ and ‘Anxiety’ and ‘Depression’ or ‘HAD’
or ‘HADS’ in the title or abstract were identified. The
abstracts of these studies (n = 1403) were then inspected to
ascertain whether they contained information about the
HADS. The authors then reviewed 747 studies using the
HADS for information regarding issues (I), (II) and (III),
and 71 relevant papers were identified.
Factor structure, discriminant validity and
internal consistency
The following information was gathered: the number of
factors in HADS identified by factor analyses, the correla-
tion between the subscales of HADS, and the internal
consistency of the subscales (Cronbach’s alpha).
HADS as a case finder for anxiety disorders and depression
Sensitivity and specificity of HADS in the different
studies were chosen according to the cut-off value deter-
mined by a receiver operating characteristic (ROC) curve
giving a maximal diagnostic contribution [4,5]. In studies
without ROC curves, but with at least four cut-off values with
given sensitivities and specificities, we plotted the ROC
curves ourselves. The area under the ROC curve (AUC) is
a measure of the information value inherent in a test to
determine caseness over the whole range of possible thresh-
old values [6]. An AUC value of 0.50 reflects a test that is
unable to discriminate between cases and noncases, while a
value of 1.00 means perfect sensitivity and specificity at all
cut-off values. In the studies where the ROC curves were
plotted by us, approximations of AUC were calculated using
the trapezium rule [7]. (AUC between two cut-off points on
the curve is a trapezium. All the trapeziums are summarized.)
Reported positive and negative predictive values were
not regarded as appropriate measures for review because of
their sensitivity to varying prevalence of ‘true cases.’
Only studies where the diagnoses were made by a
structured or semistructured diagnostic interview were con-
sidered for sensitivity and specificity measures.
Concurrent validity
The performance of HADS relative to other commonly
used questionnaires and rating scales of anxiety and
depression was based on correlation coefficients for instru-
ments with a continuous scale, and sensitivity and specifi-
city for instruments categorising individuals as having a
disorder or not.
Results
Most studies using HADS have been done on selected
samples of patients with cancer or other somatic illnesses.
The psychometric properties of HADS were seldom the
main issue in these studies, the sample sizes were mostly
relatively small (n< 250), and the results were frequently
given without further discussion. From general population
samples, psychometric properties of HADS were only
reported in three papers. Spinhoven et al. [8] reported
from three different Dutch samples (total N = 5393),
Lisspers et al. [9] from a sample of 624 Swedish subjects
and Jimenez et al. [10] from a sample of 207 elderly
Spanish subjects.
Factor structure, discriminant validity and
internal consistency
Among the 19 studies reporting factor analysis of HADS
(Table 1), 11 studies (total N = 14,588) achieved a two-factor
structure, 5 studies (total N = 3459) a three-factor structure
and 2 studies (total N = 235) a four-factor structure. Most
studies used principal component analysis. The studies of
Spinhoven et al. [8] and Lisspers et al. [9] based on data
from the general population both reported a two-factor
structure (total N = 6017). Spinhoven et al. found that the
two-factor solution was stable across different age groups
from the general population and in different clinical samples
(general practice, medical outpatients with unexplained
somatic symptoms and psychiatric outpatients). Lisspers
et al. found the same two-factor structure for both males
and females. Dunbar et al. [11] tested different factor models
using a confirmatory factor analysis on samples of three
different age groups (aged approximately 18, 39 and
58 years) from the general population (n = 2547). A three-
factor model derived from the tripartite theory of anxiety
and depression [12] produced the closest fit to the data
across all the age groups, though testing the two-factor
model achieved by Moorey et al. [13] showed measures of
goodness of fit relatively close to the three-factor model
(comparative fit index 0.93 vs. 0.97 and root mean square
error of approximation 0.06 vs. 0.04).
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Based on these studies HADS performed as a bidimen-
sional test, although the factors were not absolutely consist-
ent with the subscales of Anxiety and Depression. The most
consistent finding was that the HADS-A 4 item (‘‘I can sit at
ease and feel relaxed’’) showed relatively low loadings
( < 0.60) on the anxiety factor and some loadings on the
depression factor ( > 0.45) [3,9,13–17].
Twenty-one studies reported the Pearson correlation coef-
ficient between HADS-A and HADS-D (mean .56). In seven
studies of nonpatient samples [10,17–22] the correlations
varied between .49 and .74 (mean .59). In 12 studies of
somatic patient samples [14,20,23–32] the correlations var-
ied between .40 and .64 (mean .55). The last two studies of
psychiatric patients both achieved a correlation of .56 [8,33].
Cronbach’s alpha coefficient of internal consistency was
reported in 15 studies (Table 1) and varied for HADS-A
from .68 to .93 (mean .83), and for HADS-D from .67 to
.90 (mean .82) [3,9,13–16,21,30,34–40].
HADS as a case finder for anxiety disorders and depression
Optimal balance between sensitivity and specificity for
HADS as a screening instrument was achieved most fre-
quently at a cut-off score of 8+ for both HADS-A and
HADS-D giving sensitivities and specificities for both
subscales of approximately 0.80.
The findings from the 24 papers reporting sensitivity
and specificity are summarised according to the popula-
tions studied. More details are given in Table 2. Only
one community survey (n = 330) was found [41] and
ROC curves identified 8+ to be an optimal cut-off score
for caseness for both anxiety disorders and depression
based on ICD-9. Sensitivity and specificity for both
anxiety and depression were approximately 0.90. The
author reported similar results in samples from medical
inpatient populations.
HADS was tested in three studies of primary care
populations. Wilkinson and Barczak [42] (n = 100) found
an excellent ability of HADS to detect DSM-III-defined
psychiatric morbidity, and the ROC curves showed that a
score of 8+ was the optimal threshold. The AUC was
found to be 0.96. el Rufaie and Absood [35] studied
patients (n= 217) attending a primary health care centre.
The ROC curves (calculated by us) showed that the
optimal cut-off scores for caseness were 9+ for HADS-A
(sensitivity 0.66, specificity 0.93) and 7+ for HADS-D
(sensitivity 0.66, specificity 0.97), when using DSM-III
diagnoses obtained by the Clinical Interview Schedule as
gold standard. AUC (calculated by us) was 0.86 for both
anxiety and depression. Lam et al. [43], however, identified
(by ROC curves) a lower optimal cut-off in their sample
from a general practice (n = 100), 3+ for HADS-A and
6+ for HADS-D giving the sensitivities 0.67 and 0.78 and
specificities 0.83 and 0.91, respectively. Their gold stand-
ard was not reported, but the Clinical Interview Schedule
was used, presumably giving DSM-III diagnoses.
Table 1
Factor analysis and internal consistency of the HADS
Version of Method of factor Number of
Cronbach’s a
Reference HADS n analysis factors HADS-A HADS-D
Anderson [75] Swedish 163 PCA 4
Bedford et al. [16] English 132 PCA 2 .83 .86
Brandberg et al. [39] Swedish 273 PCA 3 .85 .81
Costantini et al. [38] Italian 197 PCA 2 .85 .89
Dagnan et al. [15] English 341 PCA 2 .84 .83
Dunbar et al. [11] English 2547 CFA 3
Hammerlid et al. [36] Norwegian Swedish 351 PCA 2 .89 .82
Herrmann et al. [3] German 5338 PCA?a 2 .80 .81
Leung et al. [21] English 100 PCA 3
Chinese 100 PCA 3 .81 .74
Lewis [29] English 117 PCA 3
Lisspers et al. [9] Swedish 624 PCA 2 .84 .82
Martin and Thompson [40] English 72 MLA 4 .82 .78
Martin and Thompson [30] English 194 MLA 3 .76 .72
Moorey et al. [13] English 568 PCA 2 .93 .90
Razavi et al. [31] French 228 PCA 3
Savard et al. [14] French Canadian 162 PCA 2 .89 .89
Sigurdardottir et al. [72] Swedish 89 PCA 2
Soriano and Salavert [17] Spanish 621 PCA 2
Spinhoven et al. [8] Dutch 6165 PCA 2
Botega et al. [34] Portuguese 78 .68 .67
el Rufaie et al. [35] Arabic 217 .78 .88
Wettergren et al. [37] Swedish 20 .88 .86
CFA: confirmatory factor analysis; HADS: Hospital Anxiety and Depression Scale; HADS-A: Anxiety subscale of HADS; HADS-D: Depression subscale of
HADS; MLA: maximum likelihood factor analysis; PCA: principal component analysis.
a Not reported.
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Table 2
Estimated sensitivity specificity of the HADS at optimal cut-off valuesa
Diagnostic Diagnostic Patient
Optimal cut-off values Sensitivity Specificity
Reference system instrument Diagnosis population n A D T A D T A D T
el-Rufaie et al. [35] DSM-III CIS Anxiety, depression Primary care 217 9+ 7+ 0.66 0.66 0.93 0.97
Lam et al. [43] DSM-III? CIS Anxiety, depression Primary care 100 3+ 6+ 0.67 0.78 0.83 0.91
Wilkinson and Barczak [42] DSM-III SCID Anxiety, depression Primary care 100 8+ 0.90 0.86
Botega et al. [34] DSM-III CIS Anxiety, depression General medical 78 9+ 9+ 0.94 0.85 0.73 0.90
Costantini et al. [38] DSM-III DIS Anxiety, depression Breast Cancer 197 10+ 0.84 0.79
Hall et al. [76] DSM-III PSE Anxiety, depression Breast cancer 266 7+ 7+ 12+ 0.72 0.37 0.57 0.80 0.93 0.93
Hopwood et al. [77] DSM-III CIS Anxiety, depression Breast cancer 81 11+ 11+ 18+ 0.75 0.75 0.81 0.90 0.75 0.89
Ibbotson et al. [78] DSM-III PAS GAD, MDD Cancer 513 14+ 0.80 0.76
Lepine et al. [86] DSM-III CIDI MDD Internal medicine 150 8+ 0.74 0.77
Razavi et al. [79] DSM-III DIS Adjustment
disorders +MDD
Cancer 210 8+ 7+ 13+ 0.64 0.59 0.75 0.72 0.78 0.75
MDD only Cancer 210 11+ 7+ 19+ 0.54 0.71 0.70 0.75 0.76 0.75
Hamer et al. [46] DSM-III SCID Anxiety, depression Self-harm 100 8+ 0.88 0.78
Barczak et al. [74] DSM-III SCID Specific phobias, GAD,
dysthymia, MDD
Medical (genitourinary) 100 8+ 8+ 0.82 0.70 0.94 0.68
Johnson et al. [44] DSM-III PAS Anxiety, depression Poststroke 93 4+ 4+ 0.95 0.83 0.38 0.44
Clarke et al. [62] DSM-III-R SCID-R MDD General hospital 179 10+ 21+ 0.71 0.76 0.92 0.93
Kugaya et al. [80] DSM III-R SCID Adjustment disorders+MDD Cancer 128 8+ 5+ 11+ 0.75 0.92 0.92 0.80 0.58 0.65
MDD only Cancer 128 8+ 11+ 20+ 0.94 0.82 0.82 0.88 0.95 0.96
Razavi et al. [73] DSM-III-R DIS SCID Adjustment disorders,
depression, anxiety
Cancer 117 10+ 0.84 0.66
Hosaka et al. [85] DSM-IV ‘Structured interview’ Adjustment disorders +MDD Nonmalignant
otolaryngeal
50 12+ 0.93 0.86
Malign. otolaryngeal 50 12+ 0.91 0.96
Silverstone [81] DSM-III-R
ICD-10
SCAN Modified MDD General medical 153 8+ 17+ 1.00 1.00 0.73 0.75
Psychiatric 147 10+ 17+ 0.68 0.95 0.46 0.21
Silverstone [82] DSM-IV SCAN MDD General medical 153 8+ 0.91 0.71
Berard et al. [83] DSM-IV SCID Adjustment disorders Cancer 100 8+ 0.71 0.95
Depression Cancer 100 11+ 0.43 0.96
Ramirez et al. [84] Bedford Criteria PSE Anxiety, depression Breast cancer 91 11+ 0.84 0.83
Spinhoven et al. [8] ICD-8 PSE Depression General medical
out-patient
169 10+ 0.56 0.92
Abiodun [41] ICD-9 PSE Anxiety, depression Medical and surgical 275 8+ 8+ 0.85 0.91 0.87 0.87
Gynecological 233 8+ 8+ 0.91 0.92 0.87 0.89
Antenatal 240 8+ 8+ 0.93 0.90 0.90 0.91
Community 330 8+ 8+ 0.88 0.90 0.91 0.91
A: Anxiety subscale of the HADS; CIS: Clinical Interview Schedule; D: Depression subscale of the HADS; DIS: Diagnostic Interview Schedule; GAD: generalised anxiety disorder; HAMA: Hamilton Anxiety
Scale; MADRS: Montgomery Asberg Depression Rating Scale; MDD: major depressive disorder; PAS: Psychiatric Assessment Schedule; PSE: Present State Examination; SCAN: Structured Clinical Assessment
for Neuropsychiatric Disorders; SCID: Structured Clinical Interview for DSM-III/DSM-III-R/DSM-IV; T: total score of the HADS.
a For example, 8+ means equal to or above 8.
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We identified 12 studies that addressed optimal cut-off
scores for caseness in noncancer medical patients (total
N = 2109). For HADS-A the mean optimal cut-off score was
approximately 8+ (7.5), with resulting mean sensitivity
0.90, and mean specificity 0.78. Similarly, for HADS-D
the mean optimal cut-off score also was approximately
8+ (8.1), with mean sensitivity 0.83, and mean specificity
0.79. Johnson et al. [44] studied poststroke patients (n = 93)
and we estimated their optimal cut-off scores to be 5+ for
HADS-A and 4+ for HADS-D, giving significantly lower
specificity for both anxiety and depression (0.46 and 0.44,
respectively) than in studies of other medical samples.
Using the highest score of either HADS-A or HADS-D as
an indicator of psychiatric morbidity, Morriss and Wearden
[45] found that a cut-off score for caseness of 10+ resulted
in sensitivity 0.92 and specificity 0.71 in a sample of
chronic fatigue syndrome patients (n = 136). Hamer et al.
[46] presented findings from a sample of 100 self-harming
patients with an ROC curve, which showed 8+ to be the
optimal cut-off score of caseness of HADS-D giving sens-
itivity 0.88 and specificity 0.78.
In the 10 studies of cancer patients (total N = 1803), the
mean optimal cut-off score for caseness on HADS-A was
approximately 9+ (8.8), with mean sensitivity 0.72, and
mean specificity 0.81. For HADS-D the mean optimal cut-
off score of caseness was approximately 8+ (8.3), with mean
sensitivity 0.66, and mean specificity 0.83.
Concurrent validity
Six studies reported the correlations between Beck’s
Depression Inventory (BDI) and HADS. The correlations
between BDI and HADS-D were .62 to .73, BDI and
HADS-A .61 to .83 and BDI and HADS-total score
(HADS-T) .73 [9,14,47–50] (Table 3). Two studies demon-
strated that the correlations between the General Health
Questionnaire (GHQ-28) and HADS-D were .50 and .66,
and between GHQ-28 and HADS-A .50 and .68 [18,24]. The
correlations between the Clinical Anxiety Scale [51] and
HADS-A were .69 and .75 in two studies [52,53]. The
correlations between Spielberger’s State-Trait Anxiety
Inventory (STAI) and HADS were examined in five studies
[9,14,20,54,55]. Between STAI and HADS-A the correla-
tions were in the range of .64 to .81, between STAI and
HADS-D .52 to .65 and between STAI and HADS-T .68
to .71. Two studies examined the relationship between the
Table 3
Correlation coefficients between the HADS and other questionnaires and interview-based measures
Compared
Correlation coefficients between HADS and the other questionnaire
Reference questionnaire HADS-A HADS-D HADS-T
Beck et al. [47] BDI-PC .62
Lisspers et al. [9] BDI .64 .71 .73
Sua`rez-Mendosa et al. [48] BDI .83
Savard et al. [14] BDI .68 .70
Tedman et al. [49] BDI .61 .73
Watson et al. [50] BDI .69
Lewis and Wessely [60] GHQ-12 .75
Caplan [18] GHQ-28 .68 .66
Chandarana et al. [24] GHQ-28 .50 .50
Elliot [54] STAI .64 .52
Herrmann et al. [20] STAI .66 .59
Lisspers et al. [9] STAI-S .64 .68
STAI-T .66 .64 .71
Millar et al. [55] STAI-S .81
Savard et al. [14] STAI-S .78 .65
Lepine et al. [59] MADRS .62
Snaith and Taylor [52] MADRS .37 .81
Upadhyaya and Stanley [53] MADRS .80
Aylard et al. [58] MADRS (item 3) .77
CAS .67
Snaith and Taylor [52] CAS .69 .44
Upadhyaya and Stanley [53] CAS .75
Spinhoven and van der Does [56] SCL-90, Anxiety, Depression .49 .69
Watson et al. [50] SCL-90, Anxiety, Depression .73 .67
Lepine et al. [59] HAMA-S, HAMA-P, HAMA-T .34 .40. 44
Millar et al. [55] VAS .74
BDI: Beck Depression Inventory; BDI-PC: Beck Depression Inventory for Primary Care; CAS: Clinical Anxiety Scale; HADS-A: Anxiety subscale of HADS;
HADS-D: Depression subscale of HADS; HADS-T: Total score of HADS; HAMA-S: Hamilton Anxiety Scale— Somatic Items; HAMA-P: Hamilton Anxiety
Scale— Psychic Items; HAMA-T: Hamilton Anxiety Scale—Total Scale; MADRS: Montgomery–Asberg Depression Rating Scale; SCL-90: Symptom
Checklist 90 Scale; STAI-S: Spielberger State-Trait Anxiety Inventory—State Form; STAI-T: Spielberger State-Trait Anxiety Inventory—Trait Form; VAS:
Visual Analogue Scale.
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SCL-90 subscales of Anxiety and Depression and HADS
[50,56]. The correlations between SCL-90 Anxiety and
HADS-A were .49 and .73, while the correlations between
SCL-90 Depression and HADS-D were .69 in both studies.
Finally, in four studies the correlations between the interview-
basedMontgomery Asberg Depression Rating Scale [57] and
HADS-D were in the range .62 to .81, while the correlation
with HADS-T was .77 [52,53,58,59]. Low correlations (.34
to .44) were found between Hamilton Anxiety Rating Scale
and HADS-A [59].
Three studies [42,60,61] compared the sensitivity and
specificity of HADS to that of various editions of GHQ.
HADS and GHQ had close to identical sensitivities and
specificities, both at the level of 0.80 for HADS-A,
HADS-D as well as for HADS-T. Clarke et al. [62]
compared HADS, GHQ and BDI (against DSM-III-R dia-
gnoses) by using Quality ROC curves. Here the GHQ
performed marginally better than HADS and BDI.
Discussion
Bidimensionality
The results of our review support the two-factor struc-
ture of HADS. In most studies where empirically based
exploratory factor analyses were used HADS revealed
two relatively independent dimensions of anxiety and de-
pression closely identical to the Anxiety and Depression
subscales. The three-factor model supported by the theory-
driven confirmatory factor analysis of Dunbar et al. [11],
however, challenge the bidimensionality of HADS. Never-
theless, the fit measures of the two-factor model proposed
by Moorey et al. [13] were relatively close to the three-
factor model. In addition, Dunbar et al. did not test more
than one two-factor model, while four three-factor models
were tested, among whom one showed a much worse fit
than the two-factor model.
Recognising the extensive comorbidity between anxiety
and depression [63–65], the moderate to strong correlations
between HADS-A and HADS-D subscales reported were to
be expected. Burns and Eidelson [66] argued that the
correlation between any valid and reliable measure of
depression and anxiety should be at the .70 level, not
because of shared symptoms between anxiety and depres-
sion, but because of a common causal factor. However,
other authors have claimed that a low correlation between
the two measures of anxiety and depression is a hallmark of
good discriminant validity of a bidimensional test [12].
Watson et al. [50] stated that: ‘‘Phenomenologically, anxi-
ety and depression are clearly distinct from each other.
Anxiety is centered on the emotion of fear and involves
feelings of worry, apprehension, and dread; in contrast,
depression is dominated by the emotion of sadness and is
associated with feelings of sorrow, hopelessness, and
gloom. Nevertheless, despite their seeming distinctiveness,
it has proven difficult to distinguish these constructs
empirically. Many studies have shown that self-report
measures are highly correlated, with coefficients typically
in the .45 to .75 range.’’ Some authors have recommended
not only the use of correlations between subscales to assess
their divergent validity, but also a multitrait–multimethod
approach [67]. In our search, however, no papers reported
such a comprehensive assessment.
Internal consistency
It has been recommends that Cronbach’s coefficient
alpha should be at least .60 for a self-report instrument to
be reliable [68]. This demand was fulfilled in all studies of
HADS in various translations that report data on internal
consistency. Similar findings of internal consistency from
different translations of HADS supported the robustness of
the instrument.
HADS as a case finder for anxiety disorders
and depression
In this review the threshold values identified for optimal
balance between sensitivity and specificity showed rel-
atively little variability, and they were very close to 8+,
defined as the cut-off for ‘possible cases’ suggested by
Zigmond and Snaith in their original paper on HADS [1].
This threshold was found for HADS-A and HADS-D in the
general population as well as in somatic patients samples.
Two papers reported some deviating cut-off values; Lam
et al. [43] found an optimal cut-off value of HADS-A at
3+ and of HADS-D at 6+, while Johnson et al. [44] found
the optimal cut-off values of both HADS-A and HADS-D at
4+. An explanation may be that in both studies HADS was
administered completely or partly as an interview, possibly
biasing the responses to the items.
The sensitivity and specificity of HADS-A and HADS-D
with a threshold of 8+ were most often found to be in the
range of 0.70 to 0.90. The variation in both optimal cut-off
values and sensitivity and specificity might be due to
differences in diagnostic systems, ‘gold standard’ instru-
ments, HADS translations used [21,69,70], as well as to
differences in samples and procedures in administration of
HADS [71] (such an explanation may also be applied to the
varying results of the other psychometric properties of
HADS). Among three studies of general practice patients
AUCs were found to be 0.84–0.96. These results indicate
excellent case finding abilities of HADS in unselected
samples of patients seeking a general practitioner.
Concurrent validity
This review revealed that HADS, despite of its brevity,
exhibited similar sensitivity and specificity as longer ver-
sions of GHQ. When compared to other questionnaires for
anxiety and depression in common use such as BDI, STAI,
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CAS, and SCL-90 Anxiety and Depression subscales, the
correlation to HADS-D and HADS-A, respectively, were
between .60 and .80, which should be characterised as
medium to strong correlations. The same level of correla-
tions was found when HADS-D was compared to Mont-
gomery Asberg Depression Rating Scale. Accordingly, our
conclusion is that the concurrent validity of HADS is good
to very good.
Conclusions
This review confirmed the assumption that HADS is a
questionnaire that performs well in screening for the
separate dimensions of anxiety and depression and caseness
of anxiety disorders and depression in patients from non-
psychiatric hospital clinics. Even though a limited number
of studies addressed other study populations, we found
evidence that HADS has the same properties when applied
to samples from the general population, general practice
and psychiatric patients. HADS seems to have at least as
good screening properties as similar, but more comprehens-
ive, instruments used for identification of anxiety disorders
and depression.
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Abstract 
 
Background and Objective: Comorbidity between anxiety and depression and 
its clinical impact have almost exclusively been studied by a categorical approach 
in contrast to a dimensional one. Hence, the aim of this study was to explore the 
occurrence of anxiety and depression as codimensions and examine how co-
occurring anxiety and depression was associated with impairment in a 
dimensional approach compared to a categorical one.  
Study Design and Setting: In the cross-sectional Nord-Trøndelag Health Study 
1995-97 (N=61,216) the relation between anxiety and depression was studied. 
Associations between continuous anxiety and depression scores and impairment 
were compared with associations between anxiety and depression categories and 
impairment by means of generalized and conventional logistic regression 
analyses. 
Results: The relation between anxiety and depression scores was close to linear. 
Both the dimensional and the categorical approaches demonstrated strong 
associations between anxiety and depression, respectively, and impairment. The 
dose-response relation shown by the dimensional approach represented better the 
impact of co-occurring symptoms, particularly in the lower symptom range.  
Conclusion: The dimensional approach is a useful supplement to the categorical 
one in clinical practice and research addressing comorbid anxiety and depression. 
By considering both anxiety and depression symptoms their respective 
contribution is better evaluated. 
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1. Introduction  
In 1987 Goldberg et al [1] reported that the two highly correlated 
dimensions of anxiety and depression under lied the common mental disorders 
encountered in primary care. Based on these findings, he proposed a three-
dimensional model for common mental disorders, consisting of anxiety, 
depression, and somatisation [2]. Similar models for milder psychopathology have 
been developed by other groups, such as the Tripartite Model of anxiety and 
depression by Clark and Watson [3]. That model was later developed further into 
the Integrated Hierarchical Model [4]. Krueger’s model [5] identified an 
externalizing and an internalizing dimension, of which the latter encompassed the 
anxious-misery and fear sub-dimensions.  
These models have been counterparts to the categorical classification 
systems that utilize thresholds of various symptoms to identify diagnostic entities. 
While the dimensional models mainly have been developed to refine the 
theoretical constructs of e.g. anxiety and depression, categorical diagnoses are 
more practically oriented for the clinician as well as for the researcher in need of 
diagnoses as outcome measures [6]. In the dimensional models anxiety and 
depression, respectively, are assumed to be conditions distributed on a continuum 
from minimal to maximal symptom load, as so-called spectrum disorders [7]. 
When studying the prevalence and consequences of comorbid anxiety and 
depression the categorical approach have been mostly used. High occurrence of 
such comorbidity between anxiety disorders and depression have been reported in 
samples from the general population [8] and primary care [9]. Comorbidity has 
also been associated with impaired treatment response to antidepressants [10], 
impaired recovery rate from depression, increased time to recovery, decreased 
time to relapse [11], as well as increased risk for suicide [12].  
The categorical approach has, however, some limitations because of 
obliged diagnostic thresholds for clinical disorder [13]. Studies have shown that 
sub-threshold disorders have significant clinical impact regarding both morbidity, 
functional impairment, mortality, treatment, and prognosis [7, 14-18]. These facts 
support the notion of anxiety and depression as spectrum disorders consistent with 
the dimensional model [19]. However, as far as we know, a dimensional approach 
has not been applied when studying the impact of comorbid anxiety and 
depression.   
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Hence, in this study we wanted to examine the association between co-
occurring anxiety and depression, and subjective impairment by use of a 
dimensional approach. To emphasize the dimensional perspective, we introduced 
the term codimensionality, as an equivalent to comorbidity. More precisely we 
asked the following research questions: (I) How is codimensionality between 
anxiety and depression occurring in the general population as to age, gender and 
symptom intensity? (II) How is co-occurring anxiety and depression associated 
with impairment due to chronic mental health problems as seen in a dimensional 
compared to a categorical approach? 
 
 
2. Methods 
2.1. Study population 
Based on updated population register lists all inhabitants aged 20 years and 
above were invited to take part in the The Nord-Trøndelag Health Study 1995-97 
(The HUNT 2 Study) [20]. Nord-Trøndelag County encompasses 3% of the 
Norwegian population, and except for a lower mean level of education, the 
County is representative of Norway. Of 92,100 eligible subjects aged 20-89 years, 
65,648 (71.3%) participated in the study.  
 
2.2. Assessment of anxiety and depression  
The Hospital Anxiety and Depression Scale (HADS) is a self-administered 
questionnaire consisting of 14 items, seven for anxiety (HADS-A subscale) and 
seven for depression (HADS-D subscale), each scored from 0 (not present) to 3 
(highly present) on a Likert scale formulated in readily understandable language 
[21, 22]. To increase acceptability and to preclude that individuals felt tested for 
mental disorders, symptoms of severe psychopathology were not included. 
HADS-A contains items mainly concerned with restlessness and worry plus one 
item on panic attacks, while HADS-D focuses mainly on the reduced pleasure 
response aspect (anhedonia) of depression, as well as psychomotor retardation and 
depressed mood. The two-dimensional quality of HADS has been demonstrated 
by several factor analytic studies [22], as well as in the HUNT 2 population where 
the factors were identical with the sub-scales [23].With a categorical approach, a 
cut-off value of > 8 in both sub-scales has demonstrated optimal screening 
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properties in identifying anxiety disorders and major depressive disorder, yielding 
sensitivities and specificities of approximately 0.80 [22]. In the present study sub-
scale scores > 8 were denoted “high-score” anxiety (or depression) and < 8 “low-
score” anxiety (or depression). “Pure high-score anxiety” was restricted to cases 
without HADS-D scores > 8, and “pure high-score depression restricted to cases 
without HADS-A scores > 8. “Comorbid anxiety and depression” was defined by 
combined HADS-A > 8 and HADS-D > 8. 
A total of 65,344 subjects of HUNT 2 filled in HADS. Valid ratings of the 
anxiety and depression sub-scales were defined as at least five completed items on 
HADS-A and HADS-D, respectively. The score of those who filled in five or six 
items was based on the sum of completed items multiplied with 7/5 or 7/6, 
respectively. By this procedure [24] the subjects with both valid HADS-A and 
HADS-D ratings were N = 61,216 (47.3% men). The youngest and oldest age 
groups were underrepresented (table 1). 
 
2.3. Assessment of impairment 
The HUNT questionnaire contained items in which the participants were 
asked whether they had any chronic (at least for one year) physical or mental 
diseases or injuries that impaired their daily life functioning. Subjects responding 
«moderate» or «much» on impairment due to mental problems were defined as 
impaired (n=1,676), while «no» or «little» was defined as not impaired 
(n=59,574). 
 
2.4. Statistics 
To examine the relation between anxiety and depression in the population 
the mean of the HADS-A /HADS-D ratio (AD-ratio) in men and women, 
respectively, was plotted against age strata. The relation between anxiety and 
depression throughout the symptom score range was demonstrated by plotting the 
mean HADS-D score and standard deviation (SD) against each score of HADS-A, 
and vice versa. 
Associations between the dimensions of anxiety and depression, 
respectively, and impairment were examined by a dose-response approach. The 
effect of anxiety on impairment was evaluated in individuals low-score and high-
score depression, respectively. Likewise, the effect of depression was evaluated in 
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individuals with the corresponding anxiety categories. The associations were 
estimated by graphical representations of generalized additive logistic regression 
analyses adjusting for age and gender, based on the generalized additive model 
(GAM) [25]. The outcome measure of such an analysis is a plot of odds ratios 
(OR) on a logarithmic scale where the reference value (OR = 1.00) corresponds to 
the mean value of the explanatory variable. Point-to-point 95% confidence 
intervals (CI) are demonstrating the relative precision of the point-to-point 
estimates along the plot. 
Using a logistic regression models adjusting for age and gender, OR with 
CI for impairment due to chronic mental health problems were estimated for five 
different high-score anxiety/depression categories, compared to the category with 
combined low-score anxiety and low-score depression. Despite the attempt to 
define pure anxiety and depression groups by excluding cases with co-occurring 
high-score depression or anxiety, respectively, the co-occurring low-score 
depression and anxiety, respectively, might influence the association with 
impairment. Hence, to examine the effect of such co-occurring low-score 
symptoms, two models adjusting for HADS-D and HADS-A scores, respectively, 
were added.  
To evaluate effect modification in the categorical analyses, interaction 
terms between the various anxiety/depression categories and age and gender, 
respectively, were added separately to all models. A two-sided p-value < 0.05 was 
chosen to indicate statistical significance. The statistical analyses were conducted 
using the software package of SPSS 11.0 and S-Plus 6.0.  
 
 
2.5. Ethics 
HUNT-II was approved by the Norwegian Data Inspectorate and 
Regional Committee for Medical Research Ethics in Health region IV of Norway. 
 
3. Results  
3.1. “Prevalence” and consistency of codimensionality 
The age and gender stratification of mean anxiety and depression scores 
and subjective impairment due to mental health problems are shown in table 1 and 
the AD-ratios in figure 1. The mean anxiety score exceeded the depression score 
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(AD-ratio >1) in most strata. In general, women had higher anxiety scores, and 
marginally lower depression scores than men. The proportion of individuals with 
impairment due to mental health problems varied from 1.3% (men 20-29 years) to 
4.3% (women 60-69 years). The younger age groups (20-39 years) and men were 
less impaired.  
The relation between anxiety and depression throughout the symptom 
score range was close to linear, as demonstrated in figure 2. A tendency towards a 
more than proportional relation in the higher scores was found. However, the 
observations at this level were few. The mainly linear pattern was seen in all age 
and gender strata (data not shown). 
 
3.2. Codimensionality and impairment  
The GAM curves demonstrated dose-response relationships between 
anxiety score and impairment in co-occurring high-score as well as low-score 
depression (figure 3). Similar, although somewhat weaker, relationships were seen 
between depression score and impairment in co-occurring low-score and high-
score anxiety. The almost linear relationship was demonstrated from the lowest 
symptom scores.  
 
3.3. Comorbidity and impairment  
Comorbid anxiety and depression (OR=32.1; CI: 28.2, 36.5) was more 
strongly associated with impairment than high-score anxiety and high-score 
depression alone (figure 4). Pure high-score anxiety (OR=10.5; CI: 9.1-12.1) was 
less associated with impairment than high-score anxiety without restriction on 
depressive symptoms (OR=15.2; CI: 13.6, 16.9). Adjusting for depressive 
symptoms weakened (33%) the association (OR=7.4; CI: 6.4, 8.7). Pure high-
score depression (OR=3.9; CI 3.1, 4.8) was, likewise, more weakly associated 
with impairment than high-score depression without restriction on anxiety 
symptoms (OR=9.8; CI 8.9, 10.9). The association was further attenuated (55%) 
after adjusting for anxiety symptoms (OR=2.3; CI 1.9, 2.9). All 
anxiety/depression categories were more strongly associated with impairment in 
younger than older age groups. No such effect modification was observed for 
gender. 
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4. Discussion 
We found that mean anxiety scores in general exceeded mean depression 
scores in both genders, however, less markedly by increasing age. The relation 
between anxiety and depression scores was close to linear. A dose-response 
relationship between anxiety symptoms and impairment was clearly demonstrated 
in both the low-score and high-score depression categories. A similar relation was 
found between depression symptoms and impairment in the anxiety categories. 
All the high-score anxiety/depression categories were associated with subjective 
impairment, but more so in younger than older age groups. The two high-score 
anxiety categories were more strongly associated with impairment than the high-
score depression categories and the comorbid category still more than the others. 
 
4.1. Strengths and limitations of the study 
In a sample from the general population encompassing all adult age 
groups with a high participation rate, selection bias should not be a major 
problem. However, despite a high attendance rate (78%) in another Norwegian 
health survey the prevalence of (hospitalized) psychiatric disorders was 2.5 times 
higher among nonattenders than attenders [26]. Furthermore, in the younger and 
older age groups where the participation rates were lower, such bias could not be 
ruled out. Unfortunately, in the absence of an analysis of non-participation, the 
effects of an age dependent selection bias was difficult to predict. The observed 
moderating effect of age on the association between anxiety and depression, 
respectively, and impairment, might be the result of non-participation of the more 
impaired individuals in the older age groups. Assuming an overrepresentation of 
impaired subjects among the participant in the youngest age groups is, however, 
more questionable.  
Due to the cross-sectional design of the study we could not examine the 
stability of the anxiety and depression symptoms longitudinally, which would be 
of interest when interpreting the co-occurrence of the symptoms. An unstable 
relation between anxiety and depression might question the importance of 
assessing e.g. co-occurring anxiety when depression is addressed. However, the 
strong associations between symptoms even in the low-score range and 
impairment suggest that these symptoms are relatively stable.  
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Moreover, due to the cross-sectional design we could not draw any causal 
inferences between the anxiety-depression conditions and impairment. However, 
the participants were asked specifically to report chronic impairment due to 
chronic mental health problems, and not any general impairment that could cause 
anxiety or depression. Furthermore, a study design assuming that the participant 
were in the very beginning of their «disordered period» at baseline, would be very 
difficult to perform.  
Unlike the categorical approach to psychopathology defined by 
diagnostic criteria, the dimensional models have no officially accepted common, 
well-established measure of anxiety or depression. We used HADS, and our 
findings of the relationship between anxiety and depression must be interpreted 
with the limitations of that rating scale in mind. Contrary to most prevalence 
studies, depression assessed by HADS-D is not more common among women and 
is more prevalent in the older age groups [27, 28]. However, in some studies using 
the Center for Epidemiologic Studies Depression Scale [29, 30] and Zung Self-
Rating Depression Scale [31, 32] the same age effect has been observed. 
Furthermore, in the US National Comorbidity Survey (NCS) the gender 
differences in prevalence of depression without somatic symptoms (appetite and 
sleep disturbances and fatigue), like the “somatic free” HADS-D, were minimal 
[33]. 
 
4.2. The relationship between anxiety and depression symptom scores 
The finding that the AD-ratio exceeded 1.0 in most strata emphasizes the 
major role of anxiety in affective conditions. Also, when using categorical 
measures, as in the Epidemiological Catchment Area Study [34] or NCS [8] the 
same leading position of anxiety was demonstrated. In a re-analysis of these two 
major population studies, the one-year prevalence rates of any anxiety disorder 
and major depressive episode were estimated to 11.8% and 4.5%, respectively. In 
NCS anxiety disorders were also more often comorbid with major depression 
(51.2%) than the opposite (22.1%). Our finding of a decrease in AD-ratio by 
increasing age in both genders is in accordance with studies demonstrating a 
temporal pattern where anxiety is dominating in early life, gradually being more 
mixed up by depression over time [8, 35].  
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The close to linear relation between HADS-A and HADS-D indicates that 
the codimensionality between anxiety and depression is independent of score 
levels, i.e. the relation between HADS-A and HADS-D is the same in low and 
high symptoms scores. A clinical implication of this finding might be to pay more 
attention to the occurrence of codimensional conditions in the low-score range.   
 
4.3. Codimensionality and impairment 
The dose-response relation between symptom scores and subjective 
impairment was distinct in our data starting in the sub-threshold area of both sub-
scales. That finding was very similar to the results of Angst and Merikangas in the 
Zürich study [36] and Judd et al in the National Institute of Mental Health 
Collaborative Depression Study [37] regarding depression and impairment. A 
dose-response relationship has been found between symptoms of social anxiety 
[38, 39] and posttraumatic stress disorder [40], respectively, and impairment as 
well. Hence, our findings support the notion that depression is a spectrum 
disorder, and suggest that for anxiety, too. The very distinct dose-response 
relations in the low-score range for both anxiety and depression indicate that the 
dimensional view of anxiety and depression is not only of theoretical interest, but 
of clinical importance as well. Patients not fulfilling the diagnostic criteria for 
either an anxiety disorder or depression might very well be impaired from their 
symptoms [36]. 
 
4.4. Comorbidity and impairment 
High-score anxiety and high-score depression without restrictions as to 
levels of co-occurring depression and anxiety, respectively, were more strongly 
associated with impairment than pure high-score anxiety and pure high-score 
depression. The latter ones have by definition a lower total HADS score, which 
most probably is the cause of the difference. The stronger effect of pure high-
score anxiety than pure high-score depression on impairment, indicates that the 
anxiety component is stronger determinant for impairment. Furthermore, adjusting 
for anxiety symptoms in pure high-score depression weakened the association 
with impairment more (55%) than adjustment for depression symptoms in pure 
high-score anxiety (33%). 
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We have not found any studies that have examined the possible 
moderating effect of age on the association between anxiety and depression, 
respectively, and impairment. This may probably be due to smaller sample sizes 
and narrower age range in most other studies. However, provided that anxiety 
disorders and depression in general have a relatively chronic course [41], their 
reduced effect on subjective impairment by increasing age in our study could be 
explained by increasingly competent emotion regulation across the life span [42, 
43]. 
 
4.5. Dimensional versus categorical approach 
Both approaches demonstrated that anxiety as well as depression, and in 
particular the combination of the two, was strongly predictive for impairment. 
These results are in accordance with the conclusions from the Australian National 
Survey of Mental Health and Well-Being that the combination of affective 
(depression and dysthymia) and anxiety disorders was more predictive of 
disability and service utilization than any other combinations of mental disorders 
[44]. Moreover, in the Global Burden of Disease Study (GBD) [45], depression 
was ranked as one of the most important specific cause of global disability-
adjusted life year. The impact of anxiety disorders was not addressed in GBD, but 
other studies have demonstrated considerable impairment associated with anxiety 
disorders, particularly posttraumatic stress disorder [46], panic disorder [47, 48], 
social phobia [49] and generalized anxiety disorder [50]. A systematic review of 
the outcome of anxiety and depressive disorders [51] concluded, consistently with 
our results, that there is some evidence that anxiety disorders had a worse 
outcome than depressions. 
The dimensional approach demonstrated the impact of co-occurring 
symptoms throughout the entire range of scores, even in the lower part. That 
finding indicates that categorical analyses should be performed and interpreted 
with caution. Our results showed that high-score depression without any anxiety 
restriction was more than twice as strongly associated with impairment as pure 
high-score depression. Hence, ignoring the degree of co-occurring anxiety would 
induce a significant bias. Even in pure high-score depression the co-occurring 
anxiety symptoms contributed as much as the depression itself to the association 
with impairment.  
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4.6. Conclusions 
The dimensional approach may be a useful supplement to the categorical 
one in clinical practice and research, giving a more complete description and 
comprehension of comorbid anxiety and depression. Our data suggest that the 
degree of symptoms is closely related to the degree of suffering, even in the lower 
range of the symptom scales. Hence, the clinician should try to apply a 
dimensional approach when assessing anxiety as well as depression in help-
seeking patients, not at least when diagnostic criteria are not fulfilled. For the 
researcher the reported relations might be a reminder of the importance of 
considering the level of co-occurring anxiety symptoms when addressing 
depression, and vice versa. Assuming that anxiety and depression are different, 
though related conditions, ignoring a codimensional condition may bias the 
estimates of the associations studied. By setting some restrictions to the degree of 
co-occurring anxiety and depression and/or adjusting for the other one, their 
respective contribution may be better evaluated. 
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TABLE 1 
 
Mean anxiety and depression scores, and individuals with subjective impairment 
due to mental health problems in the different age and gender strata. The Nord-
Trøndelag Health Study 1995-97 (HUNT 2). 
 
    
 
 
HADS-A a 
 
HADS-D b 
 Individuals with 
impairment c 
Age  n d  (%) Mean (SD) Mean (SD)  n (%) 
20-29 Men  3,909 (41.0) 4.1 (2.9) 2.4 (2.4)  50 (1.3) 
 Women 4,713 (54.4) 4.5 (3.2) 2.2 (2.4)  77 (1.6) 
30-39 Men  5,335 (60.5) 4.2 (3.1) 2.9 (2.7)  83 (1.6) 
 Women 6,061 (74.1) 4.6 (3.4) 2.7 (2.8)  131 (2.2) 
40-49 Men  6,394 (70.3) 4.2 (3.3) 3.6 (3.0)  165 (2.6) 
 Women 6,929 (80.6) 4.6 (3.5) 3.2 (3.0)  205 (3.0) 
50-59 Men  5,251 (74.3) 4.0 (3.2) 4.1 (3.2)  167 (3.2) 
 Women 5,553 (82.1) 4.8 (3.6) 3.7 (3.1)  209 (3.8) 
60-69 Men  4,045 (77.6) 3.5 (3.0) 4.1 (3.1)  131 (3.2) 
 Women 4,285 (78.7) 4.7 (3.6) 4.1 (3.2)  182 (4.3) 
70-79 Men  3,172 (66.0) 3.3 (3.0) 4.4 (3.3)  86 (2.7) 
 Women 3,487 (61.1) 4.3 (3.4) 4.4 (3.3)  97 (2.8) 
80-89 Men  824 (39.7) 3.1 (3.0) 4.9 (3.5)  30 (3.6) 
 Women 1,162 (34.8) 4.0 (3.6) 4.7 (3.5)  48 (4.1) 
Total  61,216 (65.0) 4.3 (3.4) 3.5 (3.1)  1676 (2.7) 
 
a Hospital Anxiety and Depression Scale, anxiety sub-scale 
b Hospital Anxiety and Depression Scale, depression sub-scale 
c Self-reported impairment due to chronic mental health problems 
d With valid HADS-A and HADS-D 
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FIGURE 1. The relationship between mean anxiety and depression symptoms in 
age and gender strata. AD-ratio, mean (HADS-A / HADS-D); HADS-A, anxiety 
sub-scale of the Hospital Anxiety and Depression Scale; HADS-D, depression 
sub-scale of the Hospital Anxiety and Depression Scale. 
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FIGURE 2. Relationship between increasing anxiety scores and mean depression scores, 
and between increasing depression scores and mean anxiety scores. Standard deviations 
(SD) are demonstrated by the whiskers. HADS-A, anxiety sub-scale of the Hospital 
Anxiety and Depression Scale; HADS-D, depression sub-scale of the Hospital Anxiety and 
Depression Scale. 
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FIGURE 3. Dose-response relationships between anxiety (bottom panels) and depression (top 
panels) scores, respectively, and subjective impairment due to chronic mental health problems. 
The presentations are divided according to co-occurring low-score (left panels) and high-score 
(right panels) depression and anxiety, respectively. The curves were constructed by using 
generalized additive regression analyses adjusting for age and gender. The dotted lines indicate 
95% pointwise confidence intervals. HADS-A, anxiety sub-scale of the Hospital Anxiety and 
Depression Scale; HADS-D, depression sub-scale of the Hospital Anxiety and Depression Scale.
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FIGURE 4. Associations between the different anxiety-depression categories and 
subjective impairment due to chronic mental health problems. 95% confidence 
intervals are indicated by whiskers. All odds ratios are adjusted for age and 
gender. AD, Comorbid anxiety and depression (HADS-A>8; HADS-D>8); A1, 
High-score anxiety (HADS-A>8); D1, High-score depression (HADS-D>8); A2, 
Pure high-score anxiety (HADS-A>8; HADS-D<8); D2, Pure high-score 
depression (HADS-D>8; HADS-A<8); A3, Pure high-score anxiety adjusted for 
depression symptoms (HADS-D score); D3, Pure high-score depression adjusted 
for anxiety symptoms (HADS-A score). HADS-A, anxiety sub-scale of the 
Hospital Anxiety and Depression Scale; HADS-D, depression sub-scale of the 
Hospital Anxiety and Depression Scale. 
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Anxiety and depression in individuals with somatic
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Objective / To examine the relationship between anxiety disorders
and depression and various somatic health problems in the general
population.
Design / Cross-sectional study with survey methods and clinical
examinations.
Setting / The Health Study of Nord-Trøndelag, Norway (the HUNT
study).
Participants / 60 869 individuals aged 20/89 years.
Main outcome measures / Anxiety disorder, depression and their
comorbidity are categorized based on scores on the Hospital Anxiety
and Depression Scale. All somatic health variables are self-reported,
while blood pressure, height and weight are measured. Multivariate
nominal logistic regression analyses are used to investigate the
relationship between somatic variables and the anxiety/depression
categories.
Results / Most somatic health variables show a stronger association
with comorbid anxiety disorder/depression than with anxiety disorder
or depression alone. About one-third of individuals reporting somatic
health problems also have anxiety disorder and/or depression.
Conclusion / Somatic health problems carry a high risk of both
anxiety disorder and depression. Active identification and treatment of
these co-occurring mental disorders are of practical importance.
Key words: anxiety, comorbidity, depression, somatic health prob-
lems.
Eystein Stordal, Department of Psychiatry, Hospital Namsos, NO-
7800 Namsos, Norway. E-mail: eystein.stordal@hnt.no
Several studies have reported a high occurrence of
depressive symptoms in patients with various somatic
health problems (1,2). However, the occurrence of
anxiety symptoms in these patients is less well
examined (3). Epidemiological and clinical studies
have shown that states of anxiety and depression
frequently coexist (4/6). Patients with comorbid
anxiety disorder and depression show more impair-
ment (7), lower treatment response (8) and poorer
long-term outcome (9) compared to those with only
one disorder. The relationship between somatic health
problems and comorbid states of anxiety and depres-
sion has been given little attention in the literature.
One reason could be that in most studies self-rating
instruments have been used that measure only one of
these affects or general mental distress alone. In
addition, most studies of the relationship between
somatic health problems and these affective states have
been performed on selected samples of patients from
hospitals or primary care. Selection bias is a frequent
occurrence in such studies and can be reduced by
studying population-based samples.
The aim of this study was to investigate the
relationship between somatic health problems and
comorbid states of anxiety and depression (contrasted
to the ‘pure’ states) in a cross-sectional study of a
general population.
MATERIAL AND METHODS
Participants
Of the total population of Nord-Trøndelag County of
Norway aged 20 to 89 years, 71.3% (n/65 648)
participated in the HUNT study 1995/1997. Of these,
60 869 (66.1%) had the somatic variables examined
and had valid ratings of anxiety and depression.
Details of the data collection procedure and charac-
teristics of the study population have been published
There is a high occurrence of depressive symp-
toms in patients with somatic health problems.
. About one-third of individuals with somatic
health problems have anxiety disorders and/or
depression.
. Comorbid anxiety disorder and depression
are found to be more strongly associated with
somatic health problems than pure anxiety
disorder and pure depression.
ORIGINAL PAPER
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elsewhere (10,11). The sample characteristics are given
in Table I.
Measures of anxiety and depression
The Hospital Anxiety and Depression Scale (HADS)
is a questionnaire that is widely used to measure
anxiety and depression in somatic and psychiatric
patients as well as in general populations (12,13).
HADS has 7 items for depression and 7 for anxiety,
and each item is scored from 0 to 3, so that the
maximum score is 21 on each of the HADS subscales
(HADS-D and HADS-A). Factor analyses of HADS
in the HUNT material resulted in a two-factor
solution consistent with the two subscales (14).
Optimal cut-off levels for anxiety disorders and
depressive disorders are at scores ]/8 for both
subscales, resulting in sensitivities and specificities of
approximately 0.80 for both HADS-A and HADS-D
(13). This cut-off was applied to define four categories
of anxiety and depression (Table II): neither depres-
sion nor anxiety disorder (group 00), pure anxiety
disorder (group A), pure depression (group D), and
comorbid anxiety disorder and depression (group
AD).
Somatic health problems
In the HUNT questionnaire, somatic diseases were
asked for by the standard formulation: ‘‘Do you have
or have you ever had the following disease?’’ Con-
firmations of these diagnoses were not obtained from
hospitals or GPs. Five somatic diseases were included:
myocardial infarction, stroke, diabetes, migraine and
fibromyalgia. Impairment due to somatic diseases was
based entirely on the subjective reports of the respon-
dents. Smoking was defined as daily consumption of
any cigarettes. Alcohol problems implied at least one
Table I. Sample characteristic.1
Men Women p
n % n %
Gender 28 808 100.0 32 061 100.0
Age groups
20/29 years 3 867 20.5 4 661 19.5 B/0.001
30/39 years 5 322 21.2 6 042 19.5
40/49 years 6 377 20.4 6 915 18.8
50/59 years 5 235 14.0 5 546 13.3
60/69 years 4 033 11.3 4 279 11.5
70/79 years 3 158 9.2 3 474 11.2
80/89 years 816 3.4 1 144 6.1
Impairment 4 009 12.7 4 586 14.0 0.170
Myocardial infarction 1 333 4.0 455 1.5 B/0.001
Stroke 527 1.6 492 1.7 0.005
Diabetes 827 2.6 811 2.7 0.009
Migraine 861 3.0 1 173 3.6 B/0.001
Fibromyalgia 266 0.8 1 723 4.8 B/0.001
Musculoskeletal 8 143 26.4 10 818 32.6 B/0.001
Cardiovascular 5 035 16.8 7 379 22.5 B/0.001
Smoking 7 727 26.5 9 435 28.4 B/0.001
Alcohol problems 5 530 20.2 1 977 6.3 B/0.001
Low physical activity 3 959 13.3 5 327 17.3 B/0.001
Hypertension 5 406 16.4 4 331 13.1 B/0.001
High BMI 4 117 13.6 5 727 17.5 B/0.001
1 Absolute numbers and statistical tests are based on unweighted data and percentages on weighted data.
Table II. Categories of anxiety and depression by gender.1
Categories HADS-A range HADS-D range n % of men % of women
Pure depressive disorder (D) 0/7 8/21 2 988 5.4 4.0
Comorbid anxiety-depressive disorder (AD) 8/21 8/21 3 610 4.9 6.3
Pure anxiety disorders (A) 8/21 0/7 5 827 7.6 11.6
Neither anxiety nor depressive disorder 0/7 0/7 48 444 82.1 78.0
Gender by comorbidity groups: Pearson chi-square 510.97; d.f./3; pB/0.001.
1 Absolute numbers and statistical tests are based on unweighted data and percentages on weighted data.
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positive response to the five items of the CAGE
screening instrument (15). Musculoskeletal symptoms
were reported as pain and/or stiffness in muscles for at
least 3 months in the past year, and cardiovascular
symptoms implied reports of palpitations or breath-
lessness in recent years. Hypertension was defined as
systolic blood pressure ]/140 or diastolic blood
pressure ]/90, based on the mean of the second and
third measurements at the HUNT examination. High
body mass index (BMI) was given by an index value of
30 or above. Low physical activity was defined as self-
reported infrequent physical activity. Somatic vari-
ables that could be seen as expressions of anxiety or
depression (such as insomnia) were excluded because
of the risk of circularity.
Statistics
Analyses were performed with weighting to adjust for
differences in response rate according to age and
gender, and for age and gender differences between
the population of Nord-Trøndelag County and the
total population of Norway. The weighting procedure
was based on the National population statistics of
1996, and was identical to the procedure used in the
National Comorbidity Survey (16) and in several of
our previous studies (10,11). All statistics except crude
numbers were based on weighted data.
Gender differences in prevalences of health pro-
blems (Tables I and II) were tested with the Pearson
chi-square test. Multinominal logistic regression ana-
lysis was used to model the associations between the
somatic health problem variables and the categories of
anxiety and depression. The somatic variables were
dichotomized and entered as independent variables,
and the anxiety and depression categories as the
dependent variable (Table III, Fig. 1). The category
with neither anxiety nor depressive disorder was used
as reference group. Age, gender and age by gender
interaction were included in all the regression models
reported. The level of significance was set at p/0.05
and two-sided tests were used.
Ethics
The National Data Inspectorate and the Board of
Medical Research Ethics in Health region IV of
Norway approved the HUNT study.
RESULTS
Several thousand participants reported somatic health
problems (from 1019 (stroke) to 18 961 (musculoske-
letal symptoms)). All somatic symptoms and diag-
noses were reported as more prevalent among women
than among men, except myocardial infarction and
hypertension. Alcohol problems, too, were more
prevalent in men, but more women reported smoking
and low physical activity. Subjective impairment due
to somatic health problems, however, were equally
frequent in men and women.
The numbers of participants in the categories of
anxiety and depression are displayed in Table II.
Those who had an anxiety and/or depressive disorder
Table III. Adjusted1 odds ratios (OR) for somatic health problems according to anxiety and depression.
Depression Comorbid depression and
anxiety disorder
Anxiety disorder Total2
%3 OR 95% CI %3 OR 95% CI %3 OR 95% CI %3
Impairment4 8.9 1.95 1.78/2.14 12.4 3.05 2.81/3.30 13.2 2.03 1.88/2.19 34.5
Myocardial infarction 11.9 1.31 1.11/1.54 8.6 1.50 1.25/1.81 6.7 1.19 0.97/1.46 27.2
Stroke 15.7 2.10 1.75/2.52 10.8 1.98 1.60/2.44 9.8 1.64 1.32/2.05 36.3
Diabetes 9.2 1.14 0.96/1.37 8.1 1.27 1.06/1.54 8.4 1.12 0.93/1.35 25.7
Migraine 4.0 1.38 1.09/1.74 9.6 2.13 1.82/2.49 15.5 1.73 1.53/1.97 29.1
Fibromyalgia 6.2 2.02 1.64/2.49 17.8 4.02 3.50/4.61 18.7 2.44 2.14/2.78 42.7
Musculo-skeletal 6.8 1.78 1.64/1.93 10.4 3.11 2.90/3.35 13.3 2.11 1.99/2.24 30.5
Cardio-vascular 6.5 1.88 1.73/2.06 12.9 4.27 3.97/4.59 18.4 3.34 3.15/3.54 37.8
Smoking 4.3 1.20 1.10/1.31 7.8 1.82 1.69/1.96 12.1 1.45 1.37/1.54 24.2
Alcohol problems 4.2 1.46 1.29/1.66 7.1 1.88 1.70/2.08 14.2 1.97 1.82/2.12 25.5
Low physical activity 3.9 1.68 1.53/1.84 5.1 1.74 1.59/1.91 9.6 1.28 1.19/1.39 18.6
Hypertension 6.9 0.93 0.85/1.03 6.3 0.92 0.83/1.01 7.8 0.93 0.85/1.02 21.0
High BMI 6.2 1.21 1.10/1.33 7.0 1.18 1.08/1.29 8.9 0.94 0.87/1.02 22.1
1 Adjusted for age and gender.
2 Total percent having depression, comorbid depression and anxiety disorder, or anxiety disorder within health problem group (e.g.
stroke).
3 Proportion of all subjects within a health problem group (e.g. stroke).
4 Impairment due to somatic health problems.
Reference group (OR/1.00): Neither depression nor anxiety disorder (HADS-A and D bothB/8).
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numbered 12 425 (20.4%), while 48 444 (79.6%) had no
disorders of these types (Group 00). The prevalence of
depression with comorbid anxiety disorder was ap-
proximately the same as the prevalence of pure
depression. Anxiety disorder without depression was
more prevalent than depression without anxiety dis-
order, especially among women. Among those report-
ing somatic health problems, about one-third also had
anxiety disorder and/or depression. This prevalence
varied between different health problems; details are
given in the right column in Table III.
As a main tendency, comorbid anxiety disorder and
depression were found to be more strongly associated
with somatic health problems than pure anxiety
disorder and pure depression (Fig. 1). This main
tendency was found in both men and women. Fig. 1
illustrates this for subjective impairment due to
somatic symptoms, and the same tendency was found
for myocardial infarction, diabetes, migraine, fibro-
myalgia, musculoskeletal symptoms, cardiovascular
symptoms, smoking and low physical activity (Table
III). There were a few exceptions, however; stroke and
high BMI were more strongly associated with pure
depression than the comorbid condition, and alcohol
problems were more strongly associated with anxiety
disorder. For details on the estimates, see Table III.
DISCUSSION
Statement of principal findings
We have three main findings: (a) There was an
increased occurrence of comorbid anxiety disorder
and depression in individuals who currently had
somatic health problems compared to those with
pure anxiety disorder or depression only. (b) Such
comorbidity was frequent and represented 28% of all
cases with anxiety disorder and depression in our
sample. (c) In persons reporting somatic health
problems commonly in focus in primary health care
settings, depression, anxiety disorder and comorbid
conditions were highly frequent. In about one of three
persons with a somatic health problem, anxiety and
depression were present as well.
We could not find any studies in the literature where
the association between somatic health problems and
the comorbid anxiety/depression state had been ex-
amined, and therefore our results cannot be compared
with other samples. Intuitively, it makes sense that
those with the more severe comorbid mental disorders
are more represented among those who have somatic
health problems.
The cross-sectional design of HUNT does not allow
for any assumptions about the causal relation between
the somatic health problems and anxiety or depres-
sion.
Strengths and weaknesses
Our study has several strengths. The attendance rate
of the HUNT study was high, probably because it was
carried out in the local communities, the participation
fee was low, and the study had been run once before
and was well announced in the local media. As a
general health study, HUNT did not focus on mental
health problems in particular and thereby avoided
selection biases inherent in mental health surveys. The
general population approach also avoided the selec-
tion biases frequently occurring in special or primary
care samples. The large sample size made possible
examination of many somatic health problems with a
high number of participants, which allowed for multi-
variate statistical modelling.
The HADS subscale specificity of approximately
0.80 at cut-off ]/8 introduced a certain risk of false-
positive cases. However, a higher cut-off yielding a
better specificity excluding more false-positives would
increase the risk of false-negatives, which clinically
could be more questionable. Ideally we should have
interviewed a random sample of the participants with
scores around cut-off in order to get good prevalence
Fig. 1. Impairment due to somatic health problems in
relation to depression and anxiety disorder. The
estimates are obtained from multinominal logistic
regression analysis adjusted for age. OO/No anxiety
disorder or depression (HADS-A and D scoresB/8):
reference group. D/Depression without anxiety dis-
order (HADS-A scoreB/8, HADS-D score]/8).
AD/Comorbid anxiety disorder and depression
(HADS-A and HADS-D scores]/8). A/Anxiety
disorder without depression (HADS-A score]/8,
HADS-D scoreB/8).
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estimates. Such a procedure, however, was not part of
the HUNT design. The point prevalence we observed
for anxiety disorder and depression was in good
accordance with those reported by Kringlen et al.
from their recent survey of the population of Oslo,
Norway (17).
A limitation of this study was a 29% non-partici-
pant rate. We tried to compensate for this by using a
weighting procedure. Based on findings from other
studies (18) we can assume that persons with severe
somatic and mental health problems were under-
represented in HUNT. Another weakness is that
most of our data on somatic health problems were
based on self-report. Practical, economic and ethical
reasons precluded validation by GPs or hospitals. The
time frames of the somatic questions differed con-
siderably, and could influence the prevalences of
anxiety and depression. In this cross-sectional study
the causality sequence between several somatic health
variables and anxiety and depression is unclear.
However, our purpose was rather to compare different
anxiety and depression states in somatic health
problems than to study the mechanisms of the
relationships.
Participants with clinically significant levels of
anxiety and depression might have reported more
somatic health problems and impairment due to their
mental state. This possible information bias could
have led to minor overestimates of the associations
between the mental disorders and impairment and
somatic symptoms.
Meaning of the study
In conclusion, the clinical implication of our findings
is that clinicians should pay attention to anxiety and
depression in patients with somatic health problems as
about one in three patients consulting a general
practitioner for somatic health problems also has
anxiety disorder and/or depression. In some somatic
health-problem groups, anxiety disorder and/or de-
pression is even more frequent (Table III). Diagnosis
and treatment of anxiety and/or depressive disorder
can be quite efficient (19), and thereby contribute to
better subjective well-being and quality of life in
patients with long-standing somatic health problems.
Unanswered questions and future research
Is the burden of somatic health problems the cause of
the increased occurrence of anxiety and depression in
these individuals? Or are anxiety disorder and depres-
sion risk factors for the development of such health
problems? These questions can only be answered by
well-designed longitudinal studies, or even clinical
trials examining the long-term effects of treating
both somatic and psychiatric patients.
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Folate, Vitamin B12, Homocysteine, and the MTHFR 677C→T Polymorphism 
in Anxiety and Depression. The Hordaland Homocysteine Study 
 
Abstract 
 
Background: An association between depression and folate status has been demonstrated in 
clinical studies, whereas data are sparse on the relationship between depression 
and other components of 1-carbon metabolism such as vitamin B12, homocysteine, and the 
methylenetetrahydrofolate reductase 677C→T polymorphism. The relationship between 
anxiety and these components is less well known. This study examined the associations 
between folate, total homocysteine, vitamin B12, and the methylenetetrahydrofolate reductase 
677C→T polymorphism, and anxiety and depression in a large population-based study. 
 
Methods: Anxiety and depression, measured by the Hospital Anxiety and Depression Scale, 
were assessed in 5948 subjects aged 46 to 49 years (mean, 47.4 years) and 70 to 74 years 
(mean, 71.9 years) from the Hordaland Homocysteine Study cohort. By means of logistic 
regression models, anxiety and depression scores were examined in relation to the factors 
listed above. 
 
Results: Overall, hyperhomocysteinemia (plasma total homocysteine level ≥15.0 μmol/L [≥ 
2.02 mg/dL]) (odds ratio, 1.90; 95% confidence interval, 1.11-3.25) and T/T 
methylenetetrahydrofolate reductase genotype (odds ratio, 1.69; 95% confidence interval, 
1.09-2.62), but not low plasma folate or vitamin B12 levels, were significantly 
related to depression without comorbid anxiety disorder. Plasma folate level was inversely 
associated with depression only in the subgroup of middle-aged women. None of the 
investigated parameters showed a significant relationship to anxiety. 
 
Conclusion: Our results provide further evidence of a role of impaired 1-carbon metabolism in 
depression. 
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Abstract 
 
In the paucity of prospective studies we aimed to examine the associations between 
educational level and later anxiety disorder and depression among individuals with and 
without mental distress at baseline. We also wanted to identify factors that explained eventual 
associations. 36,150 individuals aged 20-69 years from the Nord-Trøndelag Health Study 
1984-1986 were followed up after 11 years. The analyses were performed in an incident and a 
persistent cohort defined by a low and a high mental distress level at baseline, respectively. 
Using logistic regression models, the association between educational level and 
anxiety/depression categories at follow-up were examined. Covariates related to somatic 
health, health behaviors, psychosocial status, and sociodemographic and work characteristics 
were included in the analyses.  
Significant gradients (trend test: p < 0.001) from the highest to the lowest educational 
level were observed in the association with anxiety disorder, depression, and comorbid 
disorder in the incident cohort, and with depression and comorbid disorder in the persistent 
cohort. The depression component at follow-up was more related to educational level than the 
anxiety one. The other covariates influenced the observed associations to a lesser degree.  
In conclusion the lower educational levels predicted new as well as chronic cases of 
depression, with and without comorbid anxiety disorder. 
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A recent meta-analysis (1) found higher prevalence and incidence as well as 
persistence of depression in subjects within the lowest group of socioeconomic status (SES) 
compared to those in the highest. However, in the few studies not addressing education, which 
is the most frequently used SES indicator, the results of incidence (2, 3) and persistence (3-5) 
were inconsistent.  
The majority of published studies addressing SES and depression have a cross-
sectional design. To our knowledge the number of longitudinal studies on this topic is limited 
to four (2-5), and these differ in sample size, measure of depression, follow-up time and 
covariates examined. Only one of these focused on SES, including education, as the main 
predictor of depression (5).  
Although anxiety disorders are closely related to depression (6, 7), we are not aware of 
longitudinal studies of their relation to education. The association between education and 
comorbid anxiety disorder and depression (comorbid disorder) has hardly been addressed at 
all.  
The association between SES and depression is not fully understood. In contrast to e.g. 
schizophrenia, there is most evidence for low SES as a predictor of depression, at least in 
women (1, 8). Some studies (9, 10), however, support the selection theory (11) as well that 
depression hinders upward and promotes downward social mobility.  
In a cross-sectional study (12) using occupational grade as a proxy for SES, work 
characteristics, including skill discretion and decision authority, explained most of the SES-
depression gradient. Economic situation was used as the measure of SES in a prospective 
study (13), where health behavior (smoking, alcohol consumption, physical activity) and 
body-mass index rather than physical disease, explained the SES-depression gradient. 
However, physical and psychological functioning w assessed only at follow-up and the 
different health behaviors were not evaluated separately. One of the prospective studies (3) 
addressed somatic health and health behaviors, but the effects of specific variables were not 
evaluated. Nor was the effect of unfavorable psychosocial status, such as living alone (3, 4), 
being socially isolated (3), or being unemployed (3, 4) examined.  
The aims of our study were to examine, in a prospective study of 36,150 individuals 
followed for 11 years, whether low education is a predictor of new and chronic cases of 
anxiety disorder, depression and comorbid disorder; and if so, whether somatic illness, use of 
health services, health behaviors, or sociodemographic or work characteristics may explain 
the relationships.  
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MATERIALS AND METHODS 
The cohorts 
All inhabitants of Nord-Trøndelag County of Norway, aged 20 years and above  
(N=87,285) were invited to participate in the Nord-Trøndelag Health Study 1984-1986 
(HUNT 1) (14). Nord-Trøndelag County encompasses 3 percent of the Norwegian population. 
In the age group of 20-69 years, which was examined in the current study, 64,443 (89.5%) 
participated. Valid scores of an Anxiety-Depression Index (ADI-12, described under 
”Assessment of anxiety and depression”) were obtained from 51,295 individuals (71.3 
percent) in that group. Among these, 44,585 (61.9 percent) individuals were invited to take 
part in the Nord-Trøndelag Health Study 1995-1997 (HUNT 2) (14, 15) 11 years later and 
37,579 (84.3 percent) participated. However, non-valid scores of anxiety or depression were 
observed in 1,335 subject and missing information of education in further 121, reducing the 
current total cohort to 36,150 individuals (81.1 percent of those invited to HUNT 2).  
Incidence of anxiety disorder and depression was examined among the participants 
who had ADI-12 scores < the 80th percentile (N= 29,463) at baseline (the incident cohort). 
Persistence of anxiety disorder and depression was studied in the remaining participants 
(n=6,687) (the persistent cohort).  
 
 
Assessment of mental distress at baseline (ADI-12) 
Because no specific measure for anxiety or depression was used at HUNT 1, an 
Anxiety-Depression Index (ADI-12) was composed of 12 HUNT 1 questions addressing 
different aspects of anxiety, depression, life satisfaction, and personality. Individuals having 
answered at least eight of the 12 ADI questions, were given valid ADI-12 scores calculated as 
the mean of the z-scores of the 12 ADI questions. Each z-score was weighted with its loading 
on the one factor extracted from a principal component analysis of the 12 questions. Low 
ADI-12 scores indicated good mental health. In a four year follow-up after HUNT 1 where 
these 12 questions were repeated, the ADI-12 scores predicted 67 percent of the variance of 
the Hopkins Symptom Checklist (SCL-25) scores (16).  
 
Assessment of anxiety and depression at follow-up 
At follow-up anxiety and depression were assessed by the Hospital Anxiety and 
Depression Scale (HADS), a self-administered questionnaire consisting of 14 items, seven for 
anxiety (HADS-A subscale) and seven for depression (HADS-D subscale), each scored from 
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0 (not present) to 3 (maximally present) on a Likert scale formulated in readily 
understandable language (17). To increase acceptability and to preclude that individuals feel 
tested for mental disorders, symptoms of severe psychopathology were not included. HADS-
A contains items mainly concerned with restlessness and worry, as in generalized anxiety 
disorder, plus one item on panic attacks. HADS-D focuses mainly on the reduced pleasure 
response aspect (anhedonia) of depression, as well as psychomotor retardation and depressed 
mood. With a categorical approach, a cut-off value of > 8 in both subscales has demonstrated 
optimal screening properties in identifying anxiety disorders and major depressive disorder, 
with sensitivities and specificities of approximately 0.80 (18). The two-dimensional quality of 
HADS has been demonstrated by several factor analytic studies (18), as well as in the HUNT 
2 population where the factors were identical with the subscales (19).  
Valid ratings of HADS-A and HADS-D were defined as at least five completed items 
on each subscale. Those who only had filled in five or six items got their score based on the 
sum of completed items multiplied with 7/5 or 7/6, respectively. 
HADS-A and HADS-D are inter-correlated, most often in the range of 0.50 - 0.60 
(18). Hence, in order to identify more homogenous groups with anxiety disorders or 
depressions, restrictions were put on the other subscale when cases were defined. Thus, 
anxiety disorder was defined as HADS-A > 8, and HADS-D < 8 in order to avoid 
comorbidity. Accordingly, depression was defined as HADS-D > 8, and HADS-A < 8. Cases 
with comorbid disorder was defined as both HADS-A and HADS-D scores  > 8.  
 
Education 
 Education was divided into three levels: Primary school (<10 years), high school (10-
12 years), and college or university (>12 years). Considering that not all participants had 
finished their education at baseline, we composed a common educational level for HUNT 1 
and HUNT 2, using the highest reported level. When information on education was missing at 
one time point, information from the other was used. 
 
Potential mediators 
 At baseline there was self-reported information on somatic health, use of health 
services, health behavior, and sociodemographic and work characteristics. Whether they 
should be considered as confounders or intermediate variables (mediators) in the association 
between education and anxiety/depression was not obvious. Nevertheless, we included them 
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in the analyses to examine their influence on that association and denoted them “potential 
mediators”.  
At baseline, current or former diabetes, mycardial infarction, angina pectoris and 
stroke were reported. The three latter were combined to denote cardiovascular disease. Daily 
impairment due to chronic physical illness or injury was dichotomized into “Not impaired” 
and “Impaired”. Use of analgesics was defined as daily or weekly use the last month. Having 
visited a general practitioner or other physician during the last 12 months and having been 
hospitalized during the last five years, were the two measures of health services use. Problems 
of falling asleep or sleep problems almost every night or frequently were characterized as 
“Sleep problems”. Calculation of Body Mass Index (kg/m2) was based on data from the 
clinical examinations and categorized by two cut-offs, > 25kg/m2 and >30kg/m2, respectively. 
Health behaviors were dichotomized like this: Physical exercise > weekly practicing; smoking 
> one cigarette daily; alcohol consumption > ten days with alcohol use during the last two 
weeks. Psychosocial status included whether the respondents felt lonely and/or had available 
social support in case of long-lasting illness in need of bed rest. Sociodemographic 
characteristics included whether the respondents were living alone and/or were separated or 
divorced. Work characteristics included dichotomized variables as to whether the respondents 
considered their job to be stressful, whether the job allowed influence on the planning of the 
work, whether they were satisfied with their job, and whether they were unemployed.  
 
Statistics 
 Most analyses were performed separately for the incident and persistent cohorts. 
Logistic regression analyses were used to estimate odds ratios (OR) with corresponding 95 
percent confidence intervals (CI) for being a case of anxiety disorder, depression, or comorbid 
disorder at follow-up, comparing the two lower educational levels separately to the highest. 
The representation of the three educational levels as indicator variables was used to allow for 
assessment of non-linear dose-response relationships, while a linear (1 df) representation was 
used to test for linear trends.  
To examine the effect of education on HADS scores at follow-up, two logistic 
regression models were used, one with adjustment for age and gender (Model 1) and one with 
additional adjustment for anxiety/depression (ADI-12 score) at baseline (Model 2). The 
purpose of the latter was to adjust for the variation in ADI-12 within the cohorts. To examine 
whether “sub-threshold” depression (HADS < 8) in anxiety disorder would influence the 
association between educational level and anxiety disorder, the HADS-D score was added to 
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the model, and vice versa regarding “sub-threshold” anxiety (HADS-A < 8) in depression. 
Further, to evaluate possible effect modification of age and gender, product terms between 
these variables and educational level were added separately to the models.  
To examine the effect of the potential mediators, the logistic regression analyses were 
performed in three steps. First, all the mediator variables were added one by one separately to 
Model 2 above for the three anxiety/depression outcome variables. Second, those mediators 
reducing the odds ratio (OR) for being a case at the lowest versus to the highest educational 
level with at least 5 percent, were included in the analyses to evaluate the combined effect of 
all the mediators by adding each variable to the model after the other(s) were already in. 
Third, the mediators still reducing the OR in the preliminary model, were included in the final 
model. 
One aspect of the selection hypothesis was addressed by examining whether a high 
anxiety/depression score at baseline determined less educational attainment during the follow-
up period in the younger age group. To do so a logistic regression analysis adjusting for age 
and gender, which estimated the OR for an unchanged educational level at follow-up for 
individuals in the high-ADI-12 group (persistent cohort) compared to the low ADI-12 group 
(incident cohort) was performed as well. Product terms for interaction between ADI-12 group, 
gender or age were added to the model.  
The causation hypothesis could be supported if lower educational attainment was 
associated with anxiety/depression at follow-up. Hence, a logistic regression analysis 
adjusting for age, gender, and ADI-12 score was performed, estimating the OR for being a 
case at follow-up among those with unchanged educational level between baseline and 
follow-up compared to those with an increased level. 
A two-sided p-value < 0.05 was chosen to indicate statistical significance. The 
statistical analyses were conducted using the software package of SPSS 11.5. 
 
Ethics 
The Norwegian Data Inspectorate and the Regional Committee for Medical Research 
Ethics in Health region IV of Norway approved HUNT 2. These agencies were not 
established in Norway when HUNT 1 was planned and performed. Each participant in the 
HUNT 2 study was asked to sign an informed consent, stating that his or her data could be 
used for medical research (15). 
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RESULTS 
There were more similarities than differences in the findings from the two cohorts. 
Hence instead of reporting and discussing them separately, they will be treated together. 
 
Characteristics of the cohorts at baseline 
 The age and gender distribution of educational level, anxiety and depression 
categories, and potential mediators are presented in tables 1 and 2. The educational level was 
lowest in the older and highest in the younger age groups in both genders. Men had a higher 
educational level than women in the middle aged (35-49 years) and older age groups (50-69 
years), while there was no gender difference among the youngest (20-34 years). In the 
incident cohort the educational level was somewhat higher than in the persistent cohort. Most 
indicators of somatic health, health behaviors, psychosocial status, and work characteristics 
showed a more unfavorable in the persistent cohort. Rates of anxiety disorder, depression and 
comorbid disorder were approximately two, three and four times higher, respectively, in the 
persistent cohort compared with the incident cohort, but the distribution by age and gender 
was similar. In the incident cohort the rates of anxiety disorder at follow-up were generally 
higher in women, highest among younger women (10.6 percent) and lowest among older men 
(3.2 percent). The oldest age groups had lower rates of anxiety disorder than the younger 
ones. Contrary to anxiety disorder, rates of depression were somewhat higher in men, and 
highest among the oldest (2.1 percent in younger women and 10.2 percent in older men in the 
incident cohort). Rates of comorbid disorder showed no clear patterns in terms of age or 
gender, the rates were approximately 4 percent in all groups (incident cohort).   
 
Attendees versus nonattendees 
Baseline characteristics were compared between those attending and not attending 
HUNT 2. Characteristics of attendees aged 20-69 years were compared to participants in 
HUNT 1 not attending HUNT 2, but in the same age. Among the nonattendees there were 
significantly more men, more individuals in the youngest and oldest age groups, they were 
less educated and had higher ADI-12 scores. Except for a self-reported stressful job and low 
job control, the nonattendees had significantly more unfavorable characteristics as to somatic 
health, health behaviors, psychosocial factors, and sociodemographic characteristics. 
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Unadjusted associations  
 The rates of depression and comorbid disorder increased with lower educational levels 
in both cohorts, while the rates of anxiety disorder were less clearly related to educational 
level (figure 1). However, by further stratification on age group and gender, rates of anxiety 
disorder in the incident cohort showed the same gradient as depression and comorbid disorder 
among the youngest (20-34 years) and oldest (50-69 years) women (data not shown). Rates of 
all the anxiety/depression categories were in general more than three times higher in the 
persistent cohort than in the incident cohort. 
 
Adjusted analyses 
 All outcome measures of anxiety and depression, except anxiety disorder in the 
persistent cohort, were significantly associated with lower levels of education (table 3), with 
significant gradients from the lowest to the highest educational level. ORs for comorbid 
disorder were comparable with those for depression, and markedly higher than for anxiety 
disorder. The ORs in the incident cohort were in general higher than in the persistent cohort. 
Adjustments for ADI-12 scores at baseline influenced the estimates only marginally. There 
was no significant interaction between educational level and age or gender, except for anxiety 
disorder in the incident cohort, which corresponded to the finding in the unadjusted, age and 
gender stratified analyses. A subsequent logistic regression analysis stratified by age group 
and gender showed a significant association between educational level and anxiety disorder in 
the incident cohort only in the women between 20-34 years (OR=1.93; 95 percent CI: 1.42, 
2.63). Adjusting for HADS-D and HADS-A scores at follow-up in the analyses of anxiety 
disorder and depression, respectively, resulted in a major reduction in OR for anxiety disorder 
(lowest educational level: from 1.35 (95 percent CI: 1.17, 1.56) to 1.18 (95 percent CI: 1.01, 
1.37)) and a minor for depression (lowest educational level: from 1.89 (95 percent CI: 1.56, 
2.28) to 1.83 (95 percent CI: 1.51, 2.22).  
 
Associations related to educational attainment during the follow up period  
OR for having an unchanged educational level at follow-up among those in the high-
ADI-12 group at baseline compared to the low-ADI-12 group was 0.79 (95 percent CI: 0.68-
0.92). The interaction terms between baseline ADI-12 group and gender or age were not 
significant. There were no significant associations between increased educational level during 
the observational period and any of the anxiety-depression categories at follow-up (data not 
shown). 
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Potential mediators 
The effects of the various potential mediators on the association between educational 
level and the outcome variables were in general small. In the incident cohort adjustment for  
smoking status reduced the OR for anxiety disorder in the lowest educational group from 1.34 
(95 percent CI: 1.16, 1.55) to 1.28 (95 percent CI: 1.11, 1.49); adjustment for physical activity 
reduced the OR for depression in the lowest educational group from 1.86 (95 percent CI: 1.54, 
2.25) to 1.81 (95 percent CI: 1.49, 2.19); and adjustments for smoking status plus physical 
activity reduced the OR for comorbid disorder in the lowest educational group from 1.97 (95 
percent CI: 1.59, 2.44) to 1.88 (95 percent CI: 1.51, 2.33). In the persistent cohort adjustments 
for smoking status, impairment due to somatic illness, use of analgesics, and employment 
status reduced the OR for anxiety disorder in the lowest educational group  from 1.17 (95 
percent CI: 0.92, 1.50) to 1.15 (95 percent CI: 0.89, 1.48). Adjustments for social support 
status reduced the OR for depression in the lowest educational group from 1.80 (95 percent 
CI: 1.32, 2.44) to 1.75 (95 percent CI: 1.29, 2.38). Finally, adjustments for smoking status and 
use of analgesics reduced the OR in the lowest educational group for comorbid disorder from 
1.69 (95 percent CI: 1.33, 2.15)  to 1.62 (95 percent CI: 1.28, 2.07). 
 
DISCUSSION 
This cohort study showed that during a follow-up period of 11 years, educational level 
was negatively associated with depression and comorbid disorder at follow-up, in both the 
incident and persistent cohort, and with anxiety disorder in the incident cohort. The latter 
association was significant only among younger women. A high mental distress score (ADI-
12) at baseline was inversely but weakly associated with unchanged educational level during 
follow-up period. An increase in educational level during the observation period was not 
significantly associated with incidence of anxiety/depression at follow-up. The associations 
between low educational level and anxiety/depression at follow-up were only modestly 
affected by the potential mediators. 
 
Strengths and limitations of the study 
 This is the largest prospective study ever examining the association between 
educational level and subsequent anxiety and depression. The cohorts were population-based 
with a wide age range. Information regarding both somatic and mental health, as well as 
health behaviors, psychosocial status, and sociodemographic and work characteristics was 
collected, and the follow-up period was long. Mental health was not assessed by diagnostic 
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inventories at neither baseline nor follow-up. However, according to Dohrenwend the use of 
rating scales for mental health are welcomed in this field, because “…until diagnosis is less 
dependent on interviews, it is important to use a variety of methods…”(20). The use of HADS 
enabled us to study the effect of education on not only depression, but on anxiety as well, a 
focus lacking in most previous studies. The ADI-12 index is not specific as to anxiety or 
depression. Hence, in the persistent cohort individuals with anxiety disorder, depression or 
comorbid disorder at follow-up might not have had the same mental health condition at 
baseline. However, the purpose of the stratification was just as much to define a mentally 
healthy cohort at baseline. A possible selection bias indicated by the lower educational level 
and more disadvantageous characteristics among nonattendees versus the cohort participants 
with regard to mental health and the potential mediators might in fact have attenuated the true 
association between education and anxiety/depression and the effect of the potential 
mediators. 
 
Depression 
 Lower educational levels were consistently predictive of depression in both cohorts, 
which is in accordance with the results of Kaplan et al (3) who followed 4,864 individuals for 
9 years. In their cohorts the ORs for being depressed at follow-up in the lowest compared to 
the highest educational groups were 1.59 in the incident cohort and 1.60 in the persistent 
cohort. However, our results were mainly inconsistent with the few other comparable studies: 
Eaton et al (2) did not find such an association after 15 years in their rather small incident 
cohort (N=693). Bracke (4) reported an association between low educational level and 
depression in men only after three years follow-up of a persistent cohort (N=2,223), but after 
adjustment for baseline depression severity, the association was not present. Likewise, 
Sargeant et al (5) estimated a significant effect of low education on depression after one year 
in their small persistent cohort (N=423), which was not present after adjustments for number 
and length of former depressive episodes and symptom severity at baseline. In our analyses 
the association between education and depression was only weakly influenced by adjustments 
for a variety of covariates including baseline mental health, somatic illness, use of health 
services, health behaviors, psychosocial status, and work characteristics. Hence, our results 
support that education is predictive for incident as well as persistent cases of depression.  
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Anxiety disorder 
Educational level was not a strong predictor of anxiety disorder, except among 
younger women (20-34 years) in the incident cohort. The marked attenuating effect of 
adjusting for “sub-threshold” depression on the education-anxiety association further 
emphasized that anxiety, compared to depression, was not very influenced by education. This 
discrepancy between anxiety and depression may be due to some fundamental differences 
between the two conditions. The occurrence of depression is often delayed temporally 
compared to anxiety disorders (6), suggesting that depression is a more secondary 
phenomenon than anxiety (21-23). 
 
Comorbid disorder 
 Despite a higher total symptom level in comorbid disorder than in depression, 
education was not a stronger predictor of comorbid disorder than depression in either of the 
cohorts. These results further support the notion that education primarily predicts the 
depression component compared to the anxiety component.  
 
Causation or selection? 
 The findings from the incident cohort support the causation theory. However, 
educational level did not only “cause” new cases of depression, but predicted maintenance of 
mental distress as well. Furthermore, high levels of mental distress at baseline did not predict 
less additional education in the younger age group during the follow up period, which 
weakens the support for the selection hypothesis. However, getting additional education 
during the follow-up period was not predictive of having less anxiety or depression at follow 
up. Furthermore, there might be a common factor, e.g. belonging to a lower social class, or 
personality, predicting both low educational attainment and depression.  
 
How does education predict depression? 
 Whether the potential mediators are viewed as either true mediators or confounders, 
they did not explain much of the effects exerted by education on anxiety/depression. The 
examined variables included a variety of factors suggested to mediate the effects of SES on 
health in general (24). The effect of other SES indicators on depression, such as occupational 
grade, economic situastion, and income have been partly explained by work characteristics 
(13), economic situation (14), and psychosocial factors (3), respectively. The effect of 
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education on follow-up depression has mainly been explained by depressive symptoms at 
baseline (4, 5) and prior to baseline (5) in longitudinal studies.  
In the predominant absence of measured mediators of the education-
anxiety/depression relationship, education might be hypothesized to induce resilience to stress 
in an individual. In addition to attaining knowledge and competence, which probably 
influences attitudes and important choices in early adult life, education might positively 
influence coping strategies buffering the harmful effects of later life incidents. Being highly 
educated often implies belonging to a higher social class as well, which is associated with 
access to more interpersonal, material, and public resources. The individual physiologic and 
behavioral responses to chronic stress, allostatic load (25), is associated with anxiety and 
depression (26), which is suggested to be related to SES as well (27). 
The psychological pain of low SES has been suggested to cause feelings of shame, 
social anxiety and depression (28) more directly. Social anxiety is characterized by a feeling 
of being devaluated, which may be more pronounced on the lower rung of the hierarchical 
ladder. Finally, from an evolutionary point of view depression has been considered as an 
adaptive response to situations dominated by others where the consequences of opposition 
could be harmful (29). Thus, psychological effects of being low down on the social ladder 
may have detrimental effects on mental health, whatever the actual material condition of life. 
Again, in the absence of other explanatory factors for the association between education  and 
anxiety/depression these mechanism might deserve further attention. 
 
Conclusion 
 Our study supports the notion that lower educational level may predict new as well as 
chronic cases of depression, with or without comorbid anxiety disorder. This association is 
mainly unexplained by baseline anxiety/depression, somatic illness, health behaviors, 
psychosocial status, or work characteristics.  
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TABLE 3: Odds ratios for having anxiety disorder, depression or comorbid disorder, 
measured by the Hospital Anxiety and Depression Scale (HADS†) at follow-up at different 
educational levels. Model 1 is adjusted for age and gender and model 2 is adjusted for age, 
gender and anxiety/depression level‡ at baseline. The Nord-Trøndelag Health Study 1984-
86 (HUNT 1) and 1995-97 (HUNT 2). 
 
 Cases  Model 1 Model 2 
  n % OR 95% CI P OR 95% CI p 
INCIDENT COHORT§ (N=29,748)     
Anxiety disorder#       
 College / University   317 6.8 1   1   
 High school 901 7.7 1.15 1.00-1.31 1.18 1.03-1.35 
 Primary school 737 7.4 1.33 1.15-1.53 
 
1.35 1.17-1.56 
 
 Test for trend    **  ** 
 Depression††       
 College / University   143 3.2 1   1   
 High school 536 4.7 1.48 1.22-1.78 1.50 1.24-1.82 
 Primary school 752 7.5 1.86 1.54-2.25 
 
1.89 1.56-2.28 
 
 Test for trend    **  ** 
Comorbid disorder‡‡    
 College / University   121 2.4 1   1   
 High school 463 3.6 1.50 1.22-1.84 1.52 1.24-1.87 
 Primary school 488 4.2 1.92 1.55-2.36 
 
1.92 1.56-2.37 
 
 Test for trend    **  ** 
 
PERSISTENT COHORT§§ (N=6,687) 
    
 Anxiety disorder    
 College / University   161 23.7 1   1   
 High school 492 27.6 1.21 0.99-1.49 1.13 0.95-1.44 
 Primary school 562 26.1 1.21 0.98-1.50 
 
1.33 0.91-1.40 
 
 Test for trend    *  * 
 Depression       
 College / University   58 10.1 1   1   
 High school 218 14.4 1.50 1.10-2.04 1.48 1.09-2.02 
 Primary school 373 19.0 1.82 1.34-2.48 
 
1.80 1.32-2.44 
 
 Test for trend    **  ** 
Comorbid disorder    
 College / University   103 12.2 1   1   
 High school 399 16.4 1.41 1.12-1.78 1.34 1.06-1.69 
 Primary school 689 20.8 1.91 1.52-2.41 
 
1.73 1.37-2.19 
 
 Test for trend    **  ** 
 
* p > 0.05  
** p < 0.001 
† Consists of an anxiety subscale (HADS-A) and a depression subscale (HADS-D) 
‡ Anxiety Depression Index-12. The adjustment is performed due to variation in ADI-12 at baseline within 
each cohort. 
§ Cohort with Anxiety Depression Index-12 at or below the 80th percentile at baseline (HUNT 1). 
# HADS-A>8‡‡‡, HADS-D§§§ <8. 
†† HADS-D>8, HADS-A <8. 
‡‡ HADS-A>8, HADS-D >8. 
§§ Cohort with Anxiety Depression Index-12 above the 80th percentile at baseline (HUNT 1). 
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FIGURE 1: The Nord-Trøndelag Health Study 1984-86 (HUNT 1) and 1995-97 (HUNT 
2): 
11 years incidence and persistence rates of anxiety disorder, depression, and comorbid disorder, 
respectively, at the three educational levels. Incidence cohort, Individuals with Anxiety Depression 
Index-12 < 80th percentile at baseline; Persistence cohort, Individuals with Anxiety Depression 
Index-12 >80th percentile at baseline; Anxiety disorder, the Hospital Anxiety and Depression Scale, 
Anxiety subscale (HADS-A) score >8, Depression subscale (HADS-D) <8; Depression, HADS-
D>8 and HADS-A <8; Comorbid, HADS-A>8, HADS-D >8. 
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